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Summary 
Scientific background 
Infection remains a major cause of morbidity, mortality and technique failure in PD 
patients. Identification of peritonitis episodes and the causative organism is slow and 
unreliable. The immune system has evolved to be specific for different pathogens, 
suggesting a pathogen-specific “immune fingerprint” may be able to distinguish distinct 
pathogens to guide more accurate treatment decisions. microRNAs are post-transcriptional 
regulators of most human genes and have roles in the majority of biological processes and 
pathways. They are stable, accurate and specific biomarkers in biological fluids. My work 
aimed to combine the immune fingerprint model with specific microRNAs in PD effluent to 
identify peritonitis episodes and ascertain the role of extracellular microRNAs in the acute 
immune response. 
 
Approach 
The microRNA profile of PD effluent was analysed in peritonitis patients with different 
infectious organisms to identify candidate biomarkers. The cellular source of these 
microRNAs was identified, and the functional release of one microRNA (miR-223) into the 
extracellular space was analysed for functional stabilisation in extracellular vesicles. 
 
Results 
microRNA profiles are altered in infected compared to uninfected PD effluent, which may 
have diagnostic value in acute peritonitis. Four microRNAs were identified as candidate 
biomarkers (miR-223, miR-27a, miR-21 and miR-31), with distinct cell-specific expression 
patterns. Potential mRNA targets of these microRNAs were identified. miR-223 was found 
to be functionally stabilised in PD effluent from peritonitis patients, with a proportion likely 
to be incorporated into neutrophil-derived exosomes. 
 
Conclusions 
My studies prove that microRNAs are useful biomarkers of infection in PD-related 
peritonitis and have the potential to contribute to a pathogen-specific immune fingerprint. 
Exosome-encapsulated microRNAs may have a functional role in intercellular signalling 
between immune cells responding to the infection and the local tissue, to help clear the 
infection and resolve the inflammation. 
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 1 
1 Introduction 
1.1 Chronic Kidney Disease 
The kidneys are essential organs located at the back of the abdomen, which are 
approximately the size of a fist in healthy adults. These bean-shaped organs are involved 
in regulatory functions in the body, including maintaining the composition of the blood. 
They remove excess organic molecules and electrolytes, and are involved in the 
maintenance of acid-base balance and blood pressure (via salt and water balance), as well 
as production of hormones (e.g. erythropoietin) and enzymes (e.g. renin). Kidneys filter out 
excess waste products and water from the blood and produce urine to secrete these out. 
The blood is filtered in the glomeruli where it undergoes selective secretion and 
reabsorption of different molecules and water, before urine is produced in the downstream 
nephron segments.1 
 
1.1.1 Kidney disease 
If the kidneys suffer an injury then it is called kidney disease, with the length of time 
defining whether it is an acute kidney injury (AKI) or chronic kidney disease (CKD). If the 
renal function declines for less than 3 months, this is termed AKI, and the patient often 
recovers to full renal function. However, it is possible the patient may progress to CKD, if 
the injury and reduction in renal function persists for longer than 3 months. AKI and CKD 
are separate but related disorders, with AKI giving an increased chance of the occurrence 
of CKD, whilst the opposite is true as CKD is an independent risk factor for AKI. This 
progression to CKD is more likely if the AKI is severe or the patient has multiple episodes of 
AKI, regardless of the underlying pathology.2 
 
Renal replacement therapies (RRT) are required for patients with end stage renal disease 
(ESRD), to replace the normal filtration function of the kidneys. The severity of renal failure 
is assessed by the glomerular filtration rate (GFR), with a GFR of 90 to 120 ml/min/1.73 m2 
considered normal. A GFR of below 60 ml/min/1.73 m2 for 3 or more months is a sign of 
CKD, and a GFR lower than 15 ml/min/1.73 m2 is a sign of kidney failure. The most common 
cause of ESRD in the UK is diabetic nephropathy (27% of patients in 2014), with 
glomerulonephritis (13%) and polycystic kidney disease (7%) the next most common 
diagnoses (of those with known aetiology).2 
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1.1.1.1 Diagnosis 
The clinical presentation of both types of kidney diseases is marked by a range of non-
specific signs including high blood pressure, nausea and generalised itching. The diagnosis 
is therefore reliant on biochemical markers such as the estimated GFR, through 
measurement of the creatinine concentration in plasma and use of an equation established 
in the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). The GFR is an estimate 
of the amount of blood passing through the glomeruli per minute. The combination of the 
GFR and albuminuria levels (levels of protein or albumin in the urine) are used to diagnose 
AKI or CKD, and also the stage of disease, and to specify treatment options to be 
considered, as shown in Table 1.1. The latter stages of CKD are termed ESRD, or kidney 
failure. The specific guidelines on diagnosis are set out by the Kidney Disease Improving 
Global Outcomes (KDIGO) CKD Work Group, and these include a diagnosis of the underlying 
pathology, if possible, to help characterise the stage, and likely prognosis and treatment 
options.3–6 
 
1.1.1.2 Causes 
The most common causes of kidney disease are diabetes and hypertension, which are often 
chronic, lifestyle-related disorders (especially type 2 diabetes) and are becoming more 
common, meaning the prevalence of kidney disease is increasing worldwide. Elderly 
populations in developed countries have the highest rates of CKD, although rates are now 
also increasing in developing countries. In developing countries, the causes of CKD may be 
more widespread, including infections with nephrotoxic effects such as glomerulonephritis, 
human immunodeficiency virus (HIV) (and associated anti-retroviral therapies) and enteric 
infections that cause haemolytic-uraemic syndrome. Other risk factors include treatments 
with nephrotoxic effects, for example herbal treatments and their interactions with 
conventional therapies. Sometimes the cause of CKD is unknown, especially in Asia and 
sub-Saharan Africa.2,5 
 
1.1.1.3 Complications 
Both AKI and CKD can have many complications, most notably cardiovascular disease (CVD) 
and mortality. This is likely due to the commonly associated comorbidities of diabetes and 
hypertension, although CKD is an independent risk factor for both these complications. 
Other complications that require clinical interventions include volume overload, metabolic  
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GFR = Glomerular filtration rate 
AER = albumin excretion rate 
ACR = albumin-to-creatinine ratio 
 
Table 1.1: GFR and albuminuria categories used to classify CKD stage, adapted from6. 
  
GFR category GFR (ml/min/1.73m2) Terms 
G1 >90 Normal or high 
G2 60-89 Mildly decreased 
G3a 45-59 Mildly to moderately decreased 
G3b 30-44 Moderately to severely decreased 
G4 15-29 Severely decreased 
G5 <15 Kidney failure 
Albuminuria 
category 
AER (mg/24hr) ACR 
(mg/mmol) 
ACR (mg/g) Terms 
A1 <30 <3 <30 Normal to mildly 
increased 
A2 30-300 3-30 30-300 Moderately increased 
A3 >300 >30 >300 Severely increased 
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complications (e.g. acidosis), hypertension, anaemia, mineral and bone disorders, uraemia, 
dyslipidaemia and infection.4,5 
 
The biggest problem with AKI or CKD is the build-up of toxic waste products and water, as 
the kidneys cannot remove them from the blood. If the renal function declines to such an 
extent that the kidneys can no longer function to a sufficient level, then a renal 
replacement therapy must be initiated to keep the patient alive.4,5 
 
1.1.2 Renal replacement therapies 
The most effective treatment for ESRD patients is a kidney transplant, however, due to the 
lack of organs available for transplantation, dialysis is normally initiated whilst the patient 
waits for a suitable donor. After 90 days on RRT, only 10% of patients have received a 
transplant. There are two types of dialysis which patients can undergo; haemodialysis (HD) 
and peritoneal dialysis (PD). HD is initiated in 70% of patients as a primary treatment, 
whereas PD is only started in 20% of patients.2 Internationally, 269,000 patients received 
PD in 2013, compared to 2.25 million who used HD and 675,000 with a renal transplant.7 
 
1.1.2.1 Kidney transplant 
Kidney transplant is the best RRT due to the improved quality of life and increased survival, 
compared to dialysis. The first successful kidney transplant is thought to have happened in 
1954 between a pair of identical twins in the US. Through advances in immunosuppression, 
organ matching and preservation, and chemoprophylaxis of opportunistic infections, 
patient survival is now greater than 95%, and graft survival over 90%. This RRT is also 
cheaper than long-term dialysis, however the demand for organs greatly exceeds the 
supply in all parts of the world. Paired living donor schemes have attempted to bridge this 
gap, but there is still a shortfall in suitable donor organs.2,8,9 
 
1.1.2.2 Dialysis 
Dialysis is defined as the diffusion of molecules in solution across a semipermeable 
membrane along an electrochemical concentration gradient, and is used to replace the 
function of the kidneys in patients with ESRD. There are 2 main modalities of dialysis that 
patients can choose to initiate when they have kidney failure; HD and PD. Both methods 
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are effective at restoring the intracellular and extracellular fluid environment that is 
characteristic of normal kidney function.10 
 
Toxins and waste products, such as urea, have to be transported out of the blood, with the 
concentration and size of the solutes the main determinant of the diffusion rates. Small 
molecules, e.g. urea, diffuse rapidly, whilst larger more complex molecules, e.g. albumin, 
diffuse more slowly. Solutes are also removed from the blood by ultrafiltration, which is a 
convective process driven by hydrostatic or osmotic pressure gradients to remove excess 
body water.10 
 
1.1.2.2.1 Patient choice 
The patient choice between HD and PD can depend on a variety of factors, such as patient 
preference, geographical location relative to a dialysis centre, age, employment (of patient 
and family), obesity and level of residual renal function (RRF).11 Patients receiving PD are 
more likely to rate their care highly, compared to those undergoing HD,12 however, the 
rates of take-up of PD are still low.2 The apparent preference by patients for PD may be 
due to several factors including the better quality of life, flexibility, ability to conduct 
treatment at home and lower costs of PD, compared to HD.12 Furthermore, complications 
related to infections appear more common in HD than in PD, survival is superior in the first 
2-3 years of treatment and the RRF is preserved.11,13,14 
 
1.1.2.2.2 Haemodialysis 
In HD, the blood is removed from the body and cleaned in a dialysis machine, or dialyser. 
The blood is passed across synthetic semipermeable membranes, with a dialysate on the 
other side. This allows for diffusion of small toxins out of the blood and essential solutes 
into the blood, as well as ultrafiltration to remove excess water. The first human HD was 
performed in 1924 by Prof Georg Haas. This involved removing 400 ml of blood from an 
ESRD patient and filtering using collodion membrane. Although successful, research into 
this treatment was largely discontinued for 20 years, before the first “artificial kidney” was 
developed in the 1940s by Kolff et al, and used similar materials as Haas, but an automated 
system to clean more blood more rapidly. After this development, further optimisation 
showed the intermittent HD schedule was optimal. The standard current treatment regime, 
first described in the 1960s, consists of three sessions a week of in-centre HD, where the 
patient travels to a HD centre and the HD is conducted by trained professionals, with the 
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prescription calculated to remove about two-thirds of the total-body urea content during 
each treatment.10,15–17 
 
In-centre HD is both expensive and disruptive for the patient, therefore there is some 
movement towards provision of home HD. This is where a relative or friend of the patient 
is trained to conduct HD in the patient’s home, allowing more frequent dialysis sessions 
and reducing disruption to the patient’s life, allowing more flexibility to continue working 
or travelling. However, this does require both the patient and the carer to take 
responsibility for the treatment and intensive training at the dialysis centre.14,22 
 
1.1.2.2.2.1 Advantages 
Although both HD and PD offer good dialysis and effective RRT for ESRD patients, HD is 
often the more favoured treatment. This is due to a number of advantages including the 
continual assessment of the patient by medical staff, meaning doses can be adjusted in real 
time and even automatically by new advances in feedback control systems. Also, the rate 
of complications is quite low, due to the fact that trained medical professionals are 
completing, and constantly monitoring, the treatment. This is a great benefit especially for 
older, more frail patients, as they can be monitored closely and do not have to take 
responsibility for the treatment themselves, which may be a challenge for some. Also, the 
social benefits to regularly coming to the dialysis unit may be an advantage for patients 
who can become isolated, especially those who are older. In the UK, more doctors are 
familiar with HD as a treatment, due to the higher prevalence of it as an RRT than PD, 
therefore it is often favoured, and the complications are so rare that they are seen as part 
of the treatment and can be dealt with effectively and rapidly. The development of home 
HD systems has also brought down the costs associated with patient transport to the unit 
and staff hours. Although the start-up costs may be more for this treatment, the overall 
benefit is significant. Home HD is also associated with an increased quality of life therefore 
this is an important development that can be utilised further to benefit patients and reduce 
costs. The cognitive function of patients with ESRD is poor, and this increases with dialysis 
treatment of both modalities (HD and PD).10,18–22 
 
1.1.2.2.2.2 Disadvantages 
There are, however, a number of disadvantages associated with HD compared to PD. The 
nature of in-centre HD means there are associated costs for patient transport and staff 
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hours. The transport and length of treatment time also massively disrupts a patient’s 
professional and personal life, with the lack of flexibility and independence challenging, 
especially for those of a working age. One of the major clinical disadvantages to HD is that 
this therapy causes a loss of any RRF. New regimes of incremental HD are being developed 
to attempt to counter this, but RRF is still lost eventually. HD is also associated with a risk 
of intradialytic hypotension, and infection with the central venous access. The risk of 
infection is also present in PD, but infections into the blood stream can become more 
serious very rapidly. In older patients especially, another clinical complication is that 
vascular access can be challenging to gain and maintain. This complex treatment does have 
a reasonably high rate of comorbidities, although these are generally managed 
successfully. Some studies suggest that the quality of life of patients is decreased on HD, 
although this is not clear, and some may suggest an improvement in quality of life, 
compared to PD, especially when patients are on home HD. There has been a recent 
suggestion that, although cognitive function increases with dialysis, including HD, PD is 
associated with a greater increase over one year.18–24 
 
All of this shows how HD can be both a very effective RRT and have some problems that 
mean patients (and the treating doctors) may choose other RRTs. Home HD is an especially 
important development that will be essential to advancing this treatment.18,19 The 
advantages and disadvantages of PD as an RRT will be discussed in more detail below.  
 
1.2 Peritoneal dialysis 
1.2.1 General overview 
Peritoneal dialysis uses the natural ability of the peritoneal membrane to act as an 
ultrafiltration barrier. A PD solution (dialysate) is inserted into the peritoneal cavity via a 
permanent abdominal catheter. During the subsequent dwell time, the peritoneal 
membrane acts as a dialyser to remove waste products by diffusion and ultrafiltration.25,26 
The dialysate consists of water, osmotic agents and electrolytes in a buffer. The osmotic 
agents make the solution hyperosmolar and allow water to be removed from the blood 
following an osmotic gradient. Buffers, such as bicarbonate and lactate, are used to control 
acidosis. Electrolytes are also added, (e.g. sodium, calcium and magnesium) to prevent the 
excessive removal of these essential metals from the blood.27 These will be discussed 
further below. 
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There are three barriers between the dialysate and the capillary blood, these are the 
capillary wall (which is the most important for solute transport), the interstitium (offers 
some resistance to solute transport, mainly large solutes only) and the mesothelial cell 
layer (which isn’t a major barrier to water or solute transport). According to the three-pore 
hypothesis, there are three sizes of pores in the capillary endothelium which size-restrict 
solute transport. The most common type of pore is the small pores, with an average radius 
of 40 to 50 Å, which mediate the transport of lower-molecular-weight solutes. The large 
pores are less numerous and have an average radius of >150 Å, they are also more variable 
in size. Ultrasmall pores are only 3 to 5 Å wide and are called aquaporins. These 
transcellular pores allow only the transport of water molecules via an osmotic gradient. 
Waste products are removed from the blood by a concentration gradient, via diffusion or 
convection (solute transport that occurs alongside water during ultrafiltration).28–30 
 
1.2.2 Peritoneal Dialysis Development 
1.2.2.1 First uses 
PD as a technique was first successfully described in dogs in 1945 by Seligman and 
colleagues.31 It was first used in humans as a treatment for kidney failure patients, primarily 
in response to fatal uraemia in soldiers on the battlefront. The prediction that uraemia is a 
reversible process led to the development of a simple alternative to restore filtration and 
keep ESRD patients alive. The dogs used in the pioneering experiments were able to survive 
3-10 days post nephrectomy and died eventually of complications, often related to 
peritonitis and contamination of the catheter. This technique was seen as a success in dogs, 
with 40-75% of normal renal function restored, in terms of urea clearance, correct acidosis, 
and prevention of death from uraemia.31,32 This then led to a desire to optimise it for 
human patients, and a number of case studies showed successful use as a RRT, with 
extension of life and elimination of uraemia, although patients often died from other 
complications.32–34 
 
1.2.2.2 Dialysis solution development 
PD solutions consist of electrolytes and an osmotic agent in a buffer. The electrolyte can 
include sodium, potassium, magnesium and calcium, with their role to maintain the 
homeostatic balance of the body and generate a concentration gradient to remove excess 
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electrolytes. An osmotic agent is used to make the solution hyperosmolar and generate an 
osmotic gradient to allow ultrafiltration of water out of blood, most commonly used is 
glucose but it can be amino acids or icodextrin. Although glucose is a good osmotic agent, 
it can also negatively impact the peritoneal membrane via glucose degradation products 
(GDPs, discussed further below), therefore alternatives have been used. Icodextrin is a high 
molecular weight glucose polymer that does not diffuse across the peritoneal membrane, 
it absorbs by convection much slower than glucose. This, and amino acids, as alternatives 
both also have their own disadvantages (discussed further below). The buffer is important 
to maintain the pH as biocompatible as possible, and the most commonly used is either 
lactate or bicarbonate.35–37 
 
The three main components of PD solutions are important to allow efficient dialysis, 
however their impact on the peritoneal membrane has recently become important. Due to 
the nature of the components, they are naturally not “biocompatible”, and can increase 
the rate of fibrosis, epithelial/mesothelial-to-mesenchymal transition (EMT/MMT) and 
systemic inflammation associated with PD. More biocompatible solutions have therefore 
been developed. As mentioned before GDPs can negatively impact the compatibility of the 
PD solution with the peritoneal membrane which is encounters. GDPs are generated from 
glucose after heat sterilisation, and are both directly and indirectly toxic to cells, as well as 
nephrotoxic in animal models. GDPs rapidly forms advanced glycation end-products (AGE), 
which are also toxic to the peritoneal membrane. To combat these toxic by-products, low-
GDP solutions have been developed to help maintain RRF and peritoneal membrane 
integrity better. One way of reducing GDPs formed in heat sterilisation is to decrease the 
pH, making it acidic. However, this can also have negative impacts on the peritoneal 
membrane causing fibrosis and EMT/MMT, ultimately leading to technique failure. Multi-
component systems allowing the development of neutral pH, low-GDP solutions have 
greatly advanced the biocompatibility of PD solutions. To avoid the generation of GDPs, 
other osmotic agents have been developed. Amino acids are useful osmotic agents and do 
not produce GDPs, however they are limited by the development of metabolic acidosis. 
Icodextrin is a viable alternative to glucose as an osmotic agent and has biocompatibility 
benefits. This polydispersed, high molecular weight glucose polymer does not diffuse 
across the peritoneal membrane, maintaining the osmotic gradient. It does not generate 
GDP or AGE, and has other clinical benefits including better ultrafiltration and attenuated 
metabolic effects that are caused by systemic glucose absorption.35,37–39 
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The use of biocompatible PD solutions can reduce the cumulative and progressive injury to 
the peritoneal membrane caused by traditional PD solutions. They have many benefits 
including the preservation of RRF, stability of peritoneal membrane characteristics, 
reduced incidence and severity of peritonitis episodes (due to decreased impairment of 
peritoneal host defences), reduced systemic inflammation and decreased inflow pain. 
Biocompatible PD solutions are more expensive to generate than traditional PD solutions, 
but they are seen as cost-effective due to the reduced costs of the negative impacts of a 
lack of biocompatibility (i.e. reduced technique failure due to fibrosis, fewer and less severe 
peritonitis episodes), meaning the overall cost to the healthcare provider is reduced.35,37–
41 
 
1.2.2.3 Different modalities 
PD can be conducted in one of two modalities, either as manual continuous ambulatory 
peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) 
 
1.2.2.3.1 Continuous ambulatory peritoneal dialysis (CAPD) 
This manual method of performing PD exchanges was first used in 1978 by Popvich et al.42 
This technique uses multiple manual exchanges of PD fluid per day, to be conducted by 
either a carer or the patient themselves. Before CAPD, PD was only used in intensive care 
settings as the patients required constant care and attachment to machinery. The ability to 
disconnect patients from tubing and allow them to continue normal life was revolutionary. 
From the discovery that this was an effective RRT, this has become the most common 
modality of PD in many countries as it is very effective at biochemical control and improves 
patient quality of life. PD is the most common mode of chronic dialysis in Hong Kong, as 
well as in developing countries such as El Salvador and Mexico. This technique requires 
minimal training for the patient/carer and can be done anywhere, with no electricity or 
running water required, just clean conditions and the ability to conduct a sterile PD fluid 
exchange, with the costs of medical personnel also relatively low. CAPD was initially 
described with five exchanges per day but can be done with at least three to five exchanges. 
One of the main complications often associated more highly with CAPD than APD is the 
increased incidence of peritonitis, due to the manual exchanges allowing opportunity for 
infectious organisms to enter the sterile peritoneum. Since the development of the Y-set 
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and double bag system, which allows washing out of the catheter before new PD fluid is 
introduced, the rates of peritonitis are decreased.42–46 
 
1.2.2.3.2 Automated peritoneal dialysis (APD) 
This broad term refers to all PD exchanges conducted using a machine, which includes 
continuous cyclical PD (CCPD), intermittent PD (IPD), nightly intermittent PD 
(NIPD), and tidal PD (TPD).47,48 When PD was first used in a hospital setting in the 1960s, a 
form of APD was used, where a peritoneal cycler conducted multiple 2 litre exchanges over 
10 hours.49 When CAPD was described in 1976, this became the method of choice for PD 
due to its effectiveness and flexibility.47 The first form of APD to be developed was CCPD in 
1981, where three or four exchanges are performed automatically overnight as well as an 
additional exchange that remains in the abdomen during the day.47,48,50,51 IPD historically 
had inadequate dialysis and malnutrition but was improved in the late 1960s and early 
1970s, before being adapted as TPD. IPD consists of frequent, short exchanges over 8-10 
hours (often overnight, called NIPD), three-times weekly. This still is not as efficient as other 
methods of PD, so is reserved for patients with high solute transport rates and limited 
ultrafiltration. TPD is similar to IPD in that there are many short exchanges, often overnight, 
but these exchanges do not involve a full drain, with approximately 50% of dialysate left in 
the abdomen after each exchange, until the final exchange. This is also not used as widely 
and is often selected for patients with problems or pain either with the in-flow or drain 
stages. Both IPD and TPD have periods with no dialysate in the abdomen, called dry periods 
or phases.47,48,51–53 
 
The advancement of technology has meant automatic cyclers now come with a wide range 
of technologies to make this treatment as straightforward as possible for the patient or 
carer to use. For example, these machines are often able to perform all different forms of 
APD and can be programmed with the patient’s prescription. They have easy-to-use display 
screens and can record all data about previous exchanges. The exchanges are automatically 
monitored whilst they are being done, with troubleshooting alerts for any detected 
problems.47,48 
 
APD is becoming the first-choice PD treatment for a wide range of patients. Children and 
young people often select APD due to the flexibility of adjusting fluid exchanges by small 
volumes as required, a dry phase during the day time (to help with body-image issues 
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associated with a distorted fluid-filled abdomen), and no exchanges throughout the day 
(causing minimal disruption to the patient’s or carer’s day). Elderly patients are often put 
onto APD due to the minimal manual dexterous activity required to set up an exchange. 
APD is also used when patients have low RRF and high peritoneal membrane transport 
characteristics, as well as those with ultrafiltration failure and those suffering burnout from 
CAPD. APD is not suitable for all patients due to the high start-up costs, long periods 
required in bed and clinical problems such as poor blood pressure control.47,48 
 
1.2.2.3.3 Comparison of modalities 
Both CAPD and APD have been used for a number of years, allowing observational studies 
to analyse the benefits and disadvantages of both. In terms of clinical outcomes, there 
appears to be no difference in the rates of overall survival, peritonitis, technique failure, 
other infectious complications, hospitalisation and blood pressure control.43,54–56 The rates 
of ultrafiltration are also comparable,57 although some limited, older studies suggest CAPD 
may be more effective at this.58 The maintenance of RRF is important as this is a strong 
predictor of patient outcome. Some studies suggest RRF is better maintained in CAPD,59 
whilst others suggest APD is more effective.60 More recent studies show no difference in 
RRF retention between the modalities.43,54,56 APD originally offered a beneficial reduction 
in peritonitis rates due to fewer connections and disconnections required compared to 
CAPD,43,61 however, with the introduction of the safer twin-bag system, infection rates in 
APD and CAPD patients are now comparable.43,56,62,63 One benefit of APD to the clinicians, 
and therefore the patients too, is that the prescription is more flexible with respect to dwell 
times and volumes as well as other factors.43,54,63,64 The psychosocial benefits of APD have 
meant the rates of take-up are increasing. These include a reduced disruption to the 
professional and personal life of patients, as exchanges can be performed at night.43,54,56,64 
As a result, APD is thought to offer improved quality of life,62,64 although this may not 
always be the case.43,54,64 While APD is associated with higher start-up costs compared to 
CAPD, for the more expensive equipment including the cycler itself, the overall cost of the 
two modalities is similar, with APD sometimes seen as cheaper in the long term.65,66 
Overall, the two modalities of PD are seen as equally good in many comparisons, therefore 
the choice of modality is generally through personal choice of the patient and clinician. 
 
 13 
1.2.3 Technique failure 
Despite its clinical advantages as a RRT for ESRD patients, PD can often not be sustained 
for an extended period of time. This technique failure can be the result of either infectious 
or non-infectious complications. Technique failure is defined as insufficient dialysis of the 
blood, and another type of RRT must be initiated, normally HD.67 This is quite common with 
CAPD patients, as 39% of patients experience an episode of technique failure within the 
first 3 years of treatment (defined as a switch to HD of 30 days or more).68 The main cause 
of technique failure is peritonitis, closely followed by dialysis inadequacy or ultrafiltration 
failure.67 The majority of technique failure occurs during the first two years of PD 
treatment, with risk factors including age, CVD and loss of RRF. Early technique failure is 
normally due to either choice or problems with the catheter, whilst ultrafiltration failure is 
a major cause in more long-term PD treatments. Infectious complications are a consistent 
reason for technique failure across all time frames. Another reason for stopping PD 
(particularly early on) is the availability of a transplant.69 The main clinical causes for 
technique failure can be divided into infectious and non-infectious complications. 
 
1.2.3.1 Non-infectious complications 
Long term exposure of the peritoneal membrane to non-biocompatible PD fluids can alter 
the membrane functionality, causing inflammation, fibrosis, neoangiogenesis and 
eventually ultrafiltration failure, leading to technique failure. The major cause of these 
events in non-infectious complications are glucose and GDPs in the non-biocompatible PD 
fluid. Inflammation is caused by multiple factors, including accumulation of uremic toxins 
such as water-soluble compounds (e.g. urea), and small lipid-soluble or protein bound 
compounds (e.g. asymmetric dimethylarginine and homocysteine). Modified protein 
accumulation, retention of cytokines and mechanical stress of the vascular wall (i.e. due to 
hypertension) can also disrupt the peritoneal membrane through inflammation. Co-
morbidities such as advanced age and diabetes, and extra-osseous calcification also 
contribute to this inflammatory reaction. In this process, inflammatory factors (e.g. tumour 
necrosis factor alpha (TNF-a) and interleukin-6 (IL-6)) are produced by mesothelial cells, 
and macrophages are recruited, even without an infection. Chronic inflammation of the 
peritoneal membrane can cause ultrafiltration failure itself, but it is often caused by a 
combination of inflammation with fibrosis, neoangiogenesis and EMT/MMT.70–72 
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Chronic inflammation stimulates mesothelial cells to produce transforming growth factor-
beta (TGF-β), which stimulates vasodilation, increased cell wall permeability, rapid solute 
transport and low ultrafiltration capacity, concurrent with fibrosis. One of the primary 
events in fibrosis is EMT/MMT, where mesothelial cells increase synthesis of extracellular 
matrix components and transition to fibroblasts (which then proliferate), whilst 
synthesising pro-inflammatory and pro-angiogenic factors (including IL-6 and chemokine 
(C-C motif) ligand 18 (CCL18)). These factors then recruit macrophages to the peritoneal 
cavity, increasing the inflammatory reaction and fibrosis of the peritoneal membrane.70–72 
 
Alongside fibrosis, angiogenesis is a major cause of ultrafiltration failure. Pro-angiogenic 
factors released during chronic inflammation and fibrosis increase the vascular network in 
the peritoneal membrane, which then decreases the glucose-driven osmotic pressure of 
the dialysate. Alongside this, changes in the vascular wall (such as thickening and increased 
permeability) cause an exacerbation of small solute transport. These events, primarily 
caused by mesothelial cell production of vascular endothelial growth factor (VEGF), reduce 
the time for exchange of waste products, therefore ultrafiltration fails. When this occurs, 
PD is no longer effective at filtering the blood, and another RRT must be utilised.70–72 
 
1.2.3.1.1 Encapsulating Peritoneal Sclerosis 
Encapsulating peritoneal sclerosis (EPS) is a severe form of peritoneal membrane fibrosis. 
This is a very uncommon complication of PD, with prevalence reported as between 0.4% 
and 8.9% of PD patients in a variety of different single-centre, multi-centre and national 
registry studies.73 Diagnosis is by a combination of structural and functional features, 
including computed tomography (CT) scan appearance and bowel obstruction, caused by a 
fibrous cocoon wrapped around the bowel, differentiated from membrane fibrosis caused 
by long term PD. It is common for EPS to develop up to five years after conclusion of PD 
treatment. The mortality rate of EPS patients can be as high as 55%, with this complication 
being particularly serious in the first year after diagnosis. The risk of EPS is increased with 
both duration of PD and incidence of peritonitis, as well as ultrafiltration failure and use of 
less biocompatible PD solutions. EPS can be classed into four different stages: pre-EPS, 
inflammatory, encapsulating and chronic, with treatments differing dependent on the 
stage, as well as underlying cause of EPS.73–76 
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1.2.3.2 Infectious complications 
Although PD patients have better survival prospects in the first 2 years than HD patients,11 
infectious complications can be common and often serious. Infections in PD patients 
account for approximately two thirds of all PD catheter removals and about one third of 
transfers to HD. Peritonitis is the most common infectious complication; it accounts for 
22% of all technique failures, is the cause of 4% of all deaths in PD patients and is a 
contributing factor in 16% of deaths.7,77,78 
 
1.2.3.2.1 Type of infectious 
1.2.3.2.1.1 Exit site infection 
An acute exit site infection is defined as a purulent drainage at the catheter-epidermal 
interface, which may be associated with redness, tenderness, increased granuloma and 
oedema. Exit site infections can also be chronic (where the acute infection is either not 
treated properly or recurs after antibiotic withdrawal) or equivocal (where the infection 
and associated symptoms are mild, this often progresses to an acute infection if not 
treated). If the infection does not respond to antibiotic treatment (either systemic or local 
application at the exit site, for at least two weeks), or the catheter itself shows signs of 
infections, then the catheter must be removed to prevent progression to tunnel infections 
or peritonitis. Exit site infections are more common in the first year of PD treatment than 
later on. Treatment of exit sites with prophylactic topical antibiotic cream (such as 
mupirocin) is an effective preventative measure against these infections, which are 
normally caused by touch contamination.79–82 
 
1.2.3.2.1.2 Tunnel infection 
A tunnel infection is characterised by inflammation along the tunnel of the peritoneal 
catheter. This can present clinically as erythema, oedema and tenderness over the 
subcutaneous pathway, but can be subclinical and only diagnosed by ultrasonographic 
identification of inflammation or collection along the catheter. Tunnel infections usually 
occur in the presence of an exit site infection but can occur alone, with progression to 
peritonitis likely if the infection is left untreated or does not respond to treatment. Tunnel 
infections often have more severe consequence for the patient than exit site infections, 
and are highly predictive of catheter loss either due to replacement or removal, and 
subsequent transition to an alternative RRT. Tunnel infections are treated with standard 
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first-line antibiotic treatments, although they often require longer courses than exit site 
infections (i.e. three weeks rather than two weeks).79,81–84 
 
1.2.3.3 Peritonitis 
Peritonitis is one of the most serious complications of PD, with considerable associated 
mortality and morbidity. Peritonitis is a direct contributor to approximately 20% of 
technique failures and 2-6% of deaths of PD patients. Peritonitis is not only a complication 
itself, but can contribute to peritoneal membrane fibrosis and ultrafiltration failure, and 
may also increase the risk of EPS.74,75,78,85,86 
 
1.2.3.3.1 Diagnosis 
Peritonitis is diagnosed when cloudy PD effluent is observed, along with abdominal pain 
and a leukocyte count of >100 cells/mm3 with >50% polymorphonuclear (PMN) cells. 
Standard culture techniques are used to identify the causative organism to decide on 
appropriate long-term treatment, whilst an empirical treatment regime is initiated before 
culture results are known. It is recommended by the International Society for Peritoneal 
Dialysis (ISPD) that culture-negative peritonitis should not be greater than 20% of 
peritonitis episodes in each hospital, as identifying the causative organism can greatly aid 
more accurate treatment decisions, as well as identifying the source of the infection, to 
help prevent further contamination from the same source.87,88 
 
1.2.3.3.2 Epidemiology and Microbiology 
PD-related peritonitis rates range widely across different centres and countries. Reported 
rates globally range from 0.06-1.66 episodes per year, per patient, with rates within a single 
country varying as much as 0.14-1.0 per year (across the London Thames centres). These 
large differences are likely down to variations in patient demographics, the local spectrum 
of microorganisms, patient training, infection prevention, and possibly accuracy in 
recording.78,89 
 
Peritonitis rates are generally decreasing over time, with some single-centre studies 
showing almost a 50% decrease in rates of total peritonitis episodes (0.57 
episodes/patient-year in 1993 to 0.29 in 2005 in a centre in Korea).90 Comparable results 
were also seen in single-centre studies in Brazil, Portugal and Taiwan.91–93 This is mainly 
due to a reduction in Gram positive infections, while rates of Gram negative episodes 
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remain similar. This can be attributed to improvements in PD equipment (such as the 
introduction of the twin-bag connection system) leading to a reduction in contamination 
with skin commensal organisms during connection procedures.78,94 Other factors that have 
reduced rates of infection include better identification of peritonitis risk factors and 
introduction of prophylactic antibiotic treatment.78,85,95 
 
The most common causative organism for PD-related peritonitis are Gram positive 
organisms, which accounts for 56% to 71% of all peritonitis episodes, dependent on the 
centre. This includes coagulase negative Staphylococcus spp. (CNS) and Staphylococcus 
aureus, two of the most common infecting organisms. The majority of other peritonitis 
infections are caused by Gram negative bacteria, which make up 19% to 38% of infections, 
including Escherichia coli. The guidelines from the ISPD recommend no more than 20% of 
peritonitis episodes should be counted as “culture negative”, i.e. have no detectable 
organism after microbiological culture techniques. This is true for the majority of centres 
studied, with the proportion of peritonitis episodes without a positive culture result varying 
from 16% to 23%. A small proportion of infections are caused by fungi (between 1% and 
15%). Although these represent only a small proportion of peritonitis episodes, they can 
cause severe infections with detrimental outcomes.96–98 
 
1.2.3.3.2.1 Single organism infections 
Most peritonitis episodes are caused by a single bacterial organism (up to 85%), with most 
of those being from Gram positive organisms. The primary peritonitis-causing organism is 
CNS, including S. epidermidis. This skin commensal typically causes a relatively mild 
peritonitis episode, which usually responds well to first-line antimicrobial treatment and 
can be resolved, often without hospitalisation (although different regional practices may 
mean rates of hospitalisation can vary). The next most common infecting organism is S. 
aureus, followed by Streptococcus and Enterococcus species. These all cause relatively 
minor infections that can often be resolved quickly. Episodes caused by antimicrobial-
resistant bacteria such as methicillin-resistant S. aureus (MRSA) or vancomycin-resistant 
Enterococcus (VRE) are much more serious and do not respond as well to antibacterial 
treatment. These are still quite rare but the seriousness means they can be a major 
problem, and the percentage of episodes caused by these is increasing.97,99–101 
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Although Gram negative infections are less common97, they often have more serious 
consequences for the patient. The most common Gram negative infecting organism is E. 
coli, closely followed by Pseudomonas, Klebsiella and Enterobacter. Patients with these 
diagnoses often face poorer outcomes, in terms of catheter removal, hospitalisation and 
length of hospital stay, due to the more severe infection and longer treatments required 
(often three weeks rather than two weeks, as with more minor infections)102–104. 
 
1.2.3.3.2.2 Polymicrobial infections 
Infections caused by multiple bacteria are not very common (only accounting for 10% of 
peritonitis episodes in one Australian study), with the majority caused by only two 
organisms. This low rate could be due to a local variations in reporting of culture results, 
not merely a low incidence of polymicrobial infections. The most common combinations 
were S. epidermidis and other CNS species (4.7% of cases), Enterococcus and Klebsiella 
(3.9%), and E. coli and Klebsiella (3.6%), with combinations of Gram positive and Gram 
negative more common than those with multiple organisms with the same Gram status. 
Polymicrobial episodes are generally more serious than those caused by a single organism, 
in terms of hospitalisation, catheter removal, permanent transfer to HD and death. The 
organisms present are important in the prognosis, with polymicrobial infections caused by 
only Gram positive organisms being the most mild, and those involving fungal infection the 
most serious.105–107 
 
Polymicrobial episodes generally required hospitalisation (83% of cases), with rates of 
catheter removal, permanent transfer to HD and death (43%, 38% and 4% respectively) 
higher than in episodes caused by a single organism, although rates of relapse are lower 
(probably due to the high rates of technique failure so the possibility of relapse is removed). 
The length of hospital stay is also longer in polymicrobial cases than in single organism 
infections. Episodes with a bacterial and fungal component had the most serious 
consequences, with higher rates of hospitalisation, technique failure and longer stays in 
hospital than any other group. The clinical parameters are comparable to those with fungal 
infections alone, suggesting the virulence of the fungus is the primary causative factor in a 
poor outcome. Presence of an anaerobic or Pseudomonas species is also a predictor of poor 
outcome.105–107 
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1.2.3.3.3 Fungal infections 
Fungal infection is an uncommon cause of peritonitis (accounts for between 1% and 15% 
of episodes in different studies), but it is associated with significant mortality and 
morbidity. Mortality from fungal peritonitis ranges from 5% to 53%, and technique failure 
resulting from fungal infections can be as high as 40%. Most fungal peritonitis episodes are 
caused by Candida species, accounting for 89.3% of infections in one study, with only a 
small number reportedly caused by filamentous fungi such as Aspergillus species. Clinical 
features of fungal peritonitis are no different from those of bacterial peritonitis described 
above. The likelihood of contracting fungal peritonitis is increased after antibiotic 
treatment. Treatment of fungal infections involves use of anti-fungal agents, such as 
fluconazole (for Candida species), for 4-6 weeks. It is recommended for the catheter to be 
removed immediately after fungal infectious agents have been identified, especially if 
there is no clinical improvement after 4-7 days.98,108 
 
1.2.3.3.4 Culture negative peritonitis 
Culture negative peritonitis episodes are when the standard microbiological culture 
methods cannot identify a causative organism. It is recommended by the ISPD that the rate 
of these infections do not exceed 20%. An infection can be identified as culture negative 
due to a number of technical or clinical reasons including recent antibiotic exposure 
preceding the obtaining of a sample for culture, suboptimal sample collection or culture 
methods, or infection with an unusual organism such as a fungus. They should be treated 
as all peritonitis infections are, using front line antibiotics against primarily Gram positive 
organisms, as it is supposed that most are caused by these bacteria, e.g. by touch 
contamination. If the patient is improving, then treatment should be continued, but if there 
is no improvement after 5 days then it is recommended to consider catheter removal. If 
the patient does not respond to therapy, then it might be necessary to attempt more 
specialised culture techniques to identify the causative organism, alongside catheter 
removal. There is an association between previous antibiotic treatment and culture 
negative peritonitis episodes. Culture negative peritonitis episodes are more likely to be 
resolved with antibiotic treatment, less likely to involve hospitalisation, catheter removal, 
permanent transfer to HD or death than culture positive peritonitis.88,109–111 
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1.2.3.3.5 Risk factors 
There are many factors that increase the likelihood of having a peritonitis episode, some 
of which are connected to an overall increase in the probability of having an infection in 
general (for example, diabetes mellitus and other co-morbidities) so must be managed as 
appropriate. Other risk factors are specifically related to peritonitis, for example, a positive 
nasal carrier of S. aureus is more likely to have an episode caused by S. aureus. There are 
also several demographic factors that appear to correlate with an increased risk of 
peritonitis, such as age, gender and ethnicity. Some risk factors may also be associated with 
organism-specific peritonitis episodes, for example, peaks in the incidence of CNS and 
Gram-negative organisms in warmer seasons and Corynebacterium species in winter 
demonstrate seasonal variations in organism-specific peritonitis rates. One of the major 
risk factors for peritonitis episodes caused by fungal organisms is prior exposure to 
antibiotic therapy.78,92,112 
 
1.2.3.3.6 Coagulase negative Staphylococcus 
CNS is found on human skin as part of the normal microbiota. CNS was initially 
differentiated from S. aureus (a coagulase positive pathogen) as non-pathogenic, whereas 
it is now known that CNS causes a burden on the health system. This opportunistic 
pathogen is one of the major causes of nosocomial infections due to contamination from 
the skin, often of implanted foreign bodies such as catheters, or hip replacements. S. 
epidermidis and S. epidermidis-like species are the most common group of CNS bacteria 
and are the most common CNS group to cause infections, with significant genomic diversity 
compared to other CNS species. There are 18 species of CNS bacteria isolated from humans, 
but only five have been implicated in nosocomial infections. These bacteria colonise the 
body surface, with most prevalence in mucosal surfaces. Inserted or implanted foreign 
bodies are frequently colonised by CNS, specifically the S. epidermidis group, and this can 
be the cause of many device-related infections. These can be both local (for example, exit 
site infections) and systemic (i.e. bloodstream infections), although they tend to be 
relatively minor infections (i.e. subacute and low inflammatory component). In fact, S. 
epidermidis is now recognised as the most frequent cause of nosocomial sepsis. Clinical 
CNS isolates are now often resistant to the bactericidal b-lactams (such as methicillin), with 
growing resistance to other antibiotics due to increased exposure leading to a positive 
selection pressure. Treatment of these often now requires a glycopeptide, such as 
vancomycin, although use of this can be avoided using penicillins or cephalosporins (first 
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or second generation). In serious infections from implanted/inserted medical devices, if the 
infection is not controlled by systemic antibiotic therapy, the only effective therapy is often 
removal of the device, i.e. catheter removal and transition to HD. This is the most common 
infection in PD patients due to the biofilm often formed around or in the catheter, 
therefore the growing resistance is a problem in this vulnerable population.113–115 
 
1.2.3.3.7 E. coli 
E. coli is one of the most abundant facultative anaerobes of the human intestinal 
microflora, with its preferred niche in the mucosal layer of the mammalian colon, where it 
makes up 0.1-5% of the total gut microbial population. This Gram negative rod-shaped 
bacillus can have flagella or pili on its surface to aid movement and attachment to cells. E. 
coli are thought to colonise the intestinal tract of new-borns through exposure to the 
mother’s faecal matter through birth, or through handling thereafter. This is essential to 
help establish the full microbiome of the infant gut. Disruptions in the normal microbiome, 
for example through antibiotic use, can increase the E. coli population and cause infection. 
Infections can also be caused by E. coli exiting the gut, either through faecal matter or 
disruption to the gut membrane. Potential sources of infection in peritonitis include touch 
contamination after poor hand hygiene (contamination from environmental sources or 
faecal matter), or through bowel perforation allowing the microbiome to enter the 
peritoneum. Leakage from the intestinal tract increases the chance of polymicrobial 
infections due to multiple bacteria entering the peritoneum, with E. coli a likely pathogenic 
component. There are a number of pathogenic strains of E. coli, as well as the ones that 
exist harmlessly in the intestinal tract. This highly diverse and broadly distributed species 
has remarkable genetic plasticity, which has been exploited for research purposes since it 
was first discovered, meaning they have the ability to mutate rapidly to avoid treatments, 
especially by generating resistance to b-lactams. Current treatments recommended 
include a range of aminoglycosides, ceftazidime, cefepime or carbapenem, with different 
combinations of each effective to treat Gram negative infections as an empirical first-line 
therapy. Once antibiotic-sensitivity of the infecting organism has been identified then more 
specific treatments can be initiated. E. coli infections tend to be more serious than CNS 
infections, with rates of hospitalisation, catheter removal, technique failure and mortality 
higher.104–106,110,116,117 
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1.2.3.3.8 Recurrent relapsing and repeat peritonitis 
When peritonitis episodes occur close together, they can be classified as either recurrent, 
relapsing or repeat, and these all have worse outcomes than uncomplicated peritonitis. 
Recurrent infections are infections with a different organism within four weeks of 
completion of therapy for a prior episode, and these have a worse prognosis than relapsing 
peritonitis. Relapsing infections are also within four weeks of completing therapy for a 
previous infection but caused by the same organism (or after a sterile episode). Repeat 
peritonitis is an episode caused by the same organism that occurs more than 4 weeks after 
completion of therapy for a prior episode. Relapsing peritonitis has an associated lower 
rate of cure, more ultrafiltration problems, and higher rate of technique failure. Relapsing 
peritonitis is more common than recurrent peritonitis and is more likely to be caused by 
Gram positive organisms. Fungal infections are more common in recurrent infections, 
possibly due to antibiotic exposure increasing the risk of fungal pathogenic growth. If 
infections are caused by different organisms (i.e. recurrent peritonitis) then they are 
thought to be separate clinical entities, therefore need to be treated appropriately. 
Patients with recurrent, relapsing or repeat peritonitis are likely to require catheter 
removal and subsequent transition to HD.110,118,119 
 
1.2.3.3.9 Treatment 
If a patient has peritonitis for an extended period of time, they are more likely to have a 
poor outcome, including catheter removal. This risk is increased again with specific 
infections, such as E. coli, or when peritonitis episodes are recurrent, relapsing or repeat. 
It is important to prevent catheter removal, as only a low proportion of those who undergo 
this surgical procedure is able to return to PD therapy (with reported rates ranging from 3-
13%).78,120 
 
Rapid treatment of a peritonitis episode through empiric antimicrobial therapy is 
recommended by the ISPD as a first line. This should cover both Gram-positive and Gram-
negative organisms and be used until the results of microbiological cultures can advise on 
a more specific treatment regime. This empiric treatment should be selected on a centre-
specific basis considering the local history of organism sensitivities and frequencies in 
causing peritonitis episodes. To target Gram positive organisms, the use of a first-
generation cephalosporin or vancomycin is suggested, whilst Gram-negative bacteria can 
be targeted using an aminoglycoside or ceftazidime.78,88,121 The administration of 
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antimicrobial agents into the peritoneum (IP, intraperitoneal) is more effective at managing 
and treating peritonitis episodes than intravenous (IV) dosing.88 Once the infecting 
organism has been identified microbiologically, and sensitivity to a range of antibiotics 
tested, then more specific treatments can be initiated. For example, many CNS species are 
methicillin resistant, but this will not be known until they are cultured in the presence of 
methicillin.113 
 
Ideally, a more rapid microbiological diagnosis needs to be developed to improve 
peritonitis management and outcomes by facilitating timely introduction of appropriate 
therapy.78,122 
 
1.3 Immune response 
The immune system is the collection of different factors that together protect the body 
against foreign agents, known as antigens, as well as abnormal self, including injured or 
inflamed cells and tumours. These protective factors include both cellular components and 
molecular mediators. The immune system is classified into two complementary types of 
response: the adaptive and innate immune responses.123,124 This project focuses on how 
the innate immune system responds to acute peritonitis episodes in PD patients. 
 
1.3.1 Adaptive immunity 
The adaptive immune response is the specific arm of host defence against pathogens, 
allergens and abnormal self. It consists of specialised cells, T and B cells, which can 
recognise potential threats to the host and instruct other cells to aid removal and 
destruction of potentially harmful cells or invading pathogens. The adaptive immune 
system is also called the acquired immune system due to the immunological memory that 
it possesses. This response to infection is much slower than the innate immune system but 
it is specific to the antigen or injury, and the memory allows a larger response to threats 
that have been encountered before, and this is the basis of vaccination. The innate and 
adaptive immune systems are closely linked, with cross-activation a key component of the 
host response to remove invading microbes.123–125 
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1.3.1.1 T cells 
T cells, so-called because of their maturation in the thymus, are key components of the 
adaptive immune response and contain a T cell receptor (TCR) on their surface. There are 
many different types of T cells with a range of effector, regulatory and memory functions 
which have been characterised by different cell-surface markers.126 
 
CD4+ T cells are called T helper cells, and these cells help modulate other immunologic 
processes through cell-to-cell contact and cytokine release, including B cell maturation, 
CD8+ T cell activation and phagocytosis. The different T helper cell subsets have different 
actions. For example, Th1 cells regulate the cell-mediated response typically against 
intracellular bacteria and protozoa, whilst Th2 cells modulate the humoral response against 
extracellular pathogens.127 CD8+ T cells are also known as cytotoxic T cells, due to their 
ability to actively kill cells that are either infected (e.g. with a virus) or abnormal (e.g. 
cancerous). Once activated through their TCR, they undergo clonal expansion and release 
a range of cytotoxins to kill the target cell.128 
 
Most TCRs consist of an alpha and beta chain combined, i.e. ab T cells, but a small 
proportion have a gamma and a delta chain making up their TCR, so are named gd T cells. 
These are more similar to innate immune cells in that they recognise specific patterns that 
represent abnormal antigens, such as bacterial metabolites like (E)-4-hydroxy-3-methyl-
but-2-enyl pyrophosphate (HMB-PP). However, they are classed as adaptive immune cells 
due to the rearrangement of TCR genes that is characteristic of the generation of specific 
TCRs by ab T cells.129 
 
A key component of the adaptive immune responses is immunological memory, which is 
mediated through memory T cells. These long-lived cells are generated through previous 
exposure to an antigen, and when re-exposed to the same antigen they rapidly expand to 
generate a large number of effector T cells against the specific antigen. There are many 
different types of memory T cells including central memory (in the lymph nodes and 
circulation), effector memory (in the circulation) and tissue resident memory cells (found 
in specific tissues).130,131 
 
Key in modulating and controlling immune responses, especially autoimmune reactions, 
are regulatory T cells (Tregs). These help maintain immunological tolerance through 
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suppression of autoreactive T cells that escape negative selection in the thymus. Tregs also 
prevent excessive immune reactions to stimuli by shutting down T-cell mediated immunity 
towards the end of an immune reaction.132 
 
1.3.1.2 B cells 
B cells are named due to their maturation in the bone marrow. They are activated by their 
cell surface B cell receptors (BCRs) recognising antigens, and this activation process often 
involves T cells. Once activated, B cells then differentiate into either plasma cells or 
memory B cells. Plasma cells are known as “antibody factories” due to their high production 
and release of antibodies. The antibodies bind to the specific antigen and coat it, to 
neutralise it, stick it together to promote phagocytosis (agglutination), or activate 
complement. Memory B cells act similarly to memory T cells, in that they respond quickly 
to re-exposure with the same antigen to rapidly produce specific antibodies and generate 
a robust defence against the same antigens. B cells can also act as antigen-presenting cells 
(APCs), where they take up external antigens by endocytosis and present it to T cells 
through cell surface major histocompatibility complex (MHC).133–135 
 
1.3.2 Innate immunity 
The innate immune response is the immediate response to an insult, either pathogen-
derived or as a result of an injury, with the same quality and magnitude of response 
regardless of previous exposure to the same insult, i.e. lacking immunologic memory. 
Innate immune responses developed earlier in evolution and are seen even in the simplest 
of animals due to their high levels of conservation. This response consists of a range of 
cellular components, including phagocytes and cells releasing inflammatory mediators, and 
molecular components, such as complement and cytokines. These all are incorporated into 
an inflammatory reaction that causes symptomatic pain and swelling, but also aids 
resolution of injury and tissue repair through recruiting and modulating further immune 
responses.123,124 
 
1.3.2.1 Innate immune recognition of pathogens 
The innate immune response is built upon specific cell types detecting molecular patterns 
that are specific to infecting pathogens, termed pathogen-associated molecular patterns 
(PAMPs), by PAMP recognition receptors (PRRs) which are broadly specific for a range of 
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PAMPs. PAMPs are specific to microorganisms, not present in the host, essential for their 
survival (so they cannot evade immune surveillance) and are conserved by a range of 
microorganisms across a class. Common bacterial and fungal PAMPs include components 
of the organism’s cell wall such as lipopolysaccharide (LPS) and b-glucan. Viruses are largely 
detected by the host through unique modifications on viral nucleic acids.136,137 
 
The best characterised class of PRRs are the Toll-like receptors (TLRs). These 
transmembrane proteins recognise viral nucleic acids and several bacterial components 
including LPS and lipoteichoic acid. There are currently 10 TLRs identified in humans, and 
activation of these at the cell membrane initiates intracellular signalling that ends in 
nuclear factor kappa B (NF-kB) mediated expression and secretion of inflammatory 
cytokines.138 There are a range of other PRRs that are important for recognition of 
infection, including dectin-1 and nucleotide-binding oligomerisation domain (NOD)-like 
receptors (NLRs).139,140 
 
1.3.2.2 Cellular components 
The cellular component of the innate immune system consists of phagocytes, cells that 
release inflammatory mediators, dendritic cells (DCs) and natural killer (NK) cells. 
Phagocytes, such as neutrophils and macrophages, engulf and absorb infecting 
microorganisms and other small particles including cellular debris. Dendritic cells present 
antigens to the adaptive immune system to modulate specific immune responses. Cells that 
release inflammatory mediators and modulate further immune responses include 
basophils, eosinophils and mast cells, however all immune cells are able to release 
inflammatory mediators in response to specific stimuli. NK cells can also recognise infected 
and malignant cells, then kill them through direct mechanisms unique to this cell type.123,124 
 
1.3.2.2.1 Phagocytes 
Phagocytes are literally called “cells that eat” in Greek, based on their ability to take up 
pathogens and other debris. There are a range of “professional phagocytes”, named as such 
due to their effectiveness at phagocytosis, which includes neutrophils, macrophages and 
monocytes.141 
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1.3.2.2.1.1 Neutrophils 
Neutrophils are the most effective phagocytes, with the ability to engulf many particles 
rapidly, as well as being the most abundant in circulation. They are often the first 
responders to acute infection and inflammation, where they can be the cell type present 
in the highest numbers.141 For these polymorphonuclear phagocytes to effectively clear 
infecting microorganisms they must first migrate out of the blood to the site of infection, 
phagocytose the particle and then kill it. The migration out of the bloodstream is called 
extravasation and consists of the neutrophil tethering, rolling, adhering to and crawling 
along the endothelium, then transmigrating either between or through the endothelial 
cells. This is controlled by specific markers on the endothelial cells that are induced by 
inflammatory stimuli. Chemotaxis along a chemokine gradient then attracts neutrophils to 
the site of the inflammation or infection.142 Neutrophils recognise microbes through a 
receptor-mediated process, by either PRRs or specific surface receptors for opsonised 
microbes (that are coated in antibodies or complement proteins). Once recognised, the 
microbe is phagocytosed by the neutrophil in a receptor-mediated process, into a 
vacuole.143 
 
Neutrophils can kill infecting microorganisms through degranulation, release of reactive 
oxygen species (ROS) and production of neutrophil extracellular traps (NETs). In 
degranulation, the granules in the neutrophil fuse with the vacuole containing the 
phagocytosed microorganism to form a phagosome. The granule contents are released into 
the newly formed phagosome, and these include proteases and peptidases that lyse 
phagocytosed microorganisms.143 There are two main types of granules in neutrophils; 
azurophilic granules and specific granules. Azurophilic granules are the first to be produced 
(also called primary granules) and contain different serine proteases. Specific granules are 
produced later and contain a wide range of antimicrobial agents including lactoferrin, 
calprotectin and lysozymes.143,144 There is a third type of granule called gelatinase granules 
(also known as tertiary granules) which contain metalloproteases such as gelatinase. These 
are thought to be important in neutrophil maturation.143 ROS are bactericidal chemical 
species produced through an oxidative burst which is stimulated by phagocytosis. These 
are also released into the vacuole and act in concert with the enzymes released from the 
granules to help kill internalised microbes.145 
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NETs were first discovered in 2004 as a novel method of microorganism killing.146 
Neutrophils release a mesh-like structure of DNA, histones and antimicrobial peptides from 
the granules in a process called NETosis. This can either cause neutrophil cell death or be 
through a non-lytic process by the primary responders to an infection. These NETs capture 
nearby pathogens in the sticky decondensed chromatin mesh and expose the pathogens 
to a high concentration of antimicrobial peptides, killing them and recruiting other 
phagocytes to engulf the microorganisms.146,147 The releases of NETs must be closely 
controlled due to the potential for damage to surrounding normal tissues and association 
with autoimmune diseases.148 
 
1.3.2.2.1.2 Monocytes and macrophages 
Monocytes and macrophages have a more complex pathway of differentiation and 
activation than neutrophils. Monocytes are circulating immune effector cells that can 
migrate out of the blood during infection and are able to sense and respond to both 
cytokines and PAMPs through receptors (including PRRs). They can differentiate into 
inflammatory DCs (antigen presenting cells) or macrophages in inflammation. 
Macrophages are resident phagocytes in a range of different tissues involved in 
homeostasis in normal tissues and effective phagocytes. Macrophages have a range of 
PRRs on their surface and can produce inflammatory cytokines in response to 
infection.149,150 Macrophages are traditionally divided into two main subsets; M1 and M2. 
M1 macrophages are classically activated and are conventionally seen as “pro-
inflammatory” due to their ability to produce inflammatory cytokines and kill infecting 
pathogens by phagocytosis. M2 macrophages are alternatively activated and are 
traditionally seen as “anti-inflammatory” with homeostatic functions. These main subtypes 
can be sub-divided into other types with many different roles in innate immune responses, 
activating the adaptive immune response and homeostasis. Macrophage subtypes also 
have the ability to change between phenotypes.151 The role of pro-inflammatory 
macrophages will be discussed here due to their response in an acute infection. However, 
tissue-resident macrophages are crucial in response to inflammatory stimuli, with unique 
transcription factor expression controlling phenotype and proliferation potential e.g. Gata6 
in peritoneal resident macrophages.152–155 
 
Macrophages are effective at taking up a range of different small molecules through 
pinocytosis (for liquids and solutes) and receptor-mediated endocytosis (in a clathrin-
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dependent manner), whilst they use an actin-dependent pathway of phagocytosis for 
larger particles including invading microorganisms.156 Macrophages can recognise 
microbes that have been opsonised or through PRRs detecting PAMPs.157,158 Once 
recognised, the microbes are taken up by actin skeleton rearrangement to allow 
phagocytosis and a phagosome is formed.157 Killing of microbes inside a phagosome is 
similar in macrophages as in neutrophils, with ROS and antimicrobial peptides playing key 
roles. Macrophages do however lack many of the serine proteases found in neutrophils, 
therefore other proteases are more important. A key mechanism of both preventing 
pathogen growth and killing microbes is through generation of an acidic environment in 
the phagosome.159 
 
Macrophages have multiple roles at the site of infection, as they can also act as 
coordinators of further immune responses. This includes further innate immune responses 
such as recruiting neutrophils through cytokine and chemokine production. Macrophages 
can also present antigen on their cell surface to guide adaptive immune responses.151,159 
 
1.3.2.2.2 Dendritic cells 
DCs are key mediators of immune responses through their function as APCs. DCs 
continuously sample their environment by taking up and presenting antigen on their cell 
surface bound to MHC II complexes.160 This is a key to the generation of self-tolerance, 
both central and peripheral,161 as well as sensing invading pathogens and stimulating 
effector immune cells. There are many different subsets of DCs, including CD1c+ DCs, 
CD141+ DCs and plasmacytoid DCs (pDCs), which vary in their localisation to different 
tissues, their PRRs and cytokine production.162 For example, CD1c+ DCs have low levels all 
TLRs except TLR7 and TLR9, whilst CD141+ DCs have high levels of TLR3,162,163 whilst pDCs 
are best characterised as strong producers of type-I interferon (IFN I).164 The main role for 
DCs, once they present antigen on their surface, is to modulate adaptive immune 
responses. T cells, both CD4+ and CD8+, are strongly activated even by small numbers of 
DCs. B cells are also activated both indirectly through expansion of T helper cells and 
directly through secretion of cytokines.160,162 DCs are important for continual monitoring 
of the environment and engaging a specific rapid response to infection, inflammation or 
abnormal self.160,161 
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1.3.2.2.3 Other cells in the innate immune system 
A range of other cells are involved in the innate immune response through a variety of 
mechanisms, mostly by sensing and responding to inflammatory or infectious insults, then 
producing inflammatory mediators and modulating further immune responses. 
 
Eosinophils have weak phagocytic activity, and are best known for their cytotoxic effector 
functions in parasitic infections.165 They have PRRs to recognise PAMPs, which then 
activates the release of anti-microbial peptides, including cationic proteins, and 
mitochondrial DNA-containing “traps” similar to NETs.165–168 Eosinophils are a minor subset 
of the white blood cells, but they play an important role in modulating immune responses 
to infecting pathogens through release of cytokines and chemokines, as well as sensing and 
regulating the complement pathway, amongst others.165,166 
 
Another cell type involved in releasing inflammatory mediators to modulate the innate 
immune response are basophils. They make up only approximately 1% of peripheral blood 
leukocytes and had historically been identified as important in allergic disease, due to their 
high affinity receptor for immunoglobulin E (IgE).169 However, it is now known that they 
have a range of surface receptors for many different stimuli to help modulate the immune 
response. For example, they have PRRs to respond to PAMPs and can be activated by a 
range of different stimuli to produce cytokines, especially IL-4.169,170 They can also actively 
kill infecting microbes through releasing extracellular DNA.171 Basophils may also influence 
the adaptive immune response, through antigen presentation and regulating B cell and T 
cell functions.169 
 
Mast cells are another effector cell type in the innate immune system. These cells are 
similar to basophils in that they also contain high affinity receptors for IgE and are therefore 
associated with allergic disease. However, mast cells are resident in tissues which form the 
interface between the body and the external environment, whilst basophils are found in 
the blood and migrate to the site of infection.172 Mast cells express a wide range of different 
surface receptors that can detect external stimuli, including PRRs such as TLRs, receptors 
for complement proteins, and receptors for cytokines and chemokines.172,173 Mast cells can 
have direct effects on pathogens through endocytosis or direct secretion of antimicrobial 
peptides.172,174 They can also be potent modulators of other leukocytes through release of 
soluble mediators affecting their recruitment, proliferation, survival and activation.172,175 
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1.3.2.2.4 Natural killer cells 
NK cells recognise and kill cells which are infected by intercellular pathogens (e.g. viruses) 
or are growing abnormally (e.g. cancer cells). They are normally present in the circulation 
and can migrate out into tissues when they encounter chemokines.176 The activation of NK 
cells is tightly controlled by a range of activation and inhibitory signals through different 
receptors on their surface.176–178 One key inhibitory signal is the presence of normal MHC 
I, which is used by normal cells to present peptides on their surface in the generation of 
self-tolerance to healthy cells. When this is not present, or is abnormal, the lack of this 
inhibitory signal activates NK cells, as is the case in virally infected cells or those replicating 
abnormally e.g. cancer cells.177 Although this is the main inhibitory signal NK cells recognise, 
there are a range of other signals, both inhibitory and activating, that NK cells can respond 
to.177,178 For example, natural cytotoxicity receptors (NCRs), such as NKp46, on NK cells are 
activated by the presence of viral haemagglutinin on the surface of cells.177,179 
 
Once NK cells are activated, through activation signals, the removal of inhibitory signals, or 
a combination of both, they can kill cells by direct secretion of components from their 
lysosomes across the immunological synapse to kill the target cell in a process called 
degranulation. The granule contents include perforin, which forms pores in the target cell 
membrane to allow entry of other cytotoxic proteins including granzymes. These serine 
proteases then activate caspases to induce apoptosis.178,180 NK cells can also induce 
apoptosis of target cells through release of Fas ligand (FasL), TNF-a and TNF-related 
apoptosis-inducing ligand (TRAIL). When these ligands interact with their corresponding 
death receptors on the target cells, apoptosis is triggered.178,181 The activation of NK cells 
can also stimulate other immune cells, including T cells, through release of a range of 
cytokines and chemokines.182 
 
1.3.2.3 Soluble component 
The range of different cells involved in the innate immune system also produce many 
different soluble factors that influence the acute immune response to pathogens. 
 
1.3.2.3.1 Complement 
Complement consists of over 30 proteins which can exist in soluble forms and on cell 
surfaces, and is an important component of innate immune responses. Those on cell 
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surfaces can either be receptors for activated complement proteins or regulators of 
complement activation.183 The complement system has a key role in the defence against 
infection, with other important roles in the interface between innate and adaptive immune 
responses, and aiding disposal of waste.183,184 The key function of complement proteins is 
to modulate and regulate other immune responses. For example, complement proteins can 
opsonise bacteria and immunogenic molecules to aid phagocytosis and recognition by the 
immune system, with C3 especially important in this process.183,185 Activation of the 
complement cascade leads to generation of chemoattractants such as C3a and C5a.185–189 
Complement proteins can also directly kill pathogenic cells through formation of the 
membrane attack complex (MAC). This complex of four complement proteins forms a pore 
in cell membranes to disrupt the cellular processes and cause cell lysis.190 
 
The complement system has a wide range of functions in innate immune responses, 
therefore it is tightly regulated through the different activation cascades. There are three 
pathways that lead to complement activation; the classical, mannose-binding lectin, and 
alternative activation pathways.183 Classical activation is through sensing of antigen-
antibody complexes and C-reactive protein (CRP) bound to its ligand, which leads to 
activation of the C1 complex. The mannose-binding lectin pathway is activated upon 
sensing of microbes with terminal mannose groups, whilst the alternative pathway is 
activated spontaneously at a low level and leads to complement deposition on any surface, 
including bacteria and tumour cells.183,191 These pathways are tightly controlled to enable 
accurate deployment of this effective defence system against infecting pathogens. Some 
complement complexes are crucial in augmenting antibody responses or enhancing 
immunological memory, as well as clearance of immune complexes and apoptotic cells.191 
 
1.3.2.3.2 Acute phase proteins 
Acute phase proteins are those that are altered in an inflammatory reaction, often at a 
distant site to that of the acute inflammation.192 These include CRP, the first discovered 
acute phase protein. This very sensitive marker of inflammation and tissue damage is a 
soluble PRR that binds to infecting microbes or cell debris, where it is then recognised by 
complement proteins to stimulate an acute immune response.192,193 Although CRP appears 
to be a strong marker for general, non-specific inflammation, there does appear to be an 
association between CRP levels and cardiovascular disease.193,194 Other acute phase 
proteins include those in the coagulation and fibrinolytic system (e.g. fibrinogen), 
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antiproteases (e.g. pancreatic secretory trypsin indicator), transport proteins (e.g. 
ceruloplasmin), participants in the inflammatory response (e.g. granulocyte colony-
stimulating factor) and others including serum amyloid A and procalcitonin.192,195,196 
 
1.3.2.3.3 Cytokines 
Cytokines are small molecules secreted by both immune and non-immune cells that have 
an effect on other cells. This broad category includes interleukins, interferons, chemokines 
and tumour necrosis factors, and they have key roles in modulating effector cells to defend 
against infectious and inflammatory insults.123 Cytokines can be broadly divided into “pro-
inflammatory” and “anti-inflammatory”, but often have context-dependent functions. 
 
For example, IL-6 is a pro-inflammatory cytokine, as shown by its role in the pathogenesis 
of rheumatoid arthritis and how it is effectively targeted as a treatment.197–199 However, IL-
6 can be protective against infection, as shown by deficiency causing a high susceptibility 
to bacterial infections.197,198,200 IL-6 has been measured in PD effluent as a marker of PD-
induced inflammation, peritoneal membrane transport characteristics and PD-related 
peritonitis, suggesting is has an important role at the site of inflammation and 
infection,201,202 with roles in neutrophil trafficking and apoptosis, and T cell function in 
acute infection, thereby linking the innate and adaptive immune responses.198,203–205 
 
Another key cytokine in response to inflammation is the chemokine C-C Motif Chemokine 
Ligand 2 (CCL2, also known as monocyte chemoattractant protein 1, MCP-1). Chemokines 
are specialised cytokines that induce movement of cells that are attracted to them in a 
process called chemotaxis. This pro-inflammatory chemokine is expressed by a range of 
cells upon inflammatory stimuli, including epithelial and endothelial cells, as well as 
monocytes and macrophages. CCL2 then induces recruitment of immune cells to the site 
of injury or infection, specifically monocytes, as well as memory T cells and NK cells.206 CCL2 
is induced upon epithelial cell exposure to high glucose conditions,207 infection with 
Mycobacterium bovis and Mycobacterium tuberculosis,208 and is shown to increase in 
inflammatory conditions such as asthma209 and arthritis.210 
 
TGF-b is an important family of inflammatory cytokines that can be both pro- and anti-
inflammatory, dependent on the local microenvironment. This cytokine is expressed and 
released by many different cell types and can have both autocrine and paracrine effects.211 
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It has known roles in many different biological processes, including growth and 
development.212 TGF-b is important in controlling inflammation, as knockout animals suffer 
fatal inflammation shortly after birth (of the 40% than develop normally to full term).213 
TGF-b is an important regulator of T cell proliferation and differentiation, whilst it also 
controls elements of B cell, NK cell, DC, macrophage, mast cell and granulocyte function.212 
TGF-b has been implicated in the pathology of different inflammatory diseases including 
asthma,214 autoimmune diseases215 and inflammatory bowel disease.216 
 
The complex mixture of cytokines present at the site of infection or inflammation alters the 
specific immune response by changing how different effector cells respond and 
recruitment of further immune cells. Cytokines can be produced by any cell type, with both 
immune cells and non-immune cells producing and responding to different cytokine 
combinations through cytokine receptors on their cell surface. These small molecules are 
essential mediators of immune responses and modulators of how effector cells resolve the 
infectious or inflammatory episode.123,124,217,218 
 
1.3.3 Immune fingerprint in PD-related peritonitis 
As discussed above, the immune response is very specific to distinct pathogens, through a 
range of cellular and soluble markers. It has been proposed that this could be used 
diagnostically in a clinical setting of acute infection, such as PD-related peritonitis.122 
 
The need for a new method of identification of the causative pathogen of an infectious 
episode is crucial due to the problems with current culture methods that are slow and can 
often give negative results, despite clinical presentation of an infection. Even if a culture 
result is positive for infecting organisms, it cannot discriminate between pathogens that 
cause disease or are asymptomatic, as well as those that arise from sample 
contamination.109,122 Treatment, as discussed earlier, remains empirical and has associated 
problems including off-target effects and the potential for resistance to occur.219,220 
 
The immune system has evolved to be specific for different pathogens that express distinct 
molecular patterns,221 therefore the concept of using this “immune fingerprint” to 
determine the infecting pathogen has been developed. This hypothesis suggests that the 
specific cellular and soluble biomarkers at the site of infection can be used to determine 
the infecting pathogen and even the clinical outcome. This has been applied first to PD-
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related peritonitis due to the ease of accessing samples at the specific site of infection.122 
It has been shown that the immune fingerprint of an acute PD-related peritonitis episode 
can be used to distinguish between culture negative, Gram positive and Gram negative 
episodes, as well as those that lead to technique failure and those caused by specific 
microbes including CNS, Streptococcus and Enterococcus, and non-Streptococcus Gram 
positive organisms (as seen in Figure 1.1).122,219,222,223 The use of biomarkers in PD effluent 
is expanding to include those for inflammation, membrane function, as well as infection, 
and this exciting field is expanding to develop biomarkers that will be clinically useful in 
point-of-care tests to be used at the bedside to aid decision making about treatments.224 
 
1.4 microRNAs 
microRNAs (miRNAs) are small, highly conserved non-coding RNA molecules that are post-
transcriptional regulators of gene expression.225 They are relatively novel gene regulators, 
with the first miRNA being discovered in 1993, in Caenorhabditis elegans.226 They are now 
known to be very important in a wide range of cellular processes, are predicted to regulate 
as much as 60% of human protein-coding genes, and are involved in the pathogenesis of 
many different diseases.225,227,228 These molecular regulators are key biomarkers in a range 
of different diseases and are a key focus of this thesis, which investigates their role in the 
acute response to PD-related peritonitis episodes. 
 
1.4.1 First miRNAs 
The first miRNA discovered was Lin-4 in the nematode Caenorhabditis elegans. The lin-4 
gene is an important negative regulator of Lin-14 but does not code for a protein. The lin-
4 gene gives two small transcripts of approximately 22 and 61 nucleotides, which had 
antisense complementarity to the 3’ un-translated region (UTR) of lin-14. lin-4 was 
predicted to be a novel class of regulatory gene that encodes small RNA molecules that can 
target the 3’ UTR of specific targets. Lin-4 and Lin-14 are important in the developmental 
pathway, controlling temporal regulation of larval development, so it was initially proposed 
that these novel small RNA regulators are important in controlling development, termed 
small temporal RNAs (stRNAs).226,229 Small regulatory RNA molecules were then discovered 
in a range of different vertebrates and invertebrates, when they were called microRNAs 
due to their small size.230–232 Nearly all of the miRNAs identified in C. elegans appeared to 
have orthologs in other species, suggesting they are highly conserved regulatory elements 
 36 
 
Figure 1.1: Immune fingerprint summary 
Diagram showing the pathogen-specific immune responses to distinguish between 
different infections and clinical outcomes in PD-related peritonitis episodes. Taken 
from222. 
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and have broad regulatory functions in many different organisms.231,232 
 
1.4.2 miRBase 
From this initial discovery of a few small RNA molecules that could regulate C. elegans 
development, there are now a large number of miRNAs across many different organisms. 
miRBase is an online repository for published miRNA sequences and associated annotation 
that is regularly updated to list all known and predicted miRNAs. The first version was 
published in 2002, with 218 entries. The most recent version (v22) was published in 2018 
with 38,589 entries across 271 organisms, including 2,654 mature miRNAs predicted to be 
present in the human genome.233–236 The two main aims of miRBase were to enable novel 
miRNAs to be assigned names without accidental overlap of gene names, and to generate 
a comprehensive and searchable database of all published miRNA sequences.235 miRBase 
specified the accepted nomenclature for novel miRNAs (described below) and defined the 
relationships between closely related miRNAs across different species and distinct genetic 
loci in the same species. This database not only includes the agreed name for new miRNAs 
and the published sequences, it also includes details about the miRNA including genetic 
locus, homologous sequences, hairpin structure and sequence, links to literature that 
mention the miRNA, deep sequencing reads and crosslinks to other databases where 
information about the miRNA can be gathered (e.g. EntrezGene).233–235 miRNAs are now 
known to have functions in almost all normal cellular processes, from development 
through to apoptosis, as well as in many different pathologies, including cancers.225,237,238 
 
1.4.3 Nomenclature 
Once miRNAs began to be discovered at a rapid rate it became important to have a system 
to name them consistently. miRNAs are given numerical identifiers based on their 
sequence similarity to others that have already been discovered, for example in other 
organisms. If no such sequence similarity exists, miRNAs are named sequentially i.e. if the 
last miRNA to be identified was miR-100, then the next novel miRNA will be miR-101. If a 
novel miRNA shares the same mature 22 nucleotide sequence as another miRNA in another 
organism, it is given the same name but with the species identifier as a prefix (i.e. hsa-miR-
21 for the human miRNA and mmu-miR-21 for the mouse ortholog). If the new miRNA has 
the same sequence as an already identified miRNA from a different genetic locus in the 
same organism it is given a numerical suffix, i.e. miR-6-1 and miR-6-2. miRNAs that only 
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differ by one or two bases are given suffixes to identify them as such; miR-181a and miR-
181b. As mature miRNAs are excised from a hairpin double stranded RNA structure, it is 
possible to be either from the 5’ or 3’ arm. There is normally one arm that is dominantly 
expressed, with the less predominant form named with an asterisk i.e. miR-34 and miR-
34*. miRNAs can also be identified by a suffix showing which arm of the hairpin they 
originate from, i.e. miR-49-5p and miR-49-3p.233,235,239 
 
1.4.4 Biogenesis 
When miRNAs were initially discovered in C. elegans, there were two forms of Lin-4, a 
shorter 22 nucleotide form (which we now know to be the functional mature miRNA) and 
a longer 61 nucleotide form.226 This longer form is the hairpin indicative of a miRNA before 
it has been processed to the mature form. To get from the gene itself to the mature miRNA 
form is a multistep process as described below and shown in Figure 1.2. 
 
1.4.4.1 Transcription to pri-miRNA 
miRNAs can be located anywhere in the genome, in exonic, intronic and intergenic 
locations. miRNAs are often located close to other miRNAs to form polycistronic 
transcriptional units, or clusters, which are generally co-transcribed (although the 
individual miRNAs can be subject to additional post-transcriptional regulation). If a miRNA 
is in an intronic region, it can share a promoter region with the host gene, although they 
can have distinct promoters.240,241 
 
miRNA genes are generally transcribed by RNA Polymerase II (Pol II), and this is controlled 
by a range of RNA Pol II-associated transcription factors and epigenetic regulators. Some 
miRNAs can also be transcribed by RNA Pol III, but this is unusual. The long primary 
transcript, typically over 1kb, contains a local stem-loop structure. A typical pri-miRNA 
consists of a stem loop of 33-35 bp, a terminal loop structure, and single stranded sections 
at both the 3’ and 5’ ends.240,241 
 
1.4.4.2 Cleavage to pre-miRNA 
Whilst still in the nucleus, the pri-miRNA is subject to cleavage to generate a pre-miRNA. 
This is conducted by an RNase III enzyme called Drosha, which forms the microprocessor 
complex with DiGeorge syndrome Critical Region 8 protein (DGCR8), an RNA binding  
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Figure 1.2: miRNA biogenesis and function 
Showing the process of miRNA biogenesis from transcription to function in target 
regulation, taken from242. 
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protein that interacts with the C terminus of Drosha to stabilise it. The endonuclease 
activity of Drosha acts approximately 11 bp away from the hairpin stem-loop section of the 
pri-miRNA (called the SD junction) to release a hairpin structure of approximately 65 
nucleotides consisting of an approximately 22 nucleotide-long stem loop and a terminal 
loop of approximately 48 nucleotides long. Drosha also leaves a small single stranded 
overhang on the 3’ end of approximately 2 nucleotides. Drosha and DGCR8 can both 
regulate each other to control the efficiency of pri-miRNA cleavage. Cleavage can also be 
regulated by a range of post-translational modifications mostly altering protein stability, 
location and processing activity.240,241 
 
1.4.4.3 Nuclear export 
To complete miRNA maturation, the pre-miRNA must be exported out of the nucleus into 
the cytoplasm. To do this, a complex is formed between the pre-miRNA, exportin 5 (EXP5), 
RAN (a nuclear GTP-binding protein) and guanosine tri-phosphate (GTP). Upon 
translocation through the pore, GTP is hydrolysed, which initiates complex disassembly and 
the pre-miRNA is released into the cytosol. EXP5 also protects the pre-miRNA from 
degradation in the nucleus. The regulation of this export is not particularly well known, 
especially with regard to cofactors that may influence this pathway.240,241 
 
1.4.4.4 Cleavage to miRNA duplex 
Once the pre-miRNA is exported into the cytoplasm, it is subject to further cleavage by 
another RNase III endonuclease called Dicer. Dicer binds to and cleaves the double 
stranded pre-miRNA 21-25 nucleotides from the 3’ overhang that is left by Drosha, to leave 
a small RNA duplex consisting of the miRNA guide strand bound to the miRNA passenger 
strand (miRNA:miRNA*). The process of Dicer cleavage is regulated by a range of cofactors, 
most notably by double stranded RNA binding proteins (dsRBPs) that interact with the 
endonuclease, for example TAR RNA-binding protein (TRBP) in human miRNA 
processing.240,241 
 
1.4.4.5 RNA-induced silencing complex formation 
miRNAs regulate genes by directing the RNA-induced silencing complex (RISC) towards 
specific target messenger RNA molecules (mRNAs). This is formed by two steps: miRNA 
duplex loading and subsequent unwinding.240 
 
 41 
The miRNA duplex formed after Dicer cleavage is loaded onto an Argonaute (AGO) protein 
by the 5’ end being anchored to the 5’-phosphate-binding pocket. The miRNA threads along 
the basic channel in the AGO protein until it reaches the PAZ domain (named after the PIWI, 
AGO and Zwille proteins in which it is conserved), which then binds the 3’ end of the miRNA. 
The GW182 protein also binds to the AGO protein to promote its stability. Once in position, 
the seed sequence of the miRNA is arranged into a helix to allow for efficient scanning of 
target mRNAs for complementary sequences. This whole loading process requires energy 
input and is therefore adenosine tri-phosphate (ATP)-dependent. The most common AGO 
protein in humans is AGO2, although all four AGO proteins (AGO1-4) can post-
transcriptionally regulate genes in the same way.240,241 
 
Once the miRNA duplex is loaded onto the AGO proteins, this is called the pre-RISC. To 
generate a mature RISC, the passenger miRNA strand must be removed. This can be 
conducted by the AGO protein itself (e.g. by AGO2 in humans), facilitated by the 
endonuclease C3PO. If there is a mismatch in the duplex in the middle, or the AGO protein 
is unable to slice open the duplex (as AGO1, AGO3 and AGO4 in humans are unable to do), 
the duplex may unwind without cleavage. This is promoted by mismatches at positions 2-
8 and 12-15. Passenger strand release is an ATP independent process.240,241 
 
To select which strand of the duplex is the passenger and which is the guide strand depends 
on the thermodynamic stability of the different strands in the loading process. The strand 
with the more unstable 5’ terminus is normally selected as the guide strand, followed by 
rapid degradation of the passenger strand. As strand selection is not a completely strict 
process, the strand that is not favoured (miRNA*) is still loaded and used in the RISC, just 
at a lower frequency. This whole process is regulated by a range of post-translational 
modifications on AGO that control its activity and stability.240,241 
 
1.4.5 Functions 
Once the mature RISC complex is formed, miRNAs regulate specific mRNA targets by 
binding to complementary regions in the target mRNA and regulating its translation by 
direct target cleavage, translational repression or mRNA deadenylation. 
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1.4.5.1 Target recognition 
miRNAs specifically target genes due to complementarity between the miRNA (normally 
the seed sequence) and the target mRNA (often the 3’ UTR). The seed sequence of a miRNA 
is a small, approximately 8 nucleotide section near the 5’ end of a mature miRNA. This 
region is most important to determine the specificity of binding and is therefore presented 
when the miRNA is loaded into RISC to allow for efficient scanning of potential targets. This 
region is often used to predict potential mRNA targets for miRNAs through target 
prediction algorithms such as Diana, miRDB, miRanda and TargetScan. Some miRNAs target 
other sections of mRNAs including the coding sequence, not just the 3’ UTR. It is possible 
for the rest of the miRNA to be important for target recognition, not merely the seed 
region, however, the majority of miRNAs target the 3’ UTR of mRNAs by binding with the 
seed region. Binding to this 8-nucleotide region is important, but it is not necessary to have 
perfect Watson-Crick complementarity across all eight nucleotides, with one mismatch still 
allowing sufficient targeting to regulate a target. It is common for multiple miRNA target 
sites to be present in one 3’ UTR of a gene, which increases the likelihood that the miRNA 
will repress the target. This complementary binding brings the RISC towards an mRNA to 
promote repression through multiple methods.243,244 
 
1.4.5.2 Target regulation 
miRNAs silence gene expression by repressing translation and accelerating mRNA 
degradation of targets in the cytoplasm. mRNA targets that are perfectly complementary 
to the miRNA in the RISC are cleaved directly by catalytically active AGO proteins. This is 
only possible with AGO2 in humans, therefore silencing of targets also occurs through a 
combination of translational repression, deadenylation, decapping and mRNA degradation, 
which requires the AGO protein to recruit cofactors.244–247 
 
mRNA degradation is a widespread process and accounts for the majority (66-90%) of 
miRNA-mediated target repression at steady state. This degradation occurs via the 5’-to-3’ 
mRNA decay pathway. Initially mRNAs are deadenylated by the poly(A) specific 
ribonuclease subunit complex PAN2-PAN3 and Carbon catabolite repressor 4- negative on 
TATA complex (CCR4-NOT) deadenylase complexes via GW182 (trinucleotide repeat 
containing adaptor 6A), which interacts with the deadenylase complexes and the AGO 
proteins. The mRNA is then decapped by the decapping protein 2 (DCP2), along with other 
required cofactors. The final step is degradation by the cytoplasmic nuclease 5’-to-3’ 
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exoribonuclease 1 (XRN1). Consecutive steps in this pathway are coupled through direct 
interactions between subunits of the catalytic complexes, which helps prevent 
accumulation of intermediates.244–248 
 
Repression of translation occurs at an early time point, but normally contributes a smaller 
proportion of effective target regulation than accelerating mRNA degradation (6-26%). 
However, this is an important method of regulating target gene expression, as 
demonstrated by repression of artificial mRNA reporters that lack a poly(A) tail and are 
therefore resistant to deadenylation.245–248 
 
The exact molecular mechanism of translation repression has not been elucidated, but it is 
thought to be by inhibition of cap-dependent translation at initiation. It is possible that 
mRNA decay can be linked to repression of translation, due to the earlier time point of this 
process starting. This has not been proven as a causal link and there is some evidence 
disputing that repression leads to decay, but it is one possibility.245,247,248 
 
The current model of translation repression involves RNA helicases, either directly or via 
cofactor recruitment. For example, some studies show that the RISC interacts with 
ribosome scanning by interfering with translation initiation factors such as eIF4A. This RNA 
helicase functions by unwinding secondary structures within the 5’ UTR to allow the pre-
initiation complexes to scan it and find the start codon to initiate translation. The molecular 
mechanism of preventing this is unclear, but the assembly and/or function of the pre-
initiation complex is crucial for translation repression, possibly via cofactors such as 
DDX6.244–246,248 
 
Other proposed methods of translation repression include repression of the 60S ribosomal 
subunit joining, blocking elongation once translation has initiated, causing ribosomes to 
drop-off, or direct degradation of the nascent polypeptide. There is experimental evidence 
for different mechanisms of translation repression but it is yet to be elucidated which one, 
if any, is the dominant one, with the potential for redundancy and plasticity in the 
mechanism of translation repression potentially an important factor in responding to 
different situations.244–246,248 
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1.4.5.3 Normal cellular processes 
miRNAs regulate the majority of genes and are hence important in many different cellular 
pathways. Discussed below are some examples of their function in development, apoptosis 
and metabolism, as a demonstration of their ubiquitous role in regulating all aspects of 
normal cellular processes. 
 
1.4.5.3.1 Development 
The first miRNA discovered (lin-4) was identified as important in regulating temporal 
development in C. elegans, with other miRNAs subsequently identified that have similar 
functions classified as stRNAs.226,229 Since this discovery, there has been much work looking 
into the role of miRNAs in development. Animals that cannot express miRNAs (i.e. Dicer 
knockout) do not survive or reproduce normally.238,249–251 Their role in development and 
the cell cycle of embryonic stem cells has been recognised in many ways, including the 
identification of a group of embryonic stem cell-specific miRNAs, the miR-290-295 and miR-
302 clusters, which can promote the cell cycle of embryonic stem cells and are not 
detectable in adult cells or organs. The role of these in maintaining pluripotency is 
antagonised by another miRNA, let-7, which is thought to stabilise the differentiated 
state.250–253 Other individual miRNAs have an effect on embryonic stem cell 
differentiation.251 For example, miR-1 and miR-133 regulate differentiation to cardiac 
muscle cells,254,255 miR-134 induces pre-embryonic stem cell maturation256 and miR-145 
induces lineage-restricted differentiation.257 
 
1.4.5.3.2 Apoptosis 
The majority of published work on miRNAs has been conducted into cancers, therefore the 
role of miRNAs in relation to apoptosis is well known due to the common dysregulation of 
this process in tumorigenesis. Many of the important proteins in both the intrinsic and 
extrinsic apoptotic pathways are known to be direct and functional targets of miRNAs, and 
this has a functional effect in pathogenesis. For example, miR-125b can regulate the pro-
apoptotic Bak protein to confer resistance of breast cancer to paclitaxel.258,259 The anti-
apoptotic protein Bcl-2 is regulated by numerous miRNAs including miR-15a, miR-16-1, 
miR-24-2, miR-148a and miR-204, in different cancers such as leukaemia, gastric cancer, 
colorectal cancer and breast cancer.259–263 miRNAs also target important proteins in the 
extrinsic apoptotic pathway, including Fas ligand (FasL) which is directly targeted by miR-
21 and miR-590, and Fas which is regulated by miR-146a and miR-196b. These interactions 
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are important in pancreatic cancer, leukaemia, osteosarcoma and autoimmune 
disease.259,264–267 The role of miRNAs in apoptosis and other cell death pathways is 
substantial, with direct targets implicated at all stages from initiation through to effectors, 
meaning miRNAs may have important roles in human pathologies, considering the 
importance of apoptosis in many different diseases.259 
 
1.4.5.3.3 Metabolism 
miRNAs are not only involved in the development of tissues and cells required for energy 
production, utilisation and storage, but they also have roles in the regulation of insulin 
release, amino acid and lipid metabolism, as well as energy homeostasis.268 For example, 
the islet-specific miR-375 is a negative regulator of insulin release via direct targeting of 
Myotrophin.268,269 miR-29b is linked to lipid metabolism through control of branched chain 
amino acid catabolism by targeting branched chain a-ketoacid dehydrogenase.268,270 Lipid 
energy storage and cellular lipid levels can also be altered by miRNAs, via the liver-specific 
miR-122268,271,272 and regulation of cellular acetyl-CoA levels by miR-103 and miR-107.268,272 
 
1.4.5.4 Diseases 
miRNAs have been implicated in many different human pathologies, with the majority of 
published research conducted into cancers. However, they are known to have roles in many 
different diseases including cardiovascular disease, infectious diseases and autoimmune 
diseases.250 
 
1.4.5.4.1 Cancers 
miRNAs were first associated with cancer in 2002, when the miR-15a/16-1 cluster was 
identified as a tumour suppressor due to its frequent deletion in chronic lymphocytic 
leukaemia.273 Since then, many miRNAs have been identified as either tumour suppressors 
or oncogenic (called oncomiRs) across a wide range of cancers, with one study suggesting 
that over half of all known miRNAs (at the time) were frequently altered in cancer.274 The 
importance of miRNAs in cancer is further emphasised by the effect of a loss of Drosha or 
Dicer. A decrease in Dicer and Drosha mRNA was prevalent in 60% and 51% of ovarian 
cancer patients respectively.275 Specific miRNAs can be involved in the pathogenesis of 
cancers. For example, miR-21 is a well-known oncomiR in multiple cancers including lung, 
oesophagus and colon cancers.276 miR-34, on the other hand, is a major tumour suppressor 
in multiple cancers including colon and ovary.277 
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miRNAs can also be involved in the resistance of a tumour to therapy, e.g. 
chemotherapy.278 This can be by one of five different methods; metabolism of the drug 
(e.g. miR-27b),279,280 drug transport (e.g. miR-145),281 DNA repair (e.g. miR-96),278,282 
epithelial-to-mesenchymal transition (e.g. miR-200c)283 or regulation of cancer stem cells 
(e.g. miR-145).278,284 miRNAs can also be biomarkers of cancer progression and prognosis, 
either in the tumour itself or in easily accessible bodily fluids, for prognosis prediction, 
disease classification or prediction of response to treatment, and miRNA are very good 
non-invasive biomarkers.285 The first use of miRNAs as biomarkers was in chronic 
lymphocytic leukaemia, where a miRNA signature was defined to stratify prognosis and 
progression.286 Since then, techniques have allowed more accurate screening for 
biomarkers, and many different miRNAs have been associated with cancer prognosis and 
progression. For example, microarray expression profiling has been used to identify panels 
of miRNAs that are significantly altered in pancreatic cancer, specifically those associated 
with reduced survival.287 To classify the disease stage or tissue origin can be useful to guide 
treatment options, for example, subtypes of glioblastoma can be defined by miRNA 
signatures.288 Predicting drug efficiency is especially useful to help clinical decisions, for 
example, miR-125b can be used to predict resistance of breast cancer to paclitaxel if 
measured before treatment.258 As mentioned, miRNAs can be great non-invasive 
biomarkers for cancer, and this will be discussed later on in the context of all human 
diseases. 
 
1.4.5.4.2 Cardiovascular disease 
miRNAs have been identified in different pathologies related to the heart. For example, 
decreased miR-24, miR-29 and miR-320 (the miR-29 family) have been associated with 
myocardial infarction via apoptosis and fibrosis.289–292 miRNAs have also been associated 
with heart failure (miR-765),293 arrhythmias (irregular heartbeat, miR-1 and miR-133)289,294 
and hypertension (miR-155).295,296 The role of miRNAs in cardiovascular pathologies has 
been well studied, showing how the molecular pathways, such as apoptosis, can have 
important roles in human pathologies.289 
 
1.4.5.4.3 Autoimmune diseases 
The role of miRNAs in immune homeostasis means they have been implicated in 
autoimmune disease pathogenesis.297 For example, the establishment and maintenance of 
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immune tolerance is controlled by miRNAs, including miR-181 in T cells298 and miR-185 in 
B cells.297,299 One of the miRNAs that has been implicated in many different roles in the 
regulation of the immune system, and therefore in autoimmunity, is miR-155.300 This 
miRNA is a critical modulator of immune development and responses, as it is not just a 
downstream member of inflammatory cascades301 but also influences T and B cell 
differentiation towards an inflammatory phenotype.302 Raised levels of miR-155 have been 
observed in a range of autoimmune conditions including multiple sclerosis,303 colitis304 and 
systemic lupus erythematosus.305 
 
Other miRNAs that have been implicated in autoimmune pathologies include miR-21,297 
which alters the balance of T helper cells towards pro-inflammatory Th17 cells306 and 
increases in APCs in response to TLR4 signalling307 in multiple autoimmune diseases 
including lupus,308 psoriasis309 and inflammatory bowel disease.310 miR-146a is also strongly 
involved in autoimmunity pathogenesis through induction of tolerance, specifically to TLR 
signalling,297,311 and its broad role for controlling adaptive immune responses.297,312,313 miR-
146a has been identified as either an important biomarker or key in the pathogenesis of  
type 1 diabetes,314 lupus315 and other autoimmune disorders.297,316 
 
1.4.5.4.4 Peritoneal membrane dysfunction 
miRNAs have been implicated in the dysfunction of the peritoneal membrane, through 
fibrosis and EMT/MMT. For example, TGF-b-induced fibrosis or EMT alters a range of 
miRNAs including miR-15a, miR-21, miR-29b, miR-30a, miR-129 and miR-589.317–322 Whilst 
high glucose/GDP-induced fibrosis in peritoneal membrane mesothelial cells alters levels 
of miR-15a, miR-30b, miR-34a, miR-193a and let-7e.323–325 PD fluid itself induces alterations 
in miRNA levels, both in the peritoneal membrane, and released into the PD effluent, as 
shown by animal models and clinical studies of patients who have experienced a degree of 
fibrosis or EMT, for example miR-21 and miR-182.326–329 These studies indicate miRNAs are 
sensitive to a range of stimuli and are altered in fibrosis and inflammation. 
 
1.4.5.4.5 Infectious diseases 
miRNAs can be involved in infectious diseases in three ways: modulating the pathogenicity 
of individual pathogens; affecting the efficiency of host innate and adaptive immune 
responses; and altering the magnitude and resolution of inflammatory responses.250 
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1.4.5.4.5.1 Viral infections 
Viral infection can lead to miRNA alterations in host cells, which can be an advantage for 
the virus to allow replication, either by regulating antiviral mechanisms, viral latency or lytic 
cycles, as well as initiate defence mechanisms.250 For example, the functions of miR-155 
appear to be hijacked to promote Epstein-Barr Virus (EBV) latency.330 A panel of miRNAs 
altered in EBV latency have been identified, which includes up-regulated miR-21 and miR-
34a, and down-regulated miR-96 and miR-128a/b.331 miRNAs can also be potential 
therapeutic targets, for example miR-122 is essential for Hepatitis C Virus (HCV) replication, 
therefore treatments that target miR-122 are a potential therapeutic option (e.g. locked 
nucleic acid-modified antagomirs).332 Viruses themselves have been known to produce 
their own miRNAs (v-miRNAs) that can regulate host cell proteins to create an environment 
that allows viral replication, for example in EBV.333 Due to the need for viruses to hijack 
host cell machinery to replicate, it is likely that the alterations in miRNAs are substantial, 
with only a small proportion of identified changes mentioned here. 
 
1.4.5.4.5.2 Bacterial infections 
Bacterial infections, both intracellular and extracellular pathogens, often lead to alterations 
in miRNAs, especially in cells involved in the immune response. For example, M. 
tuberculosis infected DCs and macrophages have a higher level of miR-99b, and this is a 
potential therapeutic target.334 The miRNA alterations from Mycobacterium infections also 
cover leprosy (M. leprae), where infected monocytes have increased miR-21 levels, which 
causes a decreased IL-1β and increased IL-10 response. This is potentially used to escape 
the vitamin D-dependent antimicrobial pathway, and therefore advance from the self-
limiting to progressive form of leprosy.335 Gastritis patients with Helicobacter pylori 
infections have higher levels of miR-155 and miR-146a in gastric lesions.336 Also, the levels 
of these miRNAs are altered in sepsis, which results from bacterial infections; miR-155 is 
increased and miR-146a decreased in plasma from severe sepsis patients.250,316,337 Bacteria 
do not express miRNAs, as viruses can, but they do release small RNAs (sRNAs) that may 
function to regulate gene expression in the bacteria by complementary base-pairing, akin 
to eukaryotic miRNAs. These bacterial RNA molecules are larger than miRNAs 
(approximately 50-450 nucleotides) and have roles in numerous processes including 
metabolism, biofilm formation and host-cell contact. This field of research is growing 
rapidly, with novel mechanisms of action and physiological functions being discovered 
constantly.338–340 
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1.4.5.4.6 Cross-species regulation 
Currently, it is thought that the miRNAs and sRNAs produced by infecting organisms are 
only able to act within the organism itself, but there is some evidence that small RNA 
molecules can be transferred to the host. For example, ingestion of rice has been shown to 
result in rice-derived miRNAs being present in human and animal sera, with these miRNAs 
able to regulate target genes functionally.341,342 This has not yet been applied to infectious 
diseases, but the possibility that small regulatory RNA molecules are used by infecting 
bacteria and viruses to modulate host targets is very real. 
 
1.4.5.5 Immune responses 
As shown above, miRNAs are involved in many different aspects of immune responses and 
have been implicated in associated pathologies. Below will be a more detailed discussion 
of what is known about miRNAs in relation to innate and adaptive immunity, with specific 
focus on the inflammatory acute response. miRNAs have been identified as key regulators 
of haematopoiesis,343 but this is beyond the scope of this thesis so will not be discussed 
here. 
 
miRNAs can act as post transcriptional regulators of genes involved in immune responses 
by three principles. Firstly, miRNAs can respond quicker to stimuli than other regulators, 
such as proteins, due to the fact that they do not require translation to act on their targets, 
as they regulate targets at an earlier stage. The second principle relies on the fact that 
miRNAs take longer to act when their target is already in the protein form, i.e. they have 
to wait for new mRNA to be transcribed before they can have an effect. The third principle 
is that they do not cause a complete knockdown of the target, so probably ‘fine-tune’ the 
response to a stimulus. These three principles mean that miRNAs are important in all 
aspects of the immune response, both innate and adaptive, in the acute and chronic 
responses.344 
 
1.4.5.5.1 Innate immune responses 
miRNAs have roles in many different aspects of the innate immune system, including in the 
inflammatory response, in phagocytes, inflammatory cells and NK cells. 
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1.4.5.5.1.1 Inflammation 
One of the first identifications of miRNA involvement in immune responses was that certain 
miRNAs can be induced by inflammatory stimuli, with several key miRNAs identified 
including miR-155 and miR-146a. These two miRNAs have contrasting roles in inflammatory 
pathways, with miR-155 seen as a “pro-inflammatory” miRNA and miR-146a as a regulator 
of immune responses.344–346 miR-155 can be induced by inflammatory stimuli in 
monocytes, macrophages and DCs by a range of different stimuli, activating multiple pro-
inflammatory pathways including via NF-κB.301,346–350 miR-146a is also induced by different 
inflammatory stimuli including multiple TLRs, microbial components and pro-inflammatory 
cytokines, in a range of different cell types, but it controls the inflammatory response by 
suppressing the NF-κB pathway.301,346,348,349,351–353 Other miRNAs are also altered after 
inflammatory stimuli, e.g. miR-125, with varying roles for miRNAs to both promote and 
dampen down inflammation dependent on the stimulus, cell type and local 
microenvironment.344,354 
 
1.4.5.5.1.2 Neutrophils 
Neutrophils are the most abundant type of immune cells in the body and respond rapidly 
to infectious and inflammatory stimuli. They accumulate locally as the first responders to 
an infection or inflammation at the site of the insult, for instance they are highly abundant 
in the peritoneal effluent of patients with peritoneal dialysis-related peritonitis. miRNAs 
have been shown to be important in many different neutrophil functions including their 
migration along a chemoattractant gradient, senescence, cytokine expression, 
responsiveness to infectious or inflammatory challenge, and differentiation.355–357 For 
example, miR-451 targets p38 mitogen-activated protein kinase (MAPK) to influence the 
migration of neutrophils towards an inflammatory stimulus.356,358 miR-223 is important in 
both the differentiation of neutrophils and in their expression of ROS.355,356,359 miR-1959 is 
important in the production of antimicrobial peptides,356,360 and other miRNAs are crucial 
in the expression of chemokine (C-X-C motif) ligand 8 (CXCL8) (miR-17 and miR-
155)355,361,362 and IFN-γ (including miR-142 and miR-29).355,356,363,364 The close regulation of 
all aspects of neutrophil biology shows how important miRNAs are in the functions of these 
phagocytes. 
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1.4.5.5.1.3 Other innate immune cells 
In addition to neutrophils, other immune cells involved in the innate immune response are 
similarly regulated by miRNAs. For example, miR-221 and miR-222 regulate both the resting 
and activated states of mast cells, with roles in the cell cycle, cytoskeleton organisation, 
degranulation, cytokine production and cell adherence.365–367 The production of IFN-γ by 
NK cells requires both miR-155 and miR-150,368–370 with other functions also reliant on 
miRNAs, including differentiation, cytotoxicity and secretion of other proinflammatory 
cytokines.371 
 
1.4.5.5.2 Adaptive immune responses 
miRNAs are involved in the normal cellular function of cells involved in the adaptive 
immune system through affecting their differentiation and function in a variety of ways.372 
 
1.4.5.5.2.1 T cells 
T cell differentiation is regulated by different miRNAs, including miR-155 which controls 
the lineage decisions towards different T helper cell subsets, promoting Th17 and Th1 
generation,302 while also maintaining Treg cell proliferation and homeostasis.373 Treg cell 
function is also regulated by miR-146.372,374 The role of miRNAs in different aspects of T 
helper cells is well defined, with their expansion being regulated by miR-182,375 the Th2 
response promoted by miR-126 in inflammation,376 and miR-326 promotes Th17 
differentiation.377 All this shows that miRNAs are important in modulating the direction and 
magnitude of immune responses by different T cell subsets.372 
 
1.4.5.5.2.2 B cells 
The role of miR-155 in the immune system is well documented, with a proposed role for 
this miRNA in different aspects of B cell function,378 including B cell activation through the 
germinal centre response and immunoglobulin G (IgG) class-switching.372,379,380 miR-181b 
also regulates this class-switching reaction.380,381 miRNAs have also been implicated in B 
cell apoptosis, including miR-125b,379,382 and in controlling immunoregulatory B cells to 
prevent autoantibody formation, via miR-15a.383,384 The role of miRNAs in B cell function is 
not well defined, but it is likely they are important in many other functions of these immune 
cells, as they are crucial in most normal cellular processes. 
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1.4.6 miRNAs as biomarkers 
The definition of a biomarker, as decided by the Biomarkers Definitions Working Group in 
2001, is a “characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention”.385,386 Through this definition, miRNAs have been identified as 
biomarkers through associations with a range of diseases, through increased levels in 
biopsies, for example in multiple solid cancers.285 However, miRNAs offer the added bonus 
of potential as biomarkers in biological fluids due to their stability outside cells. This allows 
non-invasive tests to detect the levels of specific miRNAs as biomarkers in a range of 
diseases.387–389 
 
1.4.6.1 Cell-free miRNAs 
miRNAs have been detected in almost all biological fluids, ranging from those that require 
no invasive sampling procedures, including saliva and urine, to those that require more 
invasive procedures to acquire, including whole blood, plasma and serum.388,389 These cell-
free miRNAs have been associated with pathologies such as cancers,390–392 diabetes,393 
infectious diseases394 and cardiovascular diseases,395 amongst many others.387–389,396 
 
1.4.6.1.1 Release from cells 
miRNAs are produced and act in the cytoplasm of cells, but they have been observed as 
stable biomarkers extracellularly therefore it is important to understand if this is an active 
process that has an intercellular communication function. It has been shown that miRNAs 
are stable and can withstand prolonged storage, multiple freeze-thaw cycles and 
incubation at room temperature. They are also resistant to RNase treatment, compared to 
other endogenous RNA species or “spiked-in” artificial miRNAs, which helps their function 
of communicating between cells without being degraded by ribonucleases that are present 
in normal biological fluids.389,396–399 All of this suggests that extracellular miRNAs are 
protected from degradation, with the most likely protection either being associated with 
proteins, lipids/lipoproteins, or being encompassed in extracellular vesicles such as 
exosomes, microvesicles or apoptotic bodies.389 While the nomenclature of extracellular 
vesicles is rapidly changing, a consistent characterisation of vesicles on size and mechanism 
of release from cells has been used here to attempt to discuss the current level of 
knowledge in this area. The formation of all three types of extracellular vesicles is discussed 
below and detailed in Figure 1.3. 
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Figure 1.3: Extracellular vesicle formation 
Showing how microvesicles, exosomes and apoptotic bodies are formed and released 
from cells, adapted from400. 
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1.4.6.1.1.1 Exosomes 
Exosomes are possibly the best known class of extracellular vesicles. These are small 
membrane vesicles (30-120 nm) released by the fusion of multivesicular bodies with the 
cell membrane, releasing the exosomes into the extracellular space.389,401 They were first 
discovered in 1983 as small vesicles in which the transferrin receptor localised after being 
released from mature sheep reticulocytes.402 Exosomes are mainly composed of lipids and 
proteins, with an enrichment of lipid rafts,403 but they also contain a range of molecules, 
including nucleic acids such as miRNAs, that are functional and can be used to signal with 
and modulate recipient cells.403–405 It is now known that the packaging of miRNAs (and 
other signalling components such as mRNAs, other non-coding RNA molecules (ncRNAs) 
and proteins) is through an active process that selects specific molecules to package into 
the vesicles to be released, with a number of molecular mechanisms.406 
 
Exosomes are important for intercellular communication through transfer of contents, 
including miRNAs, between cells. Transfer of miRNAs is important due to their implication 
in many different cellular processes and pathologies. For example, miRNAs can be released 
by T cells and taken up by APCs in a functional manner during the formation of an immune 
synapse.407 This type of intercellular communication is functional in a pathological state. 
For example, miRNA-containing exosomes released by normal bone-marrow mesenchymal 
stem cells inhibit the growth of multiple myeloma, whilst those from multiple myeloma 
patients have lower quantities of the tumour suppressor miR-15a, and therefore promote 
the disease progression.408 Transfer of miRNAs between cells via exosomes has also been 
demonstrated in different forms of cancer and cancer cell lines,405 as well as in heart 
disease,409 lung injury or disease,410,411 and other disorders.387,389 
 
1.4.6.1.1.2 Microvesicles 
Microvesicles are larger extracellular vesicles (100-1000 nm) released by the direct budding 
of cytoplasmic protrusions from the cell surface membrane,401,412 meaning their lipid 
content and surface markers are different to exosomes, and much the same as the cellular 
membrane from which they originate.389,413 When microvesicles were first identified from 
platelets, they were thought to be cellular debris,414 but it is now known they have 
important functions in signalling between cells and altering recipient cell phenotypes.415 
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Microvesicles are similar to exosomes in that they contain a wide range of molecules for 
intercellular signalling, including miRNAs,415 which are selectively packaged into the 
vesicles, as with exosomes.416 The use of microvesicles to signal between cells, specifically 
through transfer of miRNAs has been observed in many different pathological conditions. 
For example, microvesicles from platelets are implicated in miRNA transfer in myocardial 
infarction,417 atherosclerosis418 and lung cancer.419 Microvesicles containing miRNAs have 
also been identified in different types of cancer (e.g. glioblastoma),416,420 and in other 
disease states including atherosclerosis,421 ischemia422 and systemic lupus 
erythematosus.423 The role of miRNAs in microvesicles is not as clear as with exosomes 
owing to the lack of consensus on nomenclature and method of isolation of these larger 
extracellular vesicles, but they are thought to be important in the intercellular 
communication of many different normal biological processes and disease states.389 
 
1.4.6.1.1.3 Apoptotic bodies 
Apoptotic bodies are the third classification of extracellular vesicles. These are larger than 
exosomes and microvesicles (1-5 µm) and are formed through membrane blebbing during 
the later stages of apoptosis, therefore their lipid and surface protein makeup is 
representative of the apoptotic cells.424 Apoptotic bodies also contain a range of signalling 
molecules including miRNAs.389,424 The loading of miRNAs into apoptotic bodies was first 
identified in 2009,425 but is not as well defined as with exosomes or microvesicles, with 
some enrichment of specific miRNAs over others, although this may be due to a 
pathological process rather than an active enrichment. What is known is that the 
enrichment of miRNAs in apoptotic bodies is different to that seen in other extracellular 
vesicles. For example, the profile of miRNAs in exosomes, microvesicles and apoptotic 
bodies released by keratinocytes are different across the different types of extracellular 
vesicles.426 
 
Apoptotic bodies are less well studied than exosomes or microvesicles, and the role of 
miRNAs in intercellular signalling through apoptotic bodies has not been characterised as 
thoroughly. After the initial discover that miR-126 could be transferred from apoptotic 
endothelial cells to stabilise atherosclerotic plaques,425 there have been only limited 
studies looking into other functional transfer of miRNAs to recipient cells. For example, one 
group showed miRNA transfer by apoptotic bodies in bone homeostasis.427 Another 
suggested the shuttling of miR-221 and miR-222 by apoptotic bodies from macrophages 
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has an important role in promoting proliferation of lung epithelial cells.428 Given that 
apoptosis is a key component in the pathogenesis of many diseases, it is likely that 
apoptotic bodies, and their packaged miRNAs, will be increasingly recognised to play a role 
in disease pathways. 
 
1.4.6.1.1.4 Protein-bound miRNAs 
Another way of stabilising extracellular miRNAs is through binding to proteins, either 
protein or lipoprotein complexes. Lipoproteins are a biochemical assembly of a single 
phospholipid layer with proteins embedded, which are involved in transport of molecules 
from the liver to peripheral tissues. These highly soluble complexes are often used to carry 
nucleic acids due to their ability to bind water-insoluble materials. Lipoproteins can either 
be high density lipoproteins (HDL) or low density lipoproteins (LDL) complexes.389,429 They 
were first identified as carriers of miRNAs in 2011, by the ability of apolipoprotein A-I to 
carry small interfering RNA (siRNA) molecules to the liver.430 The first confirmation of 
miRNA carriage by HDL came two years later, as the mechanism was suggested to be 
regulated by neutral sphingomyelinase, meaning it may be an active process. That study 
also showed a specific miRNA signature to identify familial hypercholesterolaemia.431 Since 
then, HDL-bound miRNAs have been shown to contribute to an anti-inflammatory state in 
endothelial cells,432 be indicative of vulnerable compared to stable coronary artery 
disease,433 and be useful biomarkers for uremic patients.434 This area of study is relatively 
novel, with much still to learn about the process. The majority of current work is 
investigating miRNA loading onto HDL, as this is the most abundant lipoprotein complex, 
but it is likely that LDL also carries and stabilises extracellular miRNAs.435 
 
miRNAs can also be stabilised extracellularly by AGO proteins that form part of the RISC. 
This novel idea was only recently discovered, with the first identification by two groups in 
2011.399,436 One group suggested that only 10% of extracellular miRNA is encapsulated in 
vesicles, with 90% bound to protein complexes. They theorised that it might be possible for 
cells to release a functional RISC into the extracellular environment.436 Cell-free miRNAs 
have been identified as preferentially bound to AGO1 or AGO2 in both plasma399,437 and 
urine.438 There have not been any studies investigating the functional relevance of this and 
how it relates to disease states, but it is likely AGO-bound proteins will turn out to be 
important in pathologies now that they have been identified as highly abundant in 
biological fluids.437 
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1.4.6.2 In biological fluids 
As discussed above, miRNAs can be stabilised outside cells by multiple different complexes. 
The use of these extracellular miRNAs as biomarkers has been explored extensively in many 
different biological fluids, including tears, saliva, cerebrospinal fluid, serum, plasma, 
amniotic fluid, urine and bronchial lavage.388,389 Discussed below are some examples of the 
use of extracellular miRNAs as biomarkers in blood (plasma, serum and whole blood) and 
PD effluent, as well as those of relevance in infections. 
 
1.4.6.2.1 Circulating blood-based miRNAs 
miRNAs have been identified in both serum and plasma, as well as in whole blood, in many 
different pathologies. miRNAs are a very good potential circulating biomarker due to their 
ability to be detected in samples that are routinely taken (i.e. minimally invasive), they can 
arise from either cell death or be actively secreted by live cells, they can be highly tissue- 
or disease-specific, they are highly stable extracellularly, and can easily be quantified.439 
The main body of work on circulating miRNAs has been conducted in cancer, suggesting 
they are relevant biomarkers for diagnosis and progression of different forms of cancer 
including breast, gastric, colorectal, hepatocellular, pancreatic, lung, cervical and prostate 
cancers.440,441 These reviews summarise what is currently known in terms of miRNAs 
altered in multiple cancers, but there is also a substantial body of work looking at circulating 
miRNAs in other diseases. For example, circulating placenta-specific miRNAs can be used 
to identify pregnancy,396 a range of inflammatory miRNAs can be indicative of type 2 
diabetes,398 and inflammatory miRNAs or miRNAs specific to cardiac tissues present in the 
circulation can suggest a cardiovascular disease diagnosis.439 
 
1.4.6.2.2 PD Effluent 
As already noted above, miRNAs are stable in most biological fluids, which includes PD 
effluent. This fluid is another easily accessible source of biomarkers, which can be used to 
assess the effectiveness of dialysis or potential reasons for a lack of efficacy such as fibrosis. 
As mentioned above, miRNAs have been identified as markers of fibrosis in the peritoneal 
membrane, but they are also useful as soluble biomarkers in PD effluent. The published 
work on this subject has so far only looked at whether miRNAs can be biomarkers for 
fibrosis of the peritoneal membrane, to prevent effective dialysis. Multiple miRNAs, 
including miR-21, miR-129 and miR-589, have been identified as important indicators of 
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peritoneal membrane transport characteristics or EMT.317,326,327,442 Animal models have 
shown how merely the injection of PD fluid into the peritoneum of a mouse or rat alters 
the miRNA profile, due to changes in the peritoneal membrane.328,443 Although no work 
has yet looked at miRNAs as biomarkers of infection in PD effluent, it is thought they will 
be useful biomarkers due to their role as cell-free biomarkers in other infectious diseases. 
 
1.4.6.3 Infection 
It is already known that miRNAs have an important role in the immune response, as 
discussed above, therefore their usefulness as circulating biomarkers in infection has been 
evaluated in viral, bacterial and parasitic infections. For example, a range of miRNAs have 
been shown to be either up- and down-regulated in patients with HIV infection.394,444 M. 
tuberculosis infection also results in altered circulating miRNA levels, with some miRNAs 
able to distinguish active from latent tuberculosis.394,445,446 miRNAs can also be effective 
biomarkers for diagnosis of malaria, caused by the Plasmodium parasites, as well as 
identifying more severe disease progression.447,448 The use of miRNAs in diagnosing 
infectious diseases has been shown to be useful in distinguishing spontaneous bacterial 
peritonitis episodes in patients with peritoneal ascites,449 showing the potential usefulness 
of these stable biomarkers in positively identifying an infection at the site of infection, as 
opposed to other inflammatory conditions. This suggests that miRNAs could be useful to 
distinguish an infection in PD, but this has yet to be evaluated. 
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1.5 Hypothesis and aims 
 
Hypothesis 
 
miRNAs are altered in acute PD-related peritonitis episodes, are biomarkers of infection, 
and play a functional role in modulating the immune responses to different pathogens. 
 
Aims 
 
The main aim of this study was to define the diagnostic and functional role of local miRNAs 
in PD effluent from patients with acute peritonitis. 
 
To achieve this aim, the following objectives were defined: 
 
• To characterise the miRNA alterations in well-defined acute PD-related peritonitis 
episodes and investigate candidate miRNA biomarkers in a patient cohort 
• To characterise the cellular source of candidate miRNAs 
• To identify potential mRNA targets for the candidate miRNAs 
• To characterise the stabilisation of miRNAs in PD effluent from peritonitis patients 
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2 Materials and Methods 
2.1 Ethic statement 
Recruitment of PD patients and healthy volunteers for this study was approved by the 
South East Wales Local Ethics Committee under reference numbers 04WSE04/27 and 
08/WSE04/17, respectively. It was conducted according to the principles expressed in the 
Declaration of Helsinki. All individuals provided written informed consent. The PD study 
was registered on the UK Clinical Research Network Study Portfolio under reference 
numbers #11838 "Patient immune responses to infection in Peritoneal Dialysis" (PERIT- PD) 
and #11839 "Leukocyte phenotype and function in Peritoneal Dialysis" (LEUK-PD). Fresh 
omentum samples from consented patients were obtained from the Wales Kidney 
Research Tissue Bank. 
 
2.2 Patient info and data collections 
The local study cohort comprised 131 adult PD patients admitted to the University Hospital 
of Wales (UHW), Cardiff, on day 1 of acute peritonitis between September 2008 and 
October 2018, as well as a limited number of samples from days 2-7 of infections. 20 stable 
individuals receiving PD for at least 3 months and with no previous infections (or at least 3 
months since previous infection) served as stable, non-infected control samples. Subjects 
known to be positive for HIV or HCV were excluded. Clinical diagnosis of acute peritonitis 
was based on the presence of abdominal pain and cloudy peritoneal effluent with >100 
white blood cells/mm3. According to the microbiological analysis of the effluent by the 
routine Microbiology Laboratory, Public Health Wales, episodes of peritonitis were defined 
as culture-negative (with unclear aetiology) or as confirmed bacterial infections caused by 
specific subgroups of Gram-positive and Gram-negative organisms. Cases of fungal 
infection and mixed or unclear culture results were excluded from this analysis. All patient 
sub cohorts described were selected from this full cohort. 
 
2.3 Cell isolation and culture 
2.3.1 Human peritoneal mesothelial cells and peritoneal fibroblasts  
Human peritoneal mesothelial cells (HPMCs) and human peritoneal fibroblasts (HPFBs) 
were isolated from omental tissue of non-PD, consented patients undergoing abdominal 
surgery. Shortly after collection from surgery, tissue was stored in a sterile plastic container 
with PBS and incubated at 4°C until tissue dissection. Omental tissue was subjected to 2 
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digestion cycles with 0.05% trypsin-EDTA solution (Invitrogen, T4174). Precisely, the tissue 
was washed with PBS in a Petri dish, to remove blood and other excessive fat, and cut into 
small pieces (depending on the tissue size). Each piece was then dissociated in a universal 
tube with 10 ml 0.05% trypsin-EDTA solution and positioned on a rotating wheel at 37°C 
for 15 min. Dissociated cells were pelleted by centrifugation at 250 g for 6 min at 20°C and 
supernatant was then carefully removed. The cell pellet was re-suspended and washed 
with 20 ml of complete M-199 medium (HPMCs) or complete Ham’s F12/DMEM medium 
(HPFBs) by centrifuging at 250 g for 6 min at 20°C. Washed cells were re-suspended in 5 ml 
of fresh complete medium and transferred into T25 flask (Nunc, Thermo Scientific) 
(passage number 0) for further growth and expansion in culture. HPMCs and HPFBs were 
maintained at 37°C in a humidified incubator with 5% CO2. Cells were harvested and 
transferred to T75 flask when the cultures reached confluency (≥80%) (passage 1). Prior to 
treatment, the growth of HPMCs was arrested by changing complete medium to M-199 
medium with 0.1% foetal calf serum (FCS) (HPMCs) or Ham’s F12/DMEM medium with 0.2% 
FCS (HPFBs) for 24 h. All the subsequent functional experiments were performed with the 
use of HPMCs or HPFBs expanded within 2 passages. 
 
For HPMCs and MeT-5A cell line, medium 199 (Life Technologies) was supplemented with 
penicillin (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM) and 10% FCS from 
Invitrogen; and bovine pancreas insulin (5 µg/ml), hydrocortisone (0.4 µg/mL) and apo- 
transferrin (5 µg/ml) from Sigma-Aldrich. 
 
For HPFBs, Ham’s F12 nutrient mixture medium (Life Technologies) was mixed at a 1:1 ratio 
with DMEM medium and supplemented with penicillin (100 U/ml), streptomycin (100 
µg/ml), L-glutamine (2 mM), 20% FCS and 100 µM NEAA from Invitrogen; and bovine 
pancreas insulin (5 µg/ml), hydrocortisone (0.4 μg/ml) and apo-transferrin (5 µg/ml) from 
Sigma-Aldrich. 
 
2.3.2 Peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood, collected 
from consented heathy volunteers. At the time of the collection, blood was mixed with 
anti-coagulant buffer made of 20 U/ml heparin and 15 mM EDTA (Fisher Scientific UK Ltd). 
Diluted blood was subsequently layered on top of Ficoll-Paque (Axis-Shield, 1114544) and 
centrifuged for 20 min at 500 g at 18°C with minimal acceleration and deceleration at 
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lowest level. Afterwards, the white mononuclear cell layer (buffy coat) between the plasma 
and red blood cells (RBCs) was collected and washed with serum-free RPMI.  
 
2.3.3 Peripheral blood monocytes 
Monocytes were isolated by magnetic activated cell sorting (MACS) from PBMCs. To block 
non-specific binding of monoclonal antibodies to Fc receptors, PBMCs were firstly 
incubated with human IgG (FcR blocking reagent, Miltenyi, 120-000-442) in MACS buffer at 
4°C for 5 min, then incubated with anti-CD14 microbeads (Miltenyi, 120-000-305) at 4°C 
for 10 min. Monocytes were then positively selected by passing through two LS columns 
(Miltenyi, 130-042-201) to obtain purities of >95% CD14+ monocytes (as determined by 
flow cytometry). 
 
To prepare MACS buffer, 2% FCS (Invitrogen) and 5 mM EDTA were added to sterile PBS 
and passed through 0.22 µm filter before use. 
 
2.3.4 Peripheral blood neutrophils 
PMN neutrophils were isolated from venous blood collected from consented healthy 
volunteers. At the time of collection, EDTA was added as an anti-coagulant. Blood was then 
layered on top of Ficoll-Paque Plus (GE Healthcare, 17-1440-02) and centrifuged for 30 min 
at 470 g at room temperature with minimal acceleration and no brake. The PMN and RBC 
layer was then washed with sterile PBS. Erythrocyte contamination was reduced by RBC 
precipitation (by 4% Dextran in PBS) and hypotonic lysis (by 10 mM NaCl). After washing, 
high purity PMNs were isolated by negative magnetic separation using EasySep Human 
Neutrophil Enrichment Kit (StemCell Technologies, 19257) for PMNs. After washing and 
resuspension in culture medium, purity was measured by flow cytometry, with purities 
>99.5% CD15+ neutrophils achieved (with <0.5% contamination of CD14+ monocytes). 
 
For isolated monocytes and neutrophils, complete RPMI 1640 medium used in cell culture 
was made by adding 10% FCS (Invitrogen), 50 µg/ml penicillin/streptomycin, 2 mM L-
glutamine, 1% sodium pyruvate and 100 µM non-essential amino acids (NEAA) into RPMI-
1640; all from Invitrogen. 
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2.3.5 MeT-5A cell line 
MeT-5A, a human epithelial cell line, was purchased from the American Type Culture 
Collection (ATCC). MeT-5A cells were cultured in complete M-199 medium as described for 
HPMCs above. 
 
2.3.6 Long-term cell storage 
To store cells at -70oC in Cryo Tubes after cell isolation, cells were quickly re- suspended in 
complete medium supplemented with 40% FCS (Invitrogen) and 10% DMSO. 
 
2.4 In vitro cell stimulation 
2.4.1 HPMCs and HPFBs 
HPMCs and HPFBs were cultured until confluent in a T25 flask then a T75 flask, before 
transfer to a 12-well plate (Nunc), with all treatments conducted in serum-reduced media 
(after 24 h serum-starvation) before cells reached passage 3. Cells were incubated with 
bacterial extracts (E. coli and S. epidermidis) at final protein concentrations of 50 μg/ml, 
and with PAM3 (Pam(3) CSK(4), EMC microcollections, L2000) and LPS (ultrapure from E. 
coli serotype, Enzo life sciences, O1111:B4) at a final concentration of 500 ng/ml, overnight 
at 37°C. Following incubation, supernatants were frozen at −80°C and cells were lysed using 
TRIzol (500 μl per well) then frozen at −80°C, before RNA extraction as described below. 
 
2.4.2 Monocytes 
5 × 105 primary monocytes per well were stimulated with bacterial extracts (E. coli and S. 
epidermidis, at final concentration of 50 μg/ml), PAM3 or LPS (at final concentrations of 
500 ng/ml) in 24-well plates (Nunc) for 4 h or overnight at 37°C. Following incubation, 
supernatants were frozen at −80°C, and cells were lysed using TRIzol (250 μl per well) then 
frozen at −80°C, both stored for RNA extraction as described below. 
 
2.4.3 Neutrophils 
Primary neutrophils were plated at a concentration of 5 × 106 PMN/ml in a 12-well plate 
(Nunc). After resting for 20 min, they were stimulated with bacterial extracts (E. coli and S. 
epidermidis, at final concentration of 50 μg/ml), PAM3 or LPS (at final concentrations of 
500 ng/ml) for 4 h at 37°C. Following incubation, supernatants were frozen at −80°C, and 
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cells were lysed using TRIzol (500 µl/well) or RLT buffer (600 μl for >106 cells, 350 μl for 
<106 cells) then frozen at −80°C for RNA extraction as described below. 
 
2.4.3.1 Conditioned media (CoM) generation 
After isolation and stimulation of PMNs for 4 h with 500 ng/ml LPS as above, CoM was 
generated by removing the cells by centrifugation at 300 g for 10 min at 4°C. This was 
stored at −80°C until use. 
 
2.5 Cell viability assays 
2.5.1 Lactate dehydrogenase (LDH) assay 
LDH release was used as a measure of cell viability, proportional to total cell lysis, using the 
CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, G1782). 45 min prior to 
supernatant harvesting, 10 μl of Lysis solution (10×) was added for every 100 μl of target 
cells added as a maximum lysis control. Supernatant was removed from each well of the 
culture plate. In the case of non-adherent cells (i.e. PMNs and monocytes), media was 
centrifuged at 500 g for 5 min. 50 μl of supernatant was put into a fresh clear 96-well plate 
and 50 μl of CytoTox 96® Reagent was added to each well. The plate was incubated in the 
dark for 30 min at room temperature. 50 μl of Stop Solution was then added to each well, 
and the absorbance was measured at 490 nm within 1 h. Cytotoxicity was calculated as a 
percentage of the maximum lysis control. 
 
2.5.2 AlamarBlue assay 
AlamarBlue assay was used for examination of relative cell number and/or viability. This 
method employs a non-toxic, cell permeable, blue and non-fluorescent dye, resazurin, 
converted to the pink and fluorescent dye, resorufin, in response to metabolic activity of 
cultured cells. The fluorescent and colorimetric signal is proportional to the number of 
living cells in the sample. To perform the assay, cells were incubated for 1 h in new culture 
medium without serum at 37°C and 10% (v/v) AlamarBlue reagent (Bio-Rad, BUF012B). The 
medium was then transferred to a black 96 well plate (100 μl/well) and the fluorescent 
signal was monitored using 544 nm excitation wavelength and 590 nm emission 
wavelength. Medium with 10% (v/v) AlamarBlue reagent was kept in the incubator for one 
hour before the measurement to use as a blank. 
 
 65 
2.6 Flow cytometry 
Flow cytometry was used to assess the purity of isolated cells and expression of activation 
markers on their surface. Cells were firstly washed with PBS and then stained with 
Live/dead fixable Aqua dead cell stain kit (Life Technologies, L34957) for 12 min at RT. 
Subsequently, cells were washed with fluorescently activated cell sorting (FACS) buffer, 
centrifuged at 450 g for 3 min and incubated with IvIg (Kiovig; Baxter) at 1:1000 dilution 
for 10 min at 4°C to block non-specific binding of antibodies to Fc receptors . To stain for 
cell-surface markers, cells were incubated with a cocktail of monoclonal antibodies 
conjugated with different fluorochromes (Table 2.1) at 4°C for 30 min. Cells were then 
washed with FACS buffer and fixed using 2% formaldehyde for 10 min at 4°C. After a final 
wash with FACS buffer, results were acquired using BD FACSCanto II or LSR Fortessa (BD 
Biosciences). All analysis was performed using FlowJo (version 10.4; TreeStar Inc.) and the 
cells of interest were gated based on the appearance on side scatter and forward scatter 
area/high (SSC-A/FSC-A) for intact cells, forward scatter area/high (FSC-A/FSC-H) for single 
cells and live-dead/FSC-A for live cells. Monocytes were defined as CD14+ live cells. PMNs 
were defined as CD15+ live cells, with activated PMNs defined as CD15+, CD11bhigh and 
CD62L−. 
 
To prepare FACS buffer, 2% FCS (Invitrogen) were added into sterile PBS and passed 
through 0.22 µm filter before use. 
 
2.7 Bacterial culture and lysis 
Clinical bacterial isolates were kindly provided by Dr Mark Toleman, Division of Infection 
and Immunity, Cardiff University. These isolates were chosen based on the most common 
Gram-positive and Gram-negative causative pathogens in PD-related peritonitis episodes 
encountered at UHW, Cardiff (Staphylococcus epidermidis and Escherichia coli 
respectively). Bacteria stored at −70°C in cryotubes with cryogenic medium (sterile PBS 
supplemented with sucrose, glycerol and peptone) were inoculated onto Colorex urinary 
tract infections (UTI) agar plate (E&O Laboratories Ltd, PP3000) and incubated aerobically 
for 24 h at 37°C. The following day, the growth of a single species was confirmed by the 
presence of uniform colonies with the same colour. Bacteria were transferred to 20 ml 
Luria Broth (LB, tryptone, yeast extract and NaCl) in a universal tube and incubated for 2.5 
h at 37°C with shaking to facilitate bacterial division. Bacteria were harvested when the  
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Marker Fluorophore Company Catalogue number Clone 
CD15 BV605 Biolegend 323032 W6D3 
CD62L PE-Cy5 BD 555545 DREG-56 
CD11b BV421 Biolegend 301323 ICRF44 
CD14 FITC BD 555397 M5E2 
CD14 PE-Cy7 Biolegend 301813 M5E2 
 
Table 2.1: Antibodies used for flow cytometry analysis of purity and activation of 
primary cells. 
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culture reached an optical density of 0.5-0.8 at a wavelength of 600 nm (OD600). Each tube 
was subsequently centrifuged at 3,600 rpm for 1 h and the bacterial pellet re-suspended in 
1 ml of sterile PBS before sonication. The bacterial suspensions were kept on ice during 
sonication, using a Soniprep 150 sonicator for 10 min with 10 sec on and 20 sec off cycles. 
Bacterial extracts were then transferred to Eppendorf tubes and centrifuged at 20,000 g to 
pellet cell debris. Collected supernatant was passed through Ultrafree-MC centrifugal 
filters (Durapore PVDF 0.1 μm, Millipore, UFC40VV25) and centrifuged for 10 min at 10,000 
g, at 4°C, to remove larger aggregates. At this point a small aliquot was obtained to 
measure the protein concentration with BCA Protein Assay Kit (Pierce, Thermo Fisher 
Scientific, 23225), following manufacturer’s protocol. Bacterial extracts were then stored 
at –20°C.  
 
2.8 In vivo model 
Samples for in vivo experiments were kindly provided by Dr Ann-Catherine Raby, generated 
as described previously.450 Briefly, 8-12-week-old inbred C57BL/6 mice (Charles River) were 
injected intraperitoneally with PBS (500 μl) or E. coli (ATCC 25923 strain, 2 x 107 CFU per 
mouse). At indicated time points, the mice were sacrificed, and their peritoneal cavities 
were lavaged with 2 ml of ice-cold PBS. All experimental procedures were performed under 
a Home Office project license. 
 
2.9 RNA extraction 
2.9.1 Cell-free liquid samples 
RNA was extracted from cell-free PD effluent, supernatant of cultured cells, peritoneal 
lavages from mice and all other cell-free liquid samples using the mirVanaTM PARISTM and 
Native protein purification kit (Life Technologies, AM1556), using the protocol to enrich for 
small RNAs. Samples were rendered cell-free, as in the Human Tissue Authority (HTA) 
guidelines. 500 µl of sample was mixed with an equal volume of the 2× denaturing solution 
at room temperature. 100 pM of Caenorhabditis elegans miR-39 (cel-miR-39; Life 
Technologies, MC10956) was spiked into each sample. 1 ml of Acid-Phenol Chloroform was 
then added, thoroughly mixed and centrifuged at maximum speed (20,000 g) to separate 
the mixture into aqueous and organic phases. The aqueous phase was then transferred to 
a separate tube and 1/3 volume of 100% ethanol was added and mixed thoroughly. For PD 
effluent samples only, a second separation was performed by adding nuclease-free water 
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to the original tube to replenish the aqueous phase removed, mixing thoroughly and 
separating by centrifugation at 20,000 g or 15 min. This aqueous phase was also transferred 
to a separate tube and 1/3 volume of 100% ethanol was added and mixed thoroughly. For 
all samples, this mixture was then passed through a filter cartridge, with the flow-through 
discarded. The filter cartridge was washed with 700 μl of miRNA Wash Solution 1 and 500 
μl of Wash Solution 2/3 twice, with the flow-through discarded after each wash. The RNA 
was eluted into a fresh collection tube by adding 90 μl of nuclease-free water, pre-heated 
to 95°C, to the centre of the filter cartridge. After incubating at room temperature for 5 
min, this was centrifuged and the flow-through was stored at −80°C. 
 
2.9.2 Cultured cells using TRIzolTM 
RNA was extracted from cells cultured in standard tissue culture plates using TRIzolTM 
Reagent (Invitrogen, 15596018). Supernatant of cells was removed, and RNA extracted 
from these liquid samples as above. Sufficient TRIzol was added to the sample to lyse all 
cells present, as in the manufacturer’s protocol. For example, 500 μl of TRIzol was added 
per well of a 12-well plate and 1 ml was added per 5-10 × 106 cells in samples from PD 
effluent or cells in suspension. This lysate was then transferred to a tube and left at room 
temperature for 5 min to permit complete dissociation of the nucleoproteins complex. 200 
μl of chloroform was added per 1 ml of TRIzol used, mixed well and incubated for 2-3 min. 
This was then centrifuged for 15 min at 4°C and 12,000 g, to separate the phases, and the 
aqueous phase was carefully transferred to a new tube. To precipitate the RNA, 500 μl of 
isopropanol was added to the aqueous phase per 1 ml of TRIzol reagent used for 
homogenisation, then left at room temperature for 10 min. This was centrifuged for 10 min 
at maximum speed (20,000 g), at 4°C to form a small white pellet containing the RNA. 
Supernatant was carefully removed, and the pellet was washed three times with 1 ml of 
75% ethanol, where the pellet was re-suspended then centrifuged at maximum speed for 
5 min at 4°C, with the supernatant discarded after each wash. The pellet was then air dried 
for 30-45 min and re-suspended in 10 μl of nuclease-free water. RNA yield was determined 
using a NanoDrop 2000 Spectrophotometer. 1 μl of RNA was measured for absorbance at 
230 nm, 260 nm and 280 nm, with concentrations given used to determine the amount of 
RNA to add into RT reactions. RNA was stored at −80°C until use. 
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2.9.3 Cultured cells using RNeasy Mini kit 
RNA was extracted from cells cultured in standard tissue culture plates using an RNeasy kit 
(Qiagen, 74034). Supernatant of cells was removed, and RNA extracted as above. 350 µl of 
RLT buffer was added for <106 cells (600 µl for >106 cells), left for 1-2 min, then pipetted up 
and down several times. This lysate was transferred to a tube and homogenised by passage 
through a 29-gauge needle, attached to a plastic syringe, 5-10 times. Homogenate was 
transferred to a genomic DNA (gDNA) Eliminator spin column and centrifuged, the flow-
through was retained and transferred to a new tube. 1.5x volume 100% ethanol was added 
(i.e. 900 µl if 600 µl lysis buffer used) and mixed well. This mixture was then passed through 
an RNeasy Mini spin column, with the flow-through discarded. The spin column membrane 
was washed three times with 500 µl of Buffer RPE, discarding the flow-through each time. 
The spin column was dried by another centrifugation step, then placed in a fresh collection 
tube. 30 µl of RNase-free water was used to elute the RNA. RNA yield was determined by 
NanoDrop 2000 Spectrophotometer. RNA was stored at -80°C until use. 
 
2.10 TaqMan Low density array (TLDA) 
2.10.1 Reverse transcription  
RNA was reverse-transcribed to complementary DNA (cDNA) using the MegaplexTM RT Kit 
(Life Technologies, 4366596 and 4401009). The RT master mix included: MegaplexTM RT 
Primers, dNTPs with dTTP, MultiScribeTM Reverse Transcriptase, RT buffer, MgCl2, RNase 
inhibitor and nuclease-free water. 4.5 μl of the RT master mix and 3 μl of total RNA were 
added to individual tubes in a MicroAmp® 8-Tube Strip. The amplifications were carried out 
with 40 cycles of 2 min at 16°C, 1 min at 42°C and 1 sec at 50°C, followed by 5 min at 85°C 
and a cooling step at 4°C. 
 
2.10.2 Pre-amplification 
cDNA was amplified before the PCR reaction using the TaqMan PreAmp Kit (Life 
Technologies, 4391128). The master mix included: TaqMan® PreAmp Master Mix, 
MultiplexTM PreAmp Primers and nuclease-free water. 2.5 μl of each RT product and 22.5 
μl of PreAmp master mix were added to individual tubes in a MicroAmp® 8-Tube Strip. The 
amplifications were carried out for 10 min at 95°C, 2 min at 55°C and 2 min at 72°C, 
followed by 12 cycles of 15 sec at 95°C and 4 min at 60°C, an enzyme inactivation step of 
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10 min at 99.9°C and a cooling step at 4°C. Product was diluted with 75 μl of nuclease-free 
water per tube. 
 
2.10.3 Quantitative PCR (qPCR) 
cDNA was detected using a pre-loaded 384-well plate-based microRNA array (Life 
Technologies, 4398965). 9 μl of diluted preAmp product was combined with TaqMan® 
Universal PCR Master Mix, No AmpErase® UNG, 2× (Life Technologies, 4440040) and 
nuclease-free water, then loaded into the ports in the array. After centrifugation to 
distribute into the individual wells, this was run on a ViiA 7 real-time PCR system (Life 
Technologies) using the 384 well TaqMan Low Density Array default thermal-cycling 
conditions. The comparative 2−∆∆Ct method was used to calculate sample-specific threshold 
cycle (Ct), using the RQ (relative quantification) software provided on the Thermo Fisher 
Cloud (https://apps.thermofisher.com/apps/dashboard/). The expression of target genes 
was normalized to the global expression of all targets across the plate, using standard 
settings in the Thermo Fisher software. 
 
2.11 RT-qPCR of individual samples 
2.11.1 Reverse transcription 
RNA was reverse-transcribed to cDNA using High-Capacity cDNA Reverse Transcription Kit 
(Life Technologies, 4368813). The RT master mix included: RT buffer, dNTPs, MultiScribe 
Reverse Transcriptase (all Life Technologies) and RNase inhibitor (New England BioLabs® 
Inc, M0307). miRNA-specific primers (Life Technologies, see table 2.2 for details) were also 
added to the master mix. 
 
High-Capacity cDNA Reverse Transcription Kit (Life Technologies) was used, containing RT 
master mix made of nuclease-free water, 10X RT buffer, 100 mM dNTPs, 50 U/μl 
MultiScribe Reverse Transcriptase, 10X RT random primers (all Life Technologies) and 40 
U/μl RNase inhibitor (New England BioLabs ® Inc), Quantitative PCR was performed using 
TaqMan® Universal Master Mix II, no UNG, with specific TaqMan primers (all Life 
Technologies). The volume of RNA and RT master mix varied dependent on the sample type 
and extraction method, as detailed in Table 2.3. 
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miRNA  Catalogue number 
hsa-miR-191-5p Part number 4427975 Assay ID 002299 
hsa-miR-16-5p Part number 4427975 Assay ID 000391 
sno-135 Part number 4427975 Assay ID 001230 
snRNA U6 Part number 4427975 Assay ID 001973 
hsa-miR-223-3p Part number 4427975 Assay ID 002295 
hsa-miR-139-5p Part number 4427975 Assay ID 002289 
hsa-miR-197-3p Part number 4427975 Assay ID 000497 
hsa-miR-25-3p Part number 4427975 Assay ID 000403 
hsa-miR-27a-3p Part number 4427975 Assay ID 000408 
hsa-miR-203a-3p Part number 4427975 Assay ID 000507 
hsa-miR-21-5p Part number 4427975 Assay ID 000397 
hsa-miR-31-5p Part number 4427975 Assay ID 002279 
hsa-miR-199a-3p Part number 4427975 Assay ID 002304 
hsa-miR-100-5p Part number 4427975 Assay ID 000437 
hsa-miR-99a-5p Part number 4427975 Assay ID 000435 
mmu-miR-31-5p Part number 4427975 Assay ID 000185 
cel-miR-39-3p Part number 4427975 Assay ID 000200 
 
Table 2.2: Product codes for TaqMan miRNA assays used in RT-qPCR. 
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Sample Cell-free liquid Cells (cultured or from PD effluent) 
Extraction method mirVanaTM PARISTM 
kit for small RNAs 
TRIzolTM reagent RNeasy Mini kit 
Vol of RNA added to RT 9.26 μl 5 μl (plus 4.26 μl 
water) 
5 μl (plus 4.26 μl 
water) 
Concentration of RNA 
added to RT 
Unknown 2 ng/μl 2 ng/μl 
Vol of RT Master mix 5.74 μl 10 μl 10 μl 
 
Table 2.3: Volumes of RNA and RT master mix to add to MicroAmp® 8-Tube Strip for 
reverse transcription reaction. 
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The amplifications were carried out with thermal cycling of 10 min at 25°C, 2 h at 37°C and 
5 sec at 85°C, followed by a cooling step at 4°C. Generated cDNA was diluted with 30 μl 
water prior to use as a template for qPCR. 
 
2.11.2 Quantitative PCR 
miRNA qPCR was carried out by mixing 10 μl of TaqMan 2× Universal PCR Master Mix, No 
AmpErase UNG (Life Technologies, 4440040) with 1 μl specific PCR primers (all Life 
Technologies, see table 2.2 for details). 11 μl of miRNA specific master mix was added to 9 
μl of diluted cDNA (for cell-free samples) or 4 μl cDNA further diluted with 5 μl water (for 
samples with cells). This was then plated in an Optical 96-Well Fast Plate (Life 
Technologies). The reaction was performed on ViiA7 Real-Time PCR System (Life 
Technologies) and the cycling parameters were: hold for 10 min at 95°C, 40 cycles of 15 sec 
at 95°C (denature step) and 1 min at 60°C (anneal/extend steps). Ct values were calculated 
as the cycle number when the threshold was reached. The expression of target genes was 
normalized to the expression of small nuclear RNA U6 (snRNA U6) endogenous control and 
a control sample via the comparative 2-∆∆Ct method to give sample-specific relative 
quantification values, or represented as 40-Ct (40 minus the raw Ct value) as appropriate. 
 
2.12 Extracellular vesicle (EV) characterisation 
2.12.1 Differential centrifugation for isolation of EVs 
Samples were cleared of live cells and cell debris with preliminary centrifugation steps at 
300 g and 2000 g respectively, both for 10 min at 4°C. The supernatant from these steps 
was then centrifuged at 10,000 g for 1hr, at 4°C to isolate larger EVs. Ultracentrifugation of 
the resulting supernatant at 100,000 g for 1hr, at 4°C isolated smaller EVs. For RNA 
extraction and miR-223 detection, 5 ml was used for each centrifugation step and each 
pellet (except the initial cell pellet, which was lysed with TRIzol and extracted as above for 
cell-based samples) was resuspended in 500 μl of endotoxin-free PBS (Sigma Aldrich, TMS-
012), with a 500 μl aliquot of each supernatant also taken for RNA extraction. Extraction 
was performed as above for cell-free liquid samples. 
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2.12.2 RNase and proteinase treatments 
500 μl aliquots of samples were all treated with 100 pM of Caenorhabditis elegans miR-39, 
then treated as required with either RNase A, proteinase K or both. RNase A (Life 
Technologies (Ambion) AM2272 or EN0531) was used at a concentration of 0.1 mg/ml, at 
37°C for 30 min. Proteinase K (P-2308, Sigma-Aldrich) was used at 50 µg/ml, at 55°C for 
30min. Samples were also treated with RNase A followed by proteinase K, and the reverse, 
as well as temperature controls. This protocol was optimised and described in detail 
previously.438 
 
2.12.3 Size-exclusion chromatography 
Pre-packed size exclusion columns (Cell GS, Exo-SpinTM, EXO4-20) were washed with 6 mM 
EDTA in PBS, then 2 ml of samples were added, and 15 × 1 ml aliquots were collected. RNA 
was extracted from 500 μl of each aliquot as above (for cell-free liquid samples). The 
remainder was used for the plate-based immuno-assays to detect relevant tetraspanin 
markers and CD15 (PMN surface marker). 
 
2.12.4 Plate-based immuno-assay 
500 μl of column fractions were diluted 1:1 with 6mM EDTA in PBS, then bound to protein-
binding ELISA plates in duplicate (100 μl per well, Greiner Bio-One, 756071). After overnight 
coupling and then blocking (with 1% (w/v) BSA in PBS for 2 h at room temperature), the 
bound material were labelled with primary antibodies against proteins including CD9 (R&D 
systems, JOK0713081), CD81 (Bio-Rad, MCA1847EL) and CD15 (BD Biosciences, 557895) or 
HSA (human serum albumin) (250 ng/ml) (R&D systems, MAB1455) for 2 h at room 
temperature on a plate shaker.  After three washes, goat anti-mouse-biotinylated antibody 
(Perkin Elmer, NEF823001EA), diluted 1:2500, was added for 1.5 h. After three washes, 
Europium-conjugated streptavidin (Perkin Elmer, 1244-360) was added for 45 min. After a 
final six washes, a signal was obtained using time-resolved fluorometry (TRF), measured 
using a Wallac Victor-II multi-label plate reader (Perkin Elmer). 
 
2.13 miR-223 reporter assay 
The luciferase-based reporter assay for miR-223 uptake was generated as shown in the 
schematic diagram in Figure 2.1 and detailed below. 
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Figure 2.1: Schematic diagram of miR-223 reporter assay generation. 
  
pGL3 control plasmid
pGL3 control plasmid linearisation
Cloning in artificial 3’ UTR
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Positive colony selection Colony PCR
MiniprepSequencing and
sequence alignmentAlignment of Sequence_1:  [pGL3 miR-223 reporter seq] with  Sequence_2: [Clone 6] Similarity : 210/300 (70.00 %)
Seq_1  1     GGAAAACTCGACGCAAGAAAAATCAGAGAGATCCTCATAAAGGCCAAGAAGGGCGGAAAG  60
                                                      |||||||||||||||||||
Seq_2  210   -----------------------------------------GGCCAAGAAGGGCGGAAAG  192
Seq_1  61    ATCGCCGTGTAATTCTAGATCGtggggtatttgacaaactgacaATCGtggggtatttga  120
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  191   ATCGCCGTGTAATTCTAGATCGTGGGGTATTTGACAAACTGACAATCGTGGGGTATTTGA  132
Seq_1  121   caaactgacaATCGtggggtatttgacaaactgacaCCGGTAATtggggtatttgacaaa  180
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  131   CAAACTGACAATCGTGGGGTATTTGACAAACTGACACCGGTAATTGGGGTATTTGACAAA  72
Seq_1  181   ctgacaATCGtggggtatttgacaaactgacaATCGCTAGAGTCGGGGCGGCCGGCCGCT  240
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  71    CTGACAATCGTGGGGTATTTGACAAACTGACAATCGCTAGAGTCGGGGCGGCCGGCCGCT  12
Seq_1  241   TCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTG  300
             |||||||||||                                                 
Seq_2  11    TCGAGCAGACA-------------------------------------------------  1
Features [Seq_2]:
miR-223 binding site   : [40 : 61]
miR-223 binding site   : [66 : 87]
miR-223 binding site   : [96 : 117]
miR-223 binding site   : [122 : 143]
miR-223 binding site   : [148 : 169]
1
2
3
4
6 7
89
5
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2.13.1 Plasmid generation 
An artificial 3’UTR (3’ untranslated region) reporter was designed containing multiple 
perfect binding sites for miR-223-3p. The binding sites were separated by a spacer of 4bp. 
The 3’UTR reporter was cloned into the pGL3-Control vector using the In-Fusion HD cloning 
kit (Clontech, 638909) according to the manufacturer’s instructions.  The 3’UTR reporter 
was positioned immediately after the firefly luciferase coding sequence. 
 
First, the vector was linearised downstream of the firefly luciferase coding sequence using 
Xbal, a restriction endonuclease that recognises T^CTAGA sites and cuts leaving a 5’ 
overhang.  The restriction endonuclease digestion was performed at 37°C for 2 h in a block 
heater. The linerised vector was separated on a 1% agarose gel. A band corresponding to 
approx. 5.2kb was excised from the gel. The DNA was extracted and purified using a 
NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel, 740609) according to the 
manufacturer’s instructions. The eluted DNA was quantified by NanoDrop 2000 
spectrophotometer. 
 
Second, the 3’UTR reporter was contracted by annealing two pairs of overlapping 
oligonucleotides into two double stranded DNA fragments, which contained a 15bp 
overlapping sequence with the linearised plasmid. The overlapping oligonucleotides were 
annealed by heating to 90°C for 3 min then at 37°C for 15 min, before cooling on ice. The 
cloning reaction was performed by combining the annealed oligonucleotides (3ng) and 
linearised vector (100 ng) in a molar ratio of 3:1, along with 5X In-Fusion HD Enzyme Premix 
containing T4 DNA ligase (Clontech, 638909), adjusted to a final volume of 10 µl using 
molecular grade water. The cloning reaction was incubated at 50°C for 15 min, before 
cooling on ice. 
 
2.13.2 Bacterial transformation and selection of positive colonies by colony 
PCR 
The product of the cloning reaction was used for transformation of Stellar competent E. 
coli (Takara, 636763) by heat shock. Briefly, 1 µl of product was added to 50 µl Stellar E. 
coli cells and incubated on ice for 30 min. This mixture was then heated to 42°C for 45 sec 
(heat shock), followed immediately by recovery on ice. 450 µl of SOC medium was then 
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added, followed by incubation for 90 min at 37°C on a shaking platform. The bacterial 
culture was then plated out and grown on a 2x YT agar supplemented with 100 µg/ml 
ampicillin overnight at 37°C, to select positive colonies. The next day, 6 colonies were 
selected for colony PCR. Primers were designed to surround the insert: 
Colony PCR forward primer: CAAGAAGGGCGGAAAGATCG 
Colony PCR reverse primer: ACCACAACTAGAATGCAGTGA 
Colony PCR was conducted using OneTaq Quick load 2x mastermix with standard buffer, 
with the reaction size scaled down to 15 µl. PCR reactions were performed with an initial 
denaturation step of 94°C for 30 sec, followed by 25 cycles of 94°C for 30 sec, 46°C for 30 
sec and 68°C for 40 sec, with a final extension step of 68°C for 5 min then 4°C continuously. 
The final PCR product was analysed on a 1% agarose gel to confirm successful cloning of 
insert into vector. Successful cloning was distinguishable from the vector without an insert 
by different sized bands – 280bp for successful cloning versus 115bp for unsuccessful 
cloning. 3 of the 6 colonies selected showed correct sized bands. 
 
2.13.3 Purification of plasmid DNA and sequencing 
The positive colonies were grown up in 5 ml 2x YT broth supplemented with 100 µg/ml 
ampicillin overnight at 37°C on a shaking platform. The next day, 1.6 ml was mixed with 
400 µl glycerol to make a long-term bacterial stock, which was stored at -80°C. The 
remainder of the culture was used to purify plasmid DNA using the QIAprep Spin Miniprep 
Kit (Qiagen, NA0160), following the manufacturer’s instructions. The eluted plasmid DNA 
was quantified by NanoDrop 2000 spectrophotometer. The fidelity of the pGL3-miR-223 
3’UTR reporter insert was confirmed by Sanger sequencing (Eurofins MWG) using the 
colony PCR reverse primer. 
 
Stock quantities of plasmid DNA were prepared for pGL3-miR-223 3’UTR reporter, pGL3-
Control and pRL-SV40. pRL-SV40 expresses Renilla luciferase under the control of the 
strong, constitutive SV40 promoter. 100 µl of the bacteria stocks was added to 50 ml of 2x 
YT broth, supplemented with 100 µg/ml ampicillin, at 37°C overnight, on a shaking 
platform. The next day, bacteria were pelleted, and plasmid DNA extracted by Midiprep 
(Qiagen, NA0200), according to the manufacturer’s instructions. The eluted plasmid DNA 
was quantified by NanoDrop 2000 spectrophotometer. A working stock was kept at -20°C, 
whilst the main stock was stored at -80°C. 
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2.13.4 Transfections and treatments 
MeT-5A pleural mesothelial cells was grown to approximately 70% confluency in a 48-well 
plate, before transfection with the pGL3-miR-223 3’UTR reporter. This was co-transfected 
with a the pRL-SV40 plasmid in a ratio of 1:9 (pRL-SV40[renilla]:pGL3[firefly]), to act as a 
control for transfection efficiency. Lipofectamine LTX with PLUS reagent (Life Technologies, 
15338-100) was used according to the manufacturer’s protocol.  Briefly, 40 µl of Opti-
MEMTM (Gibco, 31985-070) was combined with 0.2 µl of PLUS reagent, 0.5 µl of LTX, 20 ng 
of pRL-SV40 and 180 ng of pGL3-miR-223 3’UTR reporter or pGL3-Control plasmid. The 
mixture was incubated at room temperature for 30 min then added to cells in serum-free 
media. 
 
After 24 h, the cells were treated with either conditioned media (CoM) from PMNs (as 
generated above), samples from differential centrifugation of PD effluent (as described 
above) or transfected with mirVana miRNA mimics as a control. Transfection of the small 
miRNA mimics was performed with lipofectamine RNAi max (Life Technologies, 13778-075) 
according to the manufacturer’s protocol. Briefly, 25 µl of Opti-MEMTM was combined with 
0.75 µl of RNAi Max and 0.25 µl of the miRNA mimic (equivalent to final concentration of 
10 ng, either miR-223-3p or a miR-Control mimic). This was added to each well alongside 
fresh serum-free media. After 48 h, the cells were lysed with passive lysis buffer from the 
luciferase kit used below (Promega, E1910) for assay of luciferase expression. 
 
2.13.5 Luciferase assay 
The activity of the firefly (Photinus pyralis) luciferase was used as an output for the reporter 
assay generated in this study. The co-transfection with a control plasmid containing the 
coding sequence for Renilla (Renilla reniformis) luciferase acts as a transfection efficiency 
control. The different origin, structure and substrate requirements allow discrimination 
between the bioluminescent reactions, using a Dual-Luciferase Reporter Assay System 
(Promega, E1910), in a single sample. 
 
Briefly, the transfected and treated cells were washed with PBS, incubated with 65 µl of 
Passive Lysis Buffer at 37°C for 15 min. 20 µl of cell lysate was transferred into a white 96-
well plate. 50 µl of Luciferase Assay Reagent II (LAR II, substrate for firefly luciferase) was 
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added prior to measurement of firefly luminescence on FLUOstar OPTIMA plate reader. 
Subsequently, 50 µl of Stop & Glo Reagent (quenches previous reaction and substrate for 
Renilla luciferase) was added, before measurement of Renilla luminescence 
(representative of transfection efficiency). The results were expressed as a relative ratio of 
Firefly:Renilla luminescence. 
 
2.14 Statistical analysis 
Statistical analyses were performed using Excel 2013 or GraphPad Prism 6.0. All variables 
were tested for normal distribution using D'Agostino & Pearson omnibus normality test. 
Comparison between two non-paired normal distributed groups (parametric) was 
performed by one-sample t test, whereas paired t test was used for matched data. For the 
data that did not pass the normality test (non-parametric), Wilcoxon test was performed 
for paired data and Mann-Whitney test was used for unpaired data. 
 
Comparison among three or more groups was performed with ordinary one way-ANOVA 
for unpaired parametric data, with repeated measure one-way ANOVA for paired 
parametric data. While the comparison between matched non-parametric groups was 
performed by Friedman test, Kruskal-Wallis test was used for the comparisons between 
unpaired non- parametric groups. Descriptive statistics were described as mean ± standard 
error of the mean (SEM) unless otherwise stated. 
 
All statistical tests were two-tailed; differences were considered statistically significant as 
indicated in the figures and tables: *, p<0.05; **, p<0.01; ***, p<0.001. 
 
2.15 In silico target prediction 
miRNA target prediction programs are routinely used to find miRNAs that may regulate 
genes of interest and/or to identify possible targets of specific miRNAs. Diana, miRanda - 
mirSVR, miRDB and TargetScan are between the algorithms most commonly used for 
predictions and were chosen to identify possible new targets of the miRNAs of interest. An 
actualized summary Table 2.4 is displayed below to compare these tools. The threshold 
used for each one of these algorithms and comparison was Diana = 0.9, miRanda – mirSVR 
= - 0.95, miRDB = 80 and TargetScan = - 0.24. The use of these tools as well as their quality 
and reliability will be further discussed in Chapter 5. 
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Criteria Diana miRanda miRDB TargetScan 
Seed match + + + + 
Conservation + + + + 
Free energy + + +  
Site accessibility + + +  
Target site 
abundance 
+    
Machine learning + + +  
References 451,452 453,454 455,456 457,458 
 
Table 2.4: Features of different target prediction algorithms 
Showing the main criteria used by the 4 target prediction algorithms utilised here to predict 
mRNA targets for specific miRs, adapted from459. 
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3 Identification of altered microRNAs in PD-related peritonitis 
3.1 Introduction 
PD, as a treatment for end stage renal disease, is an effective renal replacement therapy 
due to the ultrafiltration and osmosis of waste products and water across the semi-
permeable peritoneal membrane from the blood into the dialysis solution.2 However, the 
presence of a permanent catheter, used for the exchange of dialysis solutions, greatly 
increases the risk of peritoneal infections, primarily by bacteria. The accompanying 
inflammatory reaction by the body can be detrimental for the patient, and ultimately cause 
technique failure if it is not treated effectively and rapidly. Current methods of identifying 
the causative pathogen, through culturing the organism, take a couple of days, meaning 
the patient is exposed to an empirical first-line treatment of broad-spectrum antibiotics, 
which come with possible drug-related side effects and the potential for anti-microbial 
resistance to develop.78 Identification of the causative organism more rapidly is essential 
to be able to treat peritonitis episodes more accurately and rapidly, to enable the patient 
to remain on PD for a longer time, as the most convenient and cost-effective renal 
replacement therapy for many patients.122,222 
 
It has been previously shown that the specific immune response evoked at the site of 
infection (‘immune fingerprint’) can be indicative of the causative pathogen, through 
soluble and cellular markers present in the PD effluent of patients, on day 1 of an acute 
peritonitis episode.122 It is suggested that local miRNAs may play a role in this specific 
immune response as they are involved in many major cellular processes, including the 
response to infection and inflammation.460,461 miRNAs in the PD effluent are stable and 
important in inflammation-related fibrosis in the peritoneum.327 These small, endogenous, 
non-coding, single-stranded RNA molecules are post-transcriptional gene regulators that 
are estimated to control 30-60% of human genes. Their stability, location and possible 
functions in pathways involved in response to infection and inflammation suggests they 
may contribute to the immune fingerprint model already established.222 
 
To investigate the potential of local microRNAs as pathogen-specific biomarkers, a 
screening of 377 miRNAs was conducted in PD effluent from patients presenting at UHW, 
Cardiff on day 1 of peritonitis (with a well-defined single-organism bacterial infection), 
comparing the most common Gram positive and Gram negative infections (coagulase 
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negative Staphylococcus and E. coli, respectively) with uninfected patient samples. 11 
candidate microRNAs were identified as altered in one or both types of infection, compared 
to uninfected samples. This shortlist was refined to four candidates through a small 
validation cohort of patient samples, and these four were then investigated in 109 infected 
PD effluent samples, compared to 20 stable patient samples, collected from September 
2008 to December 2017. These data generated show the potential of miRNAs to act as 
pathogen-specific biomarkers in patient PD effluent samples with levels of four miRNAs 
altered in infection. 
 
3.1.1 Aims: 
The aims of this chapter were to: 
1. Identify candidate miRNAs altered in infection through screening of PD effluent 
samples with well-defined infections 
2. Validate these findings in a small cohort of patients with well-defined infections 
and refine the candidate biomarker list 
3. Validate changes in candidate miRNAs in full cohort of 129 PD effluent samples 
from patients infected by a broad range of bacterial organisms  
 
3.2 Results 
3.2.1 Optimisation 
Cell-free samples present specific difficulties on normalisation of miRNA data, with no 
standard protocol or reference gene widely used.462 Instead of normalisation to a reference 
gene, it may be possible to control for the amount of total RNA added into the RT-qPCR 
reaction at the start. However, this was not possible due to two specific modifications of 
the RNA extraction procedure for cell-free samples. Firstly, the extraction procedure is 
optimised to extract small RNA molecules, and as consequence many larger RNA molecules 
including mRNA are lost during the procedure, meaning the total RNA extracted is not the 
total RNA originally present in the sample. Also, the use of a “spike-in” control of a C. 
elegans miRNA not present in human samples (cel-miR-39) to assess the efficiency of the 
RNA extraction procedure skews the perceived RNA content if measured by standard 
methods. With cell-free samples and a column-based extraction method, there is the 
possibility for variation in the efficiency of extraction, therefore this is an important method 
of standardisation.  
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Here, I tested different candidate referencing methods to determine the best way of 
analysing miRNA data from cell-free PD effluent, including using different microRNAs, other 
small RNAs or the cel-miR-39 added in the extraction as internal reference, as well as 
presenting the raw, un-normalised data. In preliminary experiments with 5 infected and 5 
uninfected PD effluent samples (Figure 3.1 A-D), 4 different potential reference genes were 
assessed; miR-191, miR-16, sno-135 and snRNA U6. miR-191 and miR-16 have been 
previously used for normalisation of miRNA data in other cell-free biological fluids such as 
urine, whilst sno-135 (small nucleolar RNA 135) and snRNA U6 (small nuclear RNA U6) have 
also been used in-house as reference genes for miRNA work. It was shown that snRNA U6 
was the most consistent between the groups and was therefore used as reference to 
normalise the target miRNA data. Although snRNA U6 is different between stable and 
infected samples when a larger selection of patient samples was used (15 stable patients 
compared to 12 with Gram +ve and 12 with Gram -ve infections, Figure 3.1E), there is no 
difference between the two groups of infections tested here, suggesting this method of 
normalisation will be useful when comparing levels of miRNAs between different 
infections. Figure 3.1F shows there is no difference between cel-miR-39 levels across all 
three groups, suggesting the extraction is consistently performed, and that this also a 
possible reference gene. 
 
To avoid problems with normalisation, data can be presented as raw data, or 40-Ct. This is 
the standard way of presenting raw RT-qPCR data where the Ct value has an inverse 
relationship with the amount present (i.e. high Ct means not very much is in the sample, 
and vice versa). The raw data is therefore presented as 40 (total number of cycles 
conducted in the qPCR reaction) minus the Ct value. However, as mentioned above, it was 
impossible to accurately detect the amount of RNA starting in these samples (after 
extraction), so any differences seen with this method could be due to different amounts of 
total RNA, or different efficiencies of RNA extraction. Nevertheless, any difference due to 
the efficiency of RNA extraction would also appear in the amounts of cel-miR-39 present, 
as the same amount of this was added at the start of the RNA extraction, and no difference 
in cel-miR-39 levels was detected (Figure 3.1F). Due to the problems with possible different 
amounts of total RNA present, a normalisation procedure was generally used, where 
possible. As described above, snRNA U6 was deemed the best of multiple options tried as 
a reference gene. 
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Figure 3.1: Screening of candidate reference genes in PD effluent samples 
5 stable and 5 peritonitis PD effluent samples were tested for miR-191 (A), miR-16 (B), 
sno-135 (C) and snRNA U6 (D). E shows snRNA U6 levels and F shows levels of cel-miR-39 
(“spike-in”, control for the extraction procedure) in a larger patient cohort consisting of 15 
stable PD effluent samples, 12 from patients with Gram +ve (Coagulase negative 
Staphylococcus, CNS) infections and 12 with Gram -ve (E. coli) infections. Data were 
analysed by Mann-Whitney test (A-D) or Kruskal-Wallis test (E-F) and significant 
differences are indicated: *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001.  
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3.2.2 Identification of infection-associated candidate microRNAs through 
unbiased screening 
To study the potential role of miRNAs as pathogen-specific biomarkers in PD-related 
peritonitis episodes, I aimed to identify candidate miRNAs which may have important roles 
in this disease pathway. TLDA cards were used to look at the expression patterns of 377 
miRNAs (see Table in appendix 9.2) in 30 PD effluent samples. Prior to testing these 30 
samples, optimisation of the experimental conditions was required, by determining 
whether an extra amplification step, after the reverse transcription, was necessary. This is 
often the case in samples where the RNA content is low, and due to the inability to 
accurately quantify the levels of RNA extracted from PD effluent samples, this was thought 
to be necessary. To test this, 10 stable PD effluent samples were pooled and run on 
separate TLDA cards both with and without the pre-amplification step. When no pre-
amplification took place, only 12 miRNAs amplified above the limit of detection, whereas 
122 amplified when the pre-amplification step was included (Figure 3.2). This indicated that 
the extra processing was necessary to be able to detect as many miRNAs as possible, and 
therefore was included in future experiments. 
 
For the subsequent TLDA screening, 10 PD effluent samples each from 3 groups of 
individuals receiving PD were pooled together: uninfected patients (stable), those with a 
CNS infection (Gram +ve) and those with an E. coli infection (Gram –ve). Samples were 
pooled to attempt to average out the inter-sample differences, as well as to be mindful of 
limited resources and sample volumes at this preliminary, discovery stage. CNS is the most 
common Gram +ve organism in PD patients, whilst E. coli is the most common Gram -ve 
organism. These two organisms cause the majority of peritonitis episodes at this site (UHW, 
Cardiff), and at this stage of the project they were considered sufficiently representative of 
other Gram +ve and Gram -ve bacteria. All infected samples were taken from the first 
cloudy bag on day 1 of presentation at hospital, before antibiotic treatment commenced. 
Uninfected patients had not experienced an episode of peritonitis for at least 3 months 
prior to inclusion in this study. 
 
As shown in Figure 3.3, changes in the abundance of 11 miRNAs were detected, as defined 
by greater than two-fold changes in relative expression compared to stable samples, 
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Figure 3.2: Optimisation of TLDA methodology 
10 pooled stable PD effluent samples were run on the TLDA system, both with (black) and 
without (red) a pre-amplification step, to assess whether this extra step was necessary. (A) 
shows all miRNAs that amplified across both plates, with 122 miRNAs amplifying when 
the pre-amplification step was used, as opposed to 12 miRNAs when it was not used. (B) 
shows the 12 miRNAs that amplified without pre-amplification and the differences 
observed when pre-amplification was employed. 
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Figure 3.3: Screening of microRNA candidates 
10 pooled samples from stable, Gram +ve (Coagulase negative Staphylococcus, CNS) 
infected and Gram –ve (E. coli) infected patient PD effluent samples screened for 377 
human microRNAs using a TLDA (TaqMan low density array) card. 11 candidate 
microRNAs identified with altered levels in different infections and compared to 
uninfected PD effluent. Data shown as mean values from global normalisation. 
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normalised to global expression of all targets across the whole plate. As is standard for 
TLDA cards with patient samples, global normalisation was used for these data, not 
normalisation to snRNA U6 which will be used for individual patient PD effluent samples in 
future experiments, due to the variability both within a plate and across multiple plates. 
Levels of three miRNAs (miR-223, miR-139 and miR-197) were increased in both types of 
infections, and with higher levels in Gram -ve than Gram +ve infected PD effluent. Two 
miRNAs were detected in two of the sample groups only; miR-25 was only detected in 
stable and Gram -ve infected samples, whilst miR-203 was only detected in stable and Gram 
+ve infected samples. Increased miR-27a was detected in Gram +ve infected samples whilst 
there were comparable levels in the Gram -ve infected and stable samples. Detected levels 
of two miRNAs (miR-21 and miR-31) decreased in both types of infections compared to 
uninfected samples. Three miRNAs (miR-199a, miR-100 and miR-99a) also showed 
decreased levels in both types of infection, with lower levels in Gram -ve infected samples, 
compared to Gram +ve infected samples. This confirmed that miRNA levels are altered in 
acute PD-related peritonitis episodes, compared to uninfected PD effluent, and that they 
may be altered in different types of infection. Taken together, this screening resulted in the 
identification of 11 candidate miRNAs to investigate further for their potential to serve as 
diagnostic biomarkers. 
 
3.2.3 Validation of candidate microRNA changes in individual patient PD 
effluent samples 
To validate the changes in the 11 candidate microRNAs seen in the pooled samples, they 
were measured individually in a set of 48 well-characterised samples, consisting of 10 
stable samples, 20 with well-defined CNS infections (Gram +ve) and 18 with confirmed 
coliform infections (Gram -ve, 15 E. coli, two Enterobacter and one Klebsiella infections). 
30 of these samples were those already used for the TLDA cards, whilst a further 18 were 
added to increase the power of this validation. The aim of these experiments was to 
validate the changes observed with pooled samples, on the high-throughput screening 
TLDA card, in individual samples with separate RT-qPCR reactions for each miRNA. 
 
As shown in Figure 3.4Ai, miR-223 levels were increased in both types of infection, 
compared to stable samples, although there was no difference in the levels between the 
two types of infection (Figure 3.4Aii). In contrast, miR-139 and miR-197 did not show the  
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Figure 3.4: Using a small patient cohort to identify the 4 most promising miRNA 
candidates 
11 miRNAs identified as promising candidates from TLDA screening were tested in a 
validation cohort of 10 stable, 20 Gram +ve (CNS) and 18 Gram –ve (15 with E. coli, 2 with 
Enterobacter and 1 with Klebsiella infections) infected patient PD effluent samples. Each 
miRNA was normalised to snRNA U6 and either stable samples (i) or Gram +ve (ii) infected 
samples. 11 candidates were miR-223 (A), miR-139 (B), miR-197 (C), miR-25 (D), miR-27a 
(E), miR-203 (F), miR-21 (G), miR-31 (H), miR-199a (I), miR-100 (J) and miR-99a (K). Data 
were analysed by Kruskal-Wallis test and significant differences are indicated: *, p<0.05; 
**, p<0.01; ***, p<0.005; ****, p<0.001. 
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same increase as observed in the TLDA screening (Figure 3.4B-C). These two miRNAs were 
therefore excluded from further analysis. miR-25 and miR-203 were also excluded from 
further analysis as they had been undetectable in one of the three groups in the screening 
dataset but were present in all individual samples tested here (Figure 3.4D and 3.4F). For 
miR-199a, miR-100 and miR-99a, the decrease in infection seen in the TLDA screening could 
be reproduced using individual samples (Figure 3.4I-K). However, the levels of these three 
miRNAs was low, near the detection limit, with not all samples amplifying (data not shown), 
therefore these three were excluded from further analysis. The pattern of miR-27a seen in 
the screening dataset could not be replicated here (Figure 3.4E). Previously it was increased 
in Gram +ve infections compared to both other sample types, however the data from the 
individual samples suggested that miR-27a was decreased in both types of infection. This 
miRNA was, however, still included due to its high overall levels, and the strong decrease 
in infected PD effluent samples, compared to uninfected stable samples. miR-21 and miR-
31 were present at high levels in all samples, as well as a trend to decreased levels in 
infection for both (Figure 3.4G-H). Despite these changes not being statistically significant, 
these two miRNAs were taken forward for subsequent analysis, given their previously 
shown strong association with peritoneal inflammation and fibrosis.327,463 Notably, miR-31 
was the only miRNA to show a difference between the two types of infections (Figure 3.4H), 
with lower levels in Gram -ve infected PD effluent compared to Gram +ve infections. This 
important observation suggests that miRNAs may be useful as pathogen-specific 
biomarkers to help distinguish different causative organisms and inform treatment 
decisions more accurately. The final shortlist of four candidate miRNAs (miR-223, miR-27a, 
miR-21 and miR-31) was examined in more detail in the remainder of this thesis. 
 
3.2.4 Validation of candidate microRNAs in a real-world patient cohort 
To confirm whether these four candidate biomarker miRNAs could be used in patients to 
predict early peritonitis and even distinguish between different types of infections, the 
miRNA analysis was extended to the full cohort of patients presenting at UHW, Cardiff on 
day 1 of infection, between September 2008 and December 2017. The purpose of this was 
to investigate a large number of samples, which included a range of different Gram +ve and 
Gram -ve infections as seen in clinical practice. To reach this aim, more samples were 
needed to increase the power of this study and to see if the differences observed in the 
relatively small dataset with well-defined CNS and E. coli infections were still valid in a large 
cohort representative of the variability across the PD community in the UK and beyond. 
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This cohort consisted of 109 infected PD patients presenting with acute peritonitis caused 
by a range of organisms: Gram +ve organisms (n=77), including CNS (n=40), S. aureus (n=9) 
and coryneform species (n=2); confirmed Gram -ve organisms (n=32) included E. coli 
(n=18), other coliform species (n=4), Pseudomonas spp. (n=3), Acinetobacter spp. (n=3), 
and others (see Table in appendix 9.1 for full list of samples and types of infections). These 
109 samples were compared to 20 stable, uninfected PD effluent samples from PD patients 
who had not had a peritonitis episode for at least 3 months prior to inclusion in this study. 
 
As shown in Figure 3.5A, miR-223 was greatly increased in both Gram +ve and Gram -ve 
infections, compared to stable uninfected PD effluent samples. miR-27a showed a 
significant decrease in levels in both types of infection, compared to stable samples (Figure 
3.5C). These data confirmed the earlier findings, demonstrating that the observed changes 
in miRNA levels in well-defined infections caused by two representative organisms 
translates to the full cohort of patients infected by a wide spectrum of organisms. Both 
these miRNAs showed no difference in detected levels between Gram +ve and Gram -ve 
infections (Figure 3.5B and 3.5D).  miR-21 showed a similar pattern as before, with lower 
levels in both types of infected samples compared to those without an infection (Figure 
3.5E). Earlier data with a smaller number of patient samples suggested that miR-31 levels 
were lower in Gram -ve infected patient samples (Figure 3.4H), compared to Gram +ve. 
This was not seen here (Figure 3.5H), instead there was a difference in the levels of miR-21 
between the two different types of infection. There were significantly lower levels of miR-
21 in samples from patients with a range of Gram -ve infections, compared to those with 
infections caused by Gram +ve organisms (Figure 3.5F). miR-31 was decreased in both types 
of infections, compared to stable samples (Figure 3.5G), confirming earlier results, despite 
there being no difference in levels between the different types of infections (Figure 3.5H). 
When the samples from patients infected with CNS and E. coli were removed from the 
analysis, the same directions of altered levels were seen, but the limited numbers of 
samples meant the magnitude of differences was greatly reduced (data not shown), 
indicating it is not merely an effect of the main causative organisms skewing the data.  
These findings mirror the trends from the screening data, with small alterations in 
magnitude of changes, and therefore confirmed the diagnostic potential of these four 
microRNAs in patients presenting with acute PD-related peritonitis. 
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Figure 3.5: 4 candidate microRNAs are altered in infections, in cohort of patient PD 
effluent samples 
Four candidate miRNA biomarkers were measured in a real-world patient cohort 
consisting of 20 stable uninfected PD effluent samples, 77 with Gram +ve infections and 
32 with Gram -ve infections. miR-223 (A-B), miR-27a (C-D), miR-21 (E-F) and miR-31 (G-H) 
were normalised to snRNA U6 and either stable samples (A, C, E and G) or Gram +ve 
infected samples (B, D, F and H). Data were analysed by Kruskal-Wallis test and significant 
differences are indicated: *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001. 
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3.2.5 miRNAs in resolution of infection 
As the levels of the four candidate miRNA biomarkers are altered in infection, it was 
interesting to investigate whether they could be indicative of the resolution of an acute 
peritonitis episode. Using longitudinal PD effluent samples from three patients over the 
first week of infection, the four candidate miRNAs were measured, normalised to snRNA 
U6, and compared to the levels in a stable sample from the same patient before presenting 
with peritonitis. Each patient, when they enrol on the clinical study which these samples 
are from, has a stable PD effluent sample taken as a baseline to measure against. This was 
used for the three patients shown in Figure 3.6. miR-223 (Figure 3.6A) showed a strong 
decrease across the first week of infection towards the levels seen in the respective stable 
PD effluent samples, in all three patients. This confirmed what we expected to see, as we 
predicted miR-223 would be a representative a marker of the acute response to infection 
and therefore would decrease with the resolution of the acute immune reaction. It is 
thought that the reduction in miR-223 is representative of the resolution of infection, with 
decreased inflammatory mediators and immune cells present. The other three miRNAs 
showed more variability across the three patients. miR-27a (Figure 3.6B) levels showed an 
increase towards the level in the stable PD effluent levels in one patient, a decrease in 
another patient and no change in the third patient. miR-21 (Figure 3.6C) levels showed 
similar variability as miR-27a, whilst miR-31 (Figure 3.6D) showed an increase in two 
patients over the week towards the level in the stable PD effluent sample, whilst one 
patient had the opposite pattern of expression. This inconsistency between samples was 
not unexpected due to the variability seen with patient samples, and the number of factors 
that contribute to the difference between individuals. The small number of patients 
followed in these experiments meant they could only be used as a preliminary investigation 
into the role of miRNAs in the resolution of infection. Nevertheless, miR-223 looked 
promising as it robustly decreased across all three patients investigated during the course 
of a week from the start of an acute peritonitis episode towards resolution. 
 
3.2.6 Correlations to cellular data 
miRNAs are both produced and act inside cells, although they can be found outside cells, 
either associated with protein or extracellular vesicles, where they are involved in 
intercellular signalling. It was therefore thought that the peritoneal levels of the candidate 
miRNA biomarkers may be indicative of the levels of different cell types present in PD  
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Figure 3.6: miRNAs in resolution of infection 
Showing how the four miRNA candidate biomarkers change during the resolution of three 
acute peritonitis infection episodes from three PD patients. miR-223 (A), miR-27a (B), 
miR-21 (C) and miR-31 (D) were measured in PD effluent samples from patients across 
the first week of a peritonitis episode, as well as a stable PD effluent sample from before 
they had an infection. All data are normalised to snRNA U6 and the corresponding stable 
sample from each patient. Individual patient samples are plotted separately. 
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effluent. This could help to identify the potential cellular source of the cell-free miRNAs 
detected. Both the raw and normalised levels of the four miRNAs were compared to the 
total cell count, the number of live macrophages (CD14+) and the number of live 
neutrophils (CD15+) in the PD effluent. Total cell count was selected to eliminate the 
possibility that these miRNAs were merely surrogate markers of the total number of cells 
present. Neutrophils are the most abundant cell type present in infected PD effluent, and 
it is conceivable that they may be a major source of the cell-free miRNAs. As macrophages 
are another very abundant cell type, they were also investigated for correlations with the 
miRNA data. Data were compared for 82 patient samples, where all cellular and miRNA 
data needed for such analyses were available. The cellular data was kindly generated and 
shared by Dr Ann Kift-Morgan. Linear regressions were plotted for all four miRNAs (40-Ct 
and RQ data) and snRNA U6 (used for normalisation, 40-Ct only), with graphical 
representation shown in Figure 3.7, and the statistical analysis shown in Table 3.1. 
 
For all correlations, the r2 values (representative of how closely the data fit the linear 
regression line) were very low. This was due to the significant variation associated with 
patient samples and indicated that any correlations were not particularly strong. However, 
there were multiple statistically significant correlations (p<0.05), notably between miR-223 
(40-Ct) and all cellular levels (total, macrophages and neutrophils) (Figure 3.7Gi-iii). This 
suggests that miR-223 may be important and relate to the cells that infiltrate the 
peritoneum during infection. miR-27a (40-Ct) also showed the same pattern of correlating 
with the cellular levels (Figure 3.7Ei-iii), with similar conclusions. Notably, raw snRNA U6 
levels (40-Ct) also correlated with the levels of total cells and macrophages (Figure 3.7Ii-iii). 
As snRNA U6 is present inside cells in the spliceosome and is not normally released, this is 
a logical correlation to observe. As snRNA U6 levels were used for normalisation, this would 
explain why there were no further correlations between the cellular data and the 
normalised miRNA data. It is important to note that all correlations, despite being 
statistically significant, were not very strong with low r2 values. These r2 values are the main 
indicator of the possible importance of a correlation as it shows the amount of variance 
that the linear regression (correlation) accounts for, in the dataset. This is best shown by 
the graphical representations, where any statistically significant correlations were almost 
indistinguishable from those that are not significant, suggesting they might be an artefact 
of the statistical tests with a variable and relatively small cohort of patient samples, 
together with considerable patient to patient variation.  
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Figure 3.7: Correlations of miRNA data with cell data 
Showing raw data (40-Ct) of miR-21 (A), miR-31 (C), miR-27a (E), miR-223 (G) and snRNA 
U6 (I), alongside miRNA data normalised to snRNA U6 levels for miR-21 (B), miR-31 (D), 
miR-27a (F) and miR-223 (G), correlated to the total cell count (i), number of live CD14+ 
macrophages (ii), and the number of live CD15+ neutrophils (iii). Data shown on log10 
scale for cell counts and normalised miRNA data, with data for 82 PD effluent samples 
available, from patients with acute peritonitis episodes. Colours represent types of 
infections, red for Gram +ve infections, blue for Gram -ve infections and green for no 
growth in culture results. Linear regression was plotted, with statistics (p and r2 values) 
shown on panels where statistical significance was reached (p<0.05) and in Table 3.1. 
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Table 3.1: Statistics from linear regressions of correlations between miRNA levels and 
cellular markers 
Showing the p values and r2 values from the linear regressions conducted between raw 
miRNA levels (40-Ct) or normalised relative quantification (RQ) to snRNA U6, of 4 miRNAs 
(miR-21, miR-31, miR-27a and miR-223), and total cells, number of macrophages or 
number of neutrophils. Data from PD effluent from 82 patients with acute peritonitis. 
Significant correlations are indicated: *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001. 
  
 
Total cells Macrophages Neutrophils 
p value r2 value p value r2 value p value r2 value 
miR-21 40-Ct 0.5111 ns 0.004812 0.4090 ns 0.008537 0.6642 ns 0.002368 
miR-21 RQ 0.0296 * 0.05148 0.1147 ns 0.03081 0.0539 ns 0.04565 
miR-31 40-Ct 0.0773 ns 0.03428 0.0327 * 0.05576 0.1649 ns 0.02397 
miR-31 RQ 0.3673 ns 0.009039 0.6421 ns 0.002713 0.4067 ns 0.008622 
miR-27a 40-Ct 0.0042 *** 0.08768 0.0049 *** 0.09485 0.0287 * 0.05844 
miR-27a RQ 0.0500 ns 0.04201 0.1379 ns 0.02731 0.2018 ns 0.02028 
miR-223 40-Ct 0.0007 **** 0.1198 0.0388 * 0.05230 0.0120 * 0.07623 
miR-223 RQ 0.4807 ns 0.005540 0.5949 ns 0.003551 0.4694 ns 0.006563 
snRNA U6 40-Ct 0.0042 *** 0.08732 0.0078 ** 0.08526 0.0724 ns 0.03979 
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The original immune fingerprint model (Figure 1.1) suggests that the total number of cells 
is important to distinguish Gram +ve infections from all other types of infections. 
However, what is clear to see from Figure 3.7, is that this factor alone cannot absolutely 
separate these types of infected samples (represented by red symbols) from all others. 
This indicates the power of the immune fingerprint is due to multiple interacting factors, 
not merely one important difference. 
 
3.2.7 In vivo models of peritonitis 
In human patients, the exact time point of the beginning of the infection is unknown when 
a patient presents at hospital, the microbiological culture results may be erroneous, 
different dwell times and different dialysate solutions may affect peritoneal concentrations 
of immune cells and soluble mediators, and patients may have underlying conditions that 
might affect miRNA expression in the peritoneal cavity. To circumvent these limitations, 
we took advantage of a well-defined mouse model that allowed us to study the time course 
of miRNA expression after the onset of infection, in the absence of other confounding 
factors. We therefore measured the levels of the four miRNAs of interest in a model of 
peritoneal infection established by Dr Anne-Catherine Raby and colleagues.464 Briefly, 
C57BL/6 mice aged 8-12 weeks had intraperitoneal (i.p.) injection of either PBS or live E. 
coli, and the mice were sacrificed at the indicated time points. All four miRNAs were 
detected in peritoneal lavages of these mice, both in the infected group and in mock-
treated controls. Increased abundance of miR-223 was detected in infected mice (Figure 
3.8A), as is seen in the human PD effluent samples from infected patients (Figure 3.5A). 
miR-27a levels were comparable in infected mice and controls (Figure 3.8B), in contrast to 
the decrease seen in PD effluent samples from infected patients (Figure 3.5C). miR-21 levels 
increased in infected mice (Figure 3.8C), which differed from the patient PD effluent 
samples, where levels decreased with infection (Figure 3.5E). Finally, there was a modest 
decrease in the levels of miR-31 in infected mice (Figure 3.8D), similarly to infected patient 
samples (Figure 3.5G). While the mouse model data did not exactly mirror the human 
pathology for all miRNAs studied, these findings suggested that miR-223 and miR-31 may 
have similar roles in the response to infection in humans and in mice. However, these 
findings also highlighted the limitations of using mouse models to understand human 
pathology as they indicated there are important differences in the regulation of miRNA 
expression between humans and mice, at least in the specific infection model used in the  
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Figure 3.8: Candidate miRNAs are altered in peritoneal E. coli infections in mice 
6 mice with i.p. injection of live E. coli bacteria (red) and 3 mice with i.p. injection of PBS 
(black) were culled at the specified time-points and the peritoneal cavity (site of infection) 
was washed with PBS, the 4 miRNAs were then detected in these peritoneal lavages. miR-
223 (A), miR-27a (B), miR-21 (C) and miR-31 (D) were normalised to snRNA U6 and the 
PBS control. Data were analysed by two-way ANOVA and significant differences are 
indicated: *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001. Data shown as mean values ±SEM. 
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present study. Ultimately, these data reiterate the importance of using human samples and 
models to assess changes that will be relevant to patients, and transferable to the clinic. 
 
3.3 Discussion 
In this chapter, I show that miRNAs can be detected in PD effluent from both un-infected 
and infected patients, and that levels are altered in PD-related peritonitis episodes. miRNAs 
show potential as pathogen-specific biomarkers in PD-related peritonitis, with the aim of  
eventually helping to speed up diagnosis of the causative organism in each episode. This 
will reduce the exposure of the patient to broad-spectrum antibiotics and hopefully allow 
more patients to recover from peritonitis episodes and resume PD as their RRT. 
 
3.3.1 Reference miR choice 
An important consideration when looking at miRNA data is the normalisation strategy. 
There is no consensus on a standard normalisation procedure, as there is with the 
quantification of messenger-RNA (mRNA) levels where ‘house-keeping’ genes such as 
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) or β-actin are often used.462 
Detection of cell-free miRNAs poses even more of a problem in finding a suitable reference 
gene, due to the variety of RNA species released by cells, with varying levels depending on 
the type of stimulus. For this study, it was important to find a suitable reference gene that 
did not change between different infections, as the primary aim was to identify miRNAs 
that were altered in response to different microbes. Also, it is highly likely that the radical 
changes seen in PD effluent during infection, compared to uninfected PD effluent, would 
mean it might not be possible to find a small RNA molecule that is unchanged between 
infected and stable PD effluent. From a small initial screening cohort, it was predicted that 
snRNA U6 would be the most appropriate reference gene to normalise the miRNA data to, 
as it did not appear to change much in infection. However, when a larger cohort was used, 
this was not the case and the levels were significantly different between stable and infected 
PD effluent. When different infections were compared, there was no difference between 
the levels in PD effluent from patients with Gram +ve or Gram -ve infecting organisms. Due 
to the problems mentioned above for finding a suitable reference gene for cell-free 
miRNAs, it is not uncommon to use a “spike-in” control to normalise the data to. This 
method controls only for the consistency of the RNA extraction, RT and qPCR procedures, 
rather than the amount of RNA in the sample to start with. When observed in these 
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samples, the levels of cel-miR-39, which was spiked in during the RNA extraction procedure, 
were consistently high and not altered between samples. These data show the technical 
reproducibility and reliability of the protocols from RNA extraction through to RT and qPCR. 
However, this is not the best way to normalise data as it does not take into account the 
total RNA level in the different samples to start with, therefore snRNA U6 was used for the 
majority of samples analysed. 
 
3.3.2 miRNAs in PD effluent 
As shown previously, miRNAs are stable in PD effluent and have the potential to be useful 
biomarkers.327 Much work has been done on their role in PD-related peritoneal membrane 
fibrosis and in relation to the peritoneal membrane transport characteristics70,442 and a 
number of miRNAs have been associated with changes including miR-15a, miR-17, miR-21, 
miR-30, miR-192, miR-221, miR-327, miR-377, and miR-589.326,329,465 A number of miRNAs 
have also been associated with EMT/MMT. Some miRNAs are promoters or markers of 
increased peritoneal membrane fibrosis or EMT/MMT, including miR-9, miR-21, miR-23, 
miR-34a, miR-122, miR-182, miR-199, miR-200c, miR-214, miR-292, miR-296, miR-488 and 
miR-589.319,322,323,327,466–470 Other miRNAs are downregulated with fibrosis, including miR-
29b, miR-30a, miR-31, miR-93, miR-100, miR-129, miR-152, miR-192, miR-194, miR-200a, 
miR-200b and miR-497.317,318,321,443,468 The majority of these previous studies have looked 
at cellular miRNAs, with limited study on cell-free miRNAs. Those that have investigated 
miRNAs in the circulation show serum miRNAs can be used as a marker of peritoneal 
fibrosis in a mouse model and in PD patients,329 emphasising the importance of 
extracellular miRNAs. Whilst cell-free miRNAs in PD effluent have been used as markers of 
peritoneal fibrosis,327 there are no known published studies relating to cell-free miRNAs as 
markers of infection in PD effluent, although one group has looked at miRNAs in ascites as 
markers of spontaneous bacterial peritonitis.449 This current work shows the potential of 
cell-free miRNAs as biomarkers of infection, with increased levels of miR-223 and 
decreased miR-21, miR-31 and miR-27a in cell-free PD effluent on day 1 of an acute PD-
related peritonitis episode, compared to levels in stable non-infected patients. 
 
3.3.3 Candidate biomarkers 
Identified here are four candidate biomarkers that can be used to distinguish infected PD 
effluent from uninfected PD effluent. These changes were first identified through screening 
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a wide range of miRNAs and replication in individual patient samples. The validation in a 
large patient cohort has shown the importance of these four miRNAs as potential 
biomarkers in acute PD-related peritonitis, at the site of infection. 
 
3.3.3.1 miR-223 
miR-223 increases with infection, regardless of the infecting organism. This miRNA, located 
on the X chromosome, has been studied widely in a range of different diseases, with 
particular emphasis on its role in cancer.471 miR-223 is exclusively expressed in cells of a 
myeloid lineage, and consequently shows a strong association with leukaemia and 
lymphoma.471–473 However, the potential for miRNAs to be transferred between immune 
and cancer cells, alongside the role of this miRNA in inflammation, indicated that miR-223 
has a role in solid tumours.471,473 Most interesting for this study is the role of miR-223 in 
inflammatory disorders, with a wide range of studies implicating miR-223 as a biomarker 
for diagnosis or progression, a role in the pathogenesis of inflammatory diseases, and in 
the response of the host.473,474 For example, its role in sepsis has been widely studied, with 
the majority of studies suggesting miR-223 is a good prognostic biomarker and can be used 
to distinguish sepsis from Systemic Inflammatory Response Syndrome (SIRS) and healthy 
controls.474–476 There is, however, some contradictory evidence suggesting this is not 
always the case.477 Several groups have also looked at miR-223 in the context of 
rheumatoid arthritis (RA). They suggest that miR-223 may have a role in the pathogenesis 
via an IL-6 feedback loop, with an important role as a systemic biomarker, with the 
potential to distinguish osteoarthritis (OA) from RA accurately.478–481 The limited number 
of studies investigating miR-223 in infection are mostly investigating animal models. miR-
223  is increased in HIV, HCV, Staphylococcus and Streptococcus infections, with an 
important role in the regulation of inflammation.482–486 miR-223 knockout (KO) animals 
show spontaneous inflammation and an aggravated inflammatory response to LPS or lung 
injury, suggesting miR-223 has a role in controlling inflammation.359,359,410,473,487 Another 
study showed that miR-223 is able to distinguish between spontaneous bacterial peritonitis 
and peritoneal carcinomatosis, suggesting the inflammatory reaction to infection is 
different to that induced by cancer.449 This, along with the role for miR-223 in macrophage 
polarisation and neutrophil maturation,359,473,488–491 suggests miR-223 may be an important 
regulatory of the acute inflammatory response to infection, as is seen here with the 
increase in response to bacterial peritonitis. This may be a non-specific upregulation due 
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to acute inflammation rather than specific bacterial infection, which is why there is no 
difference between Gram +ve and Gram -ve infected patients. 
 
3.3.3.2 miR-27a 
This thesis shows a decrease in miR-27a in infected PD effluent, compared to stable PD 
effluent, regardless of infection type. miR-27a is part of the intergenic miR-23a/24-2/27a 
cluster on chromosome 19p13.13, which is highly conserved between vertebrates.492 miR-
27a has been implicated in a wide range of pathologies, from cancer to CVD. It is thought 
to be an oncomiR (i.e. oncogenic miRNA) in many cancers including breast cancer, 
hepatocellular carcinoma (HCC) and prostate.493–496 However, there is contradicting 
evidence that miR-27a may act as a tumour suppressor in some cancers, including 
leukaemia, colorectal cancer and glioma.497–499 One much-studied aspect of miR-27a is the 
different polymorphisms and how they relate to disease risks. One specific single 
nucleotide polymorphism (SNP) that has been associated with increased risk of breast 
cancer and heart disease is rs895819, where a G is substituted for an A and the level of 
total miR-27a is altered.493,500 miR-27a is also altered in inflammatory pathologies, 
autoimmune conditions and infectious diseases. For example, miR-27a is increased in CD4+ 
T cells from multiple sclerosis (MS) patients during an acute relapse,501 whilst it has a 
protective role against inflammation- or sepsis-induced organ injury.502–504 miR-27a can 
inhibit some viral infection models,505,506 but it is increased in parasitic infections such as 
cerebral malaria.507 This well-established role in regulating inflammation and innate 
immunity is supported by the present finding that miR-27a is altered in acute peritonitis. 
However, not enough is known about its role in response to bacterial infections to infer 
whether it is functional in modulating the immune response at the site of infection. 
 
3.3.3.3 miR-21 
miR-21 was identified here as a miRNA that was decreased in infected compared to 
uninfected PD effluent and is altered between different infections. This miRNA is one of 
the most abundant miRNAs present in most mammalian cells, located on chromosome 17. 
It has been widely studied in cancer and is one of the most consistently identified 
oncomiRs.508–513 miR-21 has been identified as a diagnostic and prognostic biomarker in a 
range of cancers, including breast, colon, lung and pancreas.514 A substantial amount of 
research has also shown the important of miR-21 in CVD, where it is implicated in the 
pathogenesis of a range of heart conditions and can be used as a diagnostic and prognostic 
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biomarker.421,515–519 Due to the inflammatory nature of many cancers and CVD, and the 
wide range of cancers which show upregulated miR-21, it is thought to play a part in the 
inflammatory component of these disorders.516,520–523 There has also been much work 
looking into miR-21 and other inflammatory conditions, including psoriasis, colitis and MS 
where it is suggested to play a role in the pathogenesis.522,524,525 Due to the fact that it is so 
highly expressed and was one of the first miRNAs to be characterised, there are also a wide 
range of pathways that miR-21 has been shown to influence. For example, programmed 
cell death protein 4 (PDCD4) is probably the best characterised target of miR-21 and is 
important in a range of conditions, including different types of cancers and fibrosis, due to 
its crucial role in the control of apoptosis, which is an essential part of the pathogenesis of 
many disorders.508,509,512,513,515,522,523,525–530 The regulation of miR-21 expression has been 
well studied, with both transcriptional and post-transcriptional regulatory mechanisms 
well described, showing miR-21 is often involved in feedback loops which include its own 
target mRNAs.526,528 miR-21 is also increased in immune cells upon their 
activation,512,522,525,529,531 which could be another reason why it is increased in so many 
different conditions. With regards to infection, miR-21 influences the immune response to 
viral infections,508,522 and it alters the environment for intracellular pathogens such as 
Listeria monocytogenes, where it reduces the intracellular niche to control the infection in 
macrophages.527 A knockout mouse for miR-21 (miR21-/-) has been developed and studied 
in a range of conditions. miR-21 deficient animals are viable, fertile, born in the expected 
Mendelian ratios, and have no major phenotypic differences to wild-type (WT) mice of the 
same background. However, some of the predicted miR-21 targets are upregulated in miR-
21-/- mice, and the pathogenesis of multiple cancers and CVD is altered.532–534 Despite the 
majority of the literature suggesting miR-21 increases in inflammatory conditions, the data 
presented in this thesis show a decrease in miR-21 during acute peritonitis. This may 
primarily be due to the dilution factor, where miR-223 dominates the total miRNA content 
of a cloudy bag. This means that other miRNAs appear to decrease, when they are in fact 
just decreasing in relative terms, when compared to snRNA U6, which the miRNAs of 
interest are normalised to and which increased with increased numbers of cells present. 
 
3.3.3.4 miR-31 
In this thesis, miR-31 levels were reduced in response to infection in PD effluent. This 
miRNA, located on chromosome 9, has been identified as an epithelial-specific miRNA535 
and has been studied most widely in cancer. However, the role of this miRNA is more 
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varied, with it being an oncomiR in some cancers, whilst a tumour suppressor in others. 
The variation is not only between different cancers, but also between different stages of 
the same cancer.536 For example, miR-31 is one of the most deregulated oncomiRs in 
colorectal cancer, and it is increased in many different studies across all clinical stages, 
including pre-malignant polyps.536–538 However, it is decreased in breast cancer and acts as 
a tumour suppressor, by suppressing genes involved in cell motility and invasion.536,537,539 
This is not universal though, with some evidence that miR-31 acts as an oncomiR in breast 
cancer.540 miR-31 has also been studied in heart disease, with varying roles in different 
pathologies and response to different types of CVD.541–547 This miRNA has not been as 
widely studied as miR-21 or miR-223, but it has been implicated in inflammatory pathways, 
especially via NF-kB,548 as well as a range of inflammatory conditions including 
psoriasis,549,550 inflammatory bowel disease (IBD) or colitis,551–553 sepsis554 and allergic 
disease.555 miR-31 is responsible for host responses to infection, specifically viral infections 
such as hepatitis B virus (HBV),556 influenza557 and respiratory syncytial virus (RSV)558. One 
of the proposed roles for miR-31 is in recruitment of neutrophils in allergic airway disease 
(AAD),548 whilst it is thought to alter T cell responses by either skewing the Th1/Th2 
balance,554 or regulating the Treg development.537,555 It is also important in development, 
even from very early stages,537 which may be the reason why there are no reported miR-
31 full KO animal models, only animals with a miR-31 knockdown or conditional knockout, 
where the effects of a reduction in miR-31 vary between different tissues from 
inflammatory (e.g. in colon epithelium) to reduced viability (e.g. in lung cancer cells).535–537 
The variety of roles of miR-31, and the pleiotropic functions across and within different 
conditions show that this miRNA can have many different functions, depending on the 
specific stimuli present and local microenvironment. One study shows that miR-31 in cell-
free PD effluent is altered in peritoneal membrane fibrosis caused by extended PD.70 All of 
the reported evidence suggests that the decrease in miR-31 in acute PD-related peritonitis 
is to be expected as it appears to be very sensitive to a range of stimuli, so we would expect 
alterations. Further work would be needed to identify why it decreases in PD-related 
peritonitis. 
 
3.3.4 miRNAs in the resolution of infection 
Due to the altered levels of the four miRNAs on day 1 of infection, it was proposed that 
these could be markers of the severity of inflammation or acute immune response, 
therefore would gradually go back to baseline levels during the resolution of infection. The 
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variability seen with a limited number of patient samples means it is difficult to interpret 
these results further than preliminary investigations. However, miR-223 appears to reduce 
back to baseline levels robustly across all three patients, in parallel with the resolution of 
infection. The implication of miR-223 in inflammatory responses and acute 
inflammation410,449,473,474,489 is supported with the present observation that miR-223 
reduces with the resolution of the acute phase, as the number of innate immune cells and 
the inflammatory components reduce. The more contradictory roles of miR-21,508,510,522,528 
miR-31537,548,550 and miR-27a494,496,502,505 suggest there is no clear consensus on the role of 
these miRNAs in acute inflammation and bacterial infections, which is corroborated by the 
results shown here, which are not as clear in terms of resolution of infection and altered 
levels of the miRNAs in response to it. More work needs to be done to analyse the roles of 
these miRNAs in the resolution phase of PD-related peritonitis. 
 
3.3.5 Correlations to cell data 
Due to the pronounced influx of cells into the peritoneal cavity during an infection, it was 
proposed that miR-21, miR-27a, miR-31 and miR-223 may just be indicators of either the 
total number of cells present, or of a specific abundant cell type. Due to the variation of 
patient samples and the cell-free nature of the miRNAs, there were very few significant 
correlations between the data sets. The levels of miR-223 and miR-27a appeared to 
correlate with the total levels of immune cells present. This was not unexpected, especially 
for miR-223 as this miRNA is restricted to expression of cells from a myeloid lineage.473,474 
The levels of peritoneal immune cells before infection are low, therefore when further cells 
are recruited into the peritoneal cavity in response to the acute infection, it is conceivable 
that the levels of miR-223 also increase.449 The role of miR-27a in response to acute 
infection is less well defined, and the expression patterns across different cell types are not 
as clear-cut as miR-223. However, there are reports that suggest miR-27a has a role in the 
acute inflammatory/innate immune response, with altered levels in CD4+ T cells in MS 
during acute relapses.501 Also, miR-27a seems to be protective to essential organs during 
inflammation-induced injury,502–504 and control viral infections by preventing 
replication.505,506 These studies suggest that the role for miR-27a may be important during 
the initial phase of infection or inflammation, but the cellular source and role is less clear. 
The lack of correlations with miR-21 and miR-31 could be due to a number of reasons. 
Primarily, these miRNAs are altered in a range of inflammatory disorders and changed in 
both directions (i.e. up- and down-regulated), therefore there is less consensus on the role 
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of miR-21 and miR-31 in the acute response.508,548 Also, the levels of miR-21 are high in 
almost all cell types, therefore any changes related to specific cell types may be difficult to 
distinguish, due to the mixture of different cell types and stimuli present during an acute 
PD-related peritonitis infection. miR-31 is expressed at higher levels in epithelial cells than 
other cell types.535 As the correlations attempted here were with total cells and immune 
cells which have infiltrated the peritoneal cavity, the lack of correlations with miR-31 was 
expected, as these cell types are not predicted to express and release high levels of miR-
31. The primary reason why there are few correlations between the levels of the four 
candidate miRNA biomarkers is very likely the fact that infected PD effluent is a highly 
variable ill-defined mixture of cells of different types, as well as a cocktail of soluble factors 
that could all influence the levels of miRNAs measured in the cell-free effluent. 
 
3.3.6 In vivo models 
Many studies on miRNAs and translational research use animal models, often mouse or 
other small rodents, to further assess the function of novel discoveries in a whole-body 
system. The pharmacokinetics of novel treatments or the unintentional off-target effects 
cannot be identified through in vitro models alone.559 Although there is a growing tendency 
to reduce research on animals (using the principle of the 3 R’s – replacement, reduction 
and refinement), there is still a considerable need for this kind of research.560,561 In vivo 
experiments can use KO animals to investigate the role of a specific gene, where the target 
gene is removed either from the animal completely before birth through genetic 
manipulation and breeding strategies, or specific knockouts, either site-, cell- or 
stimulation-specific deletion of a gene of interest,562,563 as has been seen with the specific 
candidate miRNA biomarkers studied here.410,487,533,535 As approximately 90% of the human 
genome and 60% of the miRNA loci are shared with the mouse, in addition to the 
substantial physiological similarities, mice are often used as experimental models for 
miRNA research.233,564 However, this also means there are approximately 40% of human 
miRNAs that are not shared with mice, and the data shown here emphasises these inter-
species differences. Although there were some similarities between the data seen in 
patients and those in the mouse model (i.e. increased miR-223 and decreased miR-31), 
there were also some differences. miR-21 was decreased in infected patients, but increased 
in the mouse peritonitis model, whilst miR-27a decreased in patient PD effluent but slightly 
increased in mice in vivo. These differences could be due to the lack of evolutionary 
conservation in these miRNAs and the pathways they control, or which control their 
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expression. They could also be due to the fact that the mouse model employed here is not 
completely representative of the patient population. The patients recruited in the present 
study have comorbidities through their underlying ESRD diagnosis, that are not 
represented in the mouse model, and have a basal inflammatory state induced by the 
dialysate, which is then followed by an acute inflammatory reaction to a bacterial infection. 
The mouse model utilised perfectly healthy laboratory mice infected with a controlled 
bacterial dose. There have been a range of PD models565 and peritonitis models566 which 
could be explored in the future as appropriate alternative animal models which may be 
more relevant to PD-related peritonitis in patients. The main reason behind the differences 
seen here is unknown, however these do suggest these four miRNAs might be best studied 
in human models for translational research aiming towards better patient outcomes. It may 
be important to investigate these differences between mouse and human miRNAs further 
in the future, and to understand better whether it may be useful to study some miRNAs 
(e.g. those that show similar changes in infection in both mouse and human) in mouse 
models, either the one demonstrated here or alternative ones. 
 
3.4 Conclusion 
In summary, this Chapter shows optimisation of the methodology for detection of miRNAs 
in cell-free PD effluent, screening to identify miRNAs of interest and confirmation of four 
miRNAs (miR-223, miR-27a, miR-21 and miR-31) that are altered in acute PD-related 
peritonitis. The levels of miR-223 returned to basal levels over the resolution of infection. 
Finally, a mouse model of peritoneal infection was also assessed for its use to study miRNA 
levels during acute inflammation, but turned out to be of only relatively little relevance for 
our understanding of human disease mechanisms. 
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4 Cell-specific expression patterns of candidate microRNAs 
4.1 Introduction 
When a patient has a PD-related peritonitis episode, they experience pain, inflammation 
and an acute immune response. This includes a range of soluble factors, like cytokines and 
chemokines, as well as a cellular response. These infiltrating cells are the reason for the 
cloudy appearance of the effluent bag and are part of the clinical diagnosis of peritonitis, 
based on a dialysate cell count of >100 white blood cells/mm3, of which >50% granulocytes, 
alongside abdominal pain and positive culture results.567 To investigate the miRNAs of 
interest identified in the preceding Chapter further, in vitro models were set up where four 
cell types present in the inflamed peritoneal cavity and important in the immune response 
to infection were investigated. Neutrophils, monocytes, HPMCs and HPFBs were isolated 
and cultured in the presence of inflammatory stimuli, then miRNAs of interest were 
investigated. 
 
The main cell type that is present in a cloudy bag are neutrophils. These polymorphonuclear 
(PMN) granulocytes are key components of the innate anti-microbial immune response and 
are the most abundant leukocytes in the blood (50-70% of circulating leukocytes). These 
short-lived cells are recruited to the site of infection and their primary function is to kill 
infecting microbes by phagocytosis, degranulation and neutrophil extracellular traps 
(NETs). Phagocytosis is the major mechanism used by neutrophils (and other “professional 
phagocytes”) to remove pathogens and cell debris, where the particle to be destroyed is 
internalised into a phagosome, which then fuses with granules that contain anti-microbial 
agents including anti-microbial peptides such as α-defensins, lysozyme and lactoferrin, as 
well as reactive oxygen species (ROS). Neutrophils use degranulation to create an 
environment that is inhospitable to invading pathogens by release of granule components 
into the environment around the inflammatory site including anti-microbial peptides and 
ROS. These granular components also play a role in signalling to and recruitment of 
subsequent inflammatory cells. NETs are formed when neutrophils undergo an active cell 
death pathway and release fibrous structures that trap microbes and kill them, which is 
thought to be through exposure to high concentrations of anti-microbial agents and 
facilitating subsequent phagocytosis. NETs contain histones and a range of granular and 
cytoplasmic proteins encased in decondensed chromatin.142,568,569 
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Another key inflammatory cell that is recruited to the site of infection are macrophages. 
These “professional phagocytes” efficiently engulf and clear infecting microbes by 
phagocytosis. Macrophages are present in many tissues as tissue-specific macrophages, as 
well as in secondary lymphoid structures, as a reservoir for rapid response to infection, and 
in immune privileged sites. Once monocytes are recruited from the peripheral blood into 
the peritoneum upon infection, they then differentiate into either inflammatory or anti-
inflammatory macrophage subsets, dependent on the local microenvironment they 
encounter. Macrophages are one of the first cell type to encounter infecting pathogens and 
therefore not only have a role in the clearance of bacteria, but also in recruiting other 
inflammatory cells to aid speedy resolution of the infection. Macrophages are able to 
recognise microbes by their surface pattern recognition receptors (PRRs), that recognise 
molecular patterns not present on healthy normal self cells, including pathogen-associated 
molecular patterns (PAMPs) such as lipopolysaccharide (LPS). They can also recognise 
opsonised microbes or cell debris, as they have receptors for antibodies and complement. 
Once engulfed into a phagosome inside the macrophage, this fuses with a lysosome to form 
a phagolysosome. The microbe is then degraded by a combination of ROS, reactive nitrogen 
species (RNS) and microbicidal proteins (e.g. matrix metalloproteases, MMPs), which 
require an acidic pH to act. As well as this phagocytic activity, macrophages recruit other 
inflammatory cells, such as neutrophils, both directly through release of neutrophil 
attractants and indirectly by releasing cytokines that stimulate epithelial cells to produce 
chemokines. The different stimuli that macrophages encounter can determine which 
subtype of macrophages is preferentially differentiated, as they can be both pro- and anti-
inflammatory. During the acute response to infection they are normally pro-inflammatory 
to attempt to resolve the infection rapidly, as is seen in acute PD-related peritonitis 
episodes.156,570–575 
 
The normal, healthy peritoneum consists of a layer of mesothelial cells over a structural 
basement membrane and interstitial layer. These HPMCs have surface microvilli and are 
joined by intercellular junctions. The peritoneum covers >100 m2 in adults and is lubricated 
by typically 50-100 ml of peritoneal fluid containing water, electrolytes, solutes, proteins 
and cells. During PD, this membrane is used for ultrafiltration of waste products and excess 
water from the blood, which passes through blood vessels within the peritoneal 
membrane.567,576 Mesothelium was historically thought to have two main roles – a 
protective barrier and a frictionless interface for movement of organs and tissues. 
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However, it is now known that mesothelial cells can also have a range of different functions 
including transport of fluid and cells, inflammation initiation and resolution, and tissue 
repair.577 The role of HPMCs in PD-related peritonitis is therefore more complex than just 
acting as the barrier for ultrafiltration to occur, it is likely they have a role in recruitment of 
leukocytes to the site of infection, as well as secretion of pro- and anti-inflammatory 
cytokines to alter the inflammatory pathway.577–581 
 
In a healthy peritoneum, fibroblasts are part of the submesothelial interstitial layer. 
However, during fibrosis (induced by PD and increased by peritonitis) there is a thickening 
of this layer caused by an increased deposition of extracellular matrix (ECM) components 
by fibroblasts that have been transformed into activated myofibroblasts. Peritoneal 
membrane fibrosis is also characterised by EMT/MMT, during which mesothelial cells 
acquire a fibroblast-like phenotype, where they become motile, and invade the underlying 
stromal layer.582,583 All this means that, during PD-induced fibrosis, there is an increase in 
the number of HPFBs. As fibrosis is increased further during peritonitis due to the 
inflammation induced, there are even more HPFBs during acute infections. Fibroblasts are 
also effector cells in the inflammatory reaction to infection, as they can release chemokines 
to attract leukocytes, such as neutrophils and macrophages, as well as some cytokines, to 
help regulate acute inflammatory reactions.582,584–587 
 
The range of cells present in acute PD-related peritonitis and the huge influx of cells in a 
cloudy bag suggest the miRNAs identified previously as candidate biomarkers may be 
important in specific cell types. It has been shown that all four cell types investigated 
release miRNAs in response to a variety of stimuli,317,410,588–590 therefore it was proposed 
that the miRNAs detected in cell-free PD effluent may have a specific cellular source, where 
infection or inflammatory stimuli influence this expression. 
 
4.1.1 Aims: 
The aims of this chapter were to: 
1. Culture cells present in a cloudy bag with high purity and activate them in vitro 
2. Identify miRNAs expressed by and released by neutrophils, monocytes, HPMCs 
and HPFBs 
3. Assess whether different inflammatory stimuli alter miRNA expression levels 
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4.2 Results 
4.2.1 Optimisation of high purity cell culture 
HPMCs and HPFBs were isolated from omentum samples using protocols optimised in our 
lab previously.578 Positive identification of pure cultures was assessed by light microscopy, 
with HPMCs having a typical “cobblestone” appearance and close proximity to 
neighbouring cells, with regular sized cells indicating a healthy culture (representative 
image shown in Figure 4.1A). HPFBs were identified by observation of elongated cells that 
often overlapped by light microscopy (representative image shown in Figure 4.1B).  
 
CD14+ monocytes were isolated from peripheral blood of healthy volunteers. The purity 
was ³ 95%, as assessed by flow cytometry, with the gating strategy and representative flow 
plots shown in Figure 4.1C. Neutrophil isolation from peripheral blood of healthy 
volunteers was more challenging due to the sensitive nature of neutrophils and how easily 
they are activated. To isolate resting neutrophils required optimisation using a protocol 
designed by our collaborators in Verona, Profs Flavia Bazzoni and Marco Cassatella.591 
Purities of ³ 99% were achieved, with contamination by CD14+ monocytes <0.5% (Figure 
4.1D). The amount of RNA produced by monocytes is 10 times higher than neutrophils, 
therefore it was important to minimise the contamination with these cells, as any results 
could be skewed by a small amount of monocyte RNA present. As a result of these 
optimisation steps, all four cell types of interest could be isolated at high purity and viability 
and cultured in vitro. 
 
4.2.2 Assessment of in vitro activation 
The activation of HPMCs and HPFBs was assessed by ELISA for the chemokine C-C motif 
chemokine ligand 2 (CCL2; alternative name: monocyte chemoattractant protein 1, MCP-
1), which is released upon activation of these cells. As shown in Figures 4.2A and 4.2B, 
stimulation of these cells with E. coli extract showed a large increase in CCL2 released into 
the medium. Although not significant for the other conditions, due to the small sample size 
(n=5 for HPMCs and n=3 for HPFBs) and the preliminary nature of these experiments, it 
was taken that stimulation with a range of different inflammatory stimuli did activate both 
HPMCs and HPFBs, as detected by CCL2 ELISA. 
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Figure 4.1: Purity of cells used in in vitro assays 
HPMCs (A) and HPFBs (B) were isolated from omentum samples, with purity assessed by 
light microscopy. Monocytes and neutrophils were isolated from peripheral blood of 
healthy individuals and assessed for purity by flow cytometry, with gating strategy shown 
in C (monocytes) and D (neutrophils). Purity of CD14+ monocytes ³ 90%. Purity of CD15+ 
neutrophils ³ 95%, with contaminating CD14+ monocytes <0.5%. All data are 
representative of replicates (n=5 for HPMCs, n=3 for HPFBs, n=5 for monocytes and n=4 
for neutrophils). 
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Figure 4.2: Activation of cells in in vitro assays 
Activation of HPMCs (A) and HPFBs (B) was assessed by ELISA for CCL2 released into the 
media. Cells were stimulated with bacterial extracts (S. epidermidis or E. coli, protein 
concentration of 50 µg/ml), Pam3CSK4 or LPS (500 ng/ml) overnight. Data presented as 
mean ± SEM, with n=5 for HPMCs and n=3 for HPFBs, analysed by Friedman test with 
multiple comparisons, significant differences are indicated: *, p<0.05; **, p<0.01; ***, 
p<0.005; ****, p<0.001. Neutrophil activation was assessed by flow cytometry detection 
of CD11b (C) and CD62L (D) between un-stimulated cells (blue trace) and those stimulated 
with LPS (500ng/ml, orange trace) for 4hr, with representative plots shown. 
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Activation of neutrophils was assessed by increased CD11b and decreased CD62L 
expression on the cell surface. As observed in Figures 4.2C and 4.2D, the level of CD11b 
increased, whilst the level of CD62L decreased upon LPS stimulation. This confirmed that 
the neutrophils isolated were resting, and that they could readily be activated in vitro by 
LPS stimulation. 
 
4.2.3 Levels of miRNAs produced and released by cells 
All four cell types were cultured in the presence of a range of inflammatory stimuli (S. 
epidermidis and E. coli bacterial extract, Pam3CSK4 and LPS) to assess whether they 
expressed any of the miRNAs of interest, and whether that expression changed upon 
stimulation. Data were presented as 40-Ct due to the variable nature of primary cells. To 
confirm this was a valid representation of the data, control small RNA molecules were also 
detected. snRNA U6 was used as a control for the intracellular detection of miRNAs, to 
confirm consistent extraction and technical reproducibility across different cell types. This 
showed good reproducibility across all cell types and all culture conditions (Figure 4.3I). For 
extracellular miRNA detection, cel-miR-39 was used to confirm consistent extraction and 
technical reproducibility, which was essential due to the inability to detect the amount of 
RNA in the samples. The amount of variability in the levels of cel-miR-39 was minimal 
(Figure 4.3J), confirming the 40-Ct values can be used to observe any possible changes of 
miRNA levels released by cells into the medium. 
 
The levels of miR-223 both expressed by and released into the media supernatant by 
neutrophils and monocytes was high, regardless of the culture conditions or inflammatory 
stimuli used (Figure 4.3A-B). Expression of miR-223 by HPMCs and HPFBs was below the 
limit of detection for RT-qPCR (Ct ³ 35). Levels of miR-27a and miR-21 both expressed and 
released were consistent across all four cell types, regardless of the inflammatory stimuli 
(Figure 4.3C-F). miR-31 had the opposite expression pattern to miR-223. This miRNA was 
expressed and released at higher levels by HPMCs and HPFBs, with the levels expressed 
and released by neutrophils and monocytes near or below the limit of detection (Figure 
4.3G-H). The different inflammatory stimuli did not affect the levels of any of the miRNAs 
either within the cells or released into the cellular supernatant, above the natural variation 
seen with primary cells and natural donor-to-donor variation. These data show that the 
four miRNAs identified have cell-specific patterns of expression and release, with no 
significant alterations due to a range of inflammatory stimuli. 
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Figure 4.3: Cell-specific expression and release of miRNAs of interest 
Showing the levels of four miRNAs of interest – miR-223 (A and B), miR-27a (C and D), 
miR-21 (E and F) and miR-31 (G and H) – alongside snRNA U6 (I) and cel-miR-39 (J) as 
reference genes. Data representative of levels detected in cellular extracts (A, C, E, G and 
I) or released into culture medium (B, D, F, H and J) after culture for 4hr with bacterial 
extracts (S. epidermidis or E. coli), or other inflammatory stimuli (Pam3CSK4 or LPS). The 
miRNAs show a cell-specific pattern of expression. Data shown as mean ± SEM with n=4 
for neutrophils, n=5 for monocytes, n=5 for HPMCs and n=3 for HPFBs. 
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4.3 Discussion 
4.3.1 Cell purity and activation 
Culturing the four cell types to be investigated in this Chapter under optimum conditions 
was crucial for the establishment of relevant in vitro models, in order to assess the 
expression of miRNAs and the effect of microbial stimuli. One consideration when setting 
up the in vitro assays was to isolate resting cells at high purity and viability, to be able to 
activate them in a controlled manner. 
 
For HPMCs and HPFBs, this was relatively straightforward as these resident cells are not 
particularly sensitive to activation through isolation procedures. A lack of CCL2 released by 
HPMCs and HPFBs, until they encounter inflammatory stimuli suggests that they are not 
activated by the isolation procedure or the culture conditions. CCL2 is so-called due to the 
C-C motif that defines similarly structured chemokines, and it recruits immune cells to the 
site of infection. It is expressed in most tissues and is responsible for migration of 
monocytes, as well as other immune cells including memory T cells and natural killer cells. 
CCL2 also has a proposed role in tissue fibrosis, e.g. in response to prolonged HPMC 
exposure to high glucose in PD dialysate, mediated by Toll-like receptor 4 (TLR4) 
activation.207,579,592 Pleural mesothelial cells infected with M. bovis and M. tuberculosis also 
produced CCL2 to trigger immune responses and attract monocytes to help resolve the 
infection.208 CCL2/MCP-1 is also released by fibroblasts in response to spider venom (in skin 
fibroblasts),593 thrombin in lung fibrosis594 and in the transformation of normal fibroblasts 
to cancer-associated fibroblasts (CAFs, in lung cancer).595 These all suggest that activation 
of HPMCs and HPFBs can be monitored in vitro by assessment of CCL2 release as positive 
control. This chemokine may play a role in the immune response to infection and shows 
the importance of resident peritoneal membrane cells in the acute phase of infection. 
 
Neutrophils are extremely sensitive to a range of stimuli and become activated very easily, 
which makes them effective at responding to acute inflammatory or infectious insults, but 
difficult to work with. To avoid activating them prematurely, the protocol designed by our 
collaborators at the University of Verona591 was optimised for our lab. Using this gentle 
approach of negative selection, my data confirmed that such neutrophils were not 
activated after isolation and could be activated in a controlled manner by LPS stimulation, 
based on monitoring upregulation of CD11b expression and shedding of CD62L. CD11b is 
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also known as integrin subunit alpha M (αM), a leukocyte-specific cell-surface integrin that 
is important in many processes including adhesion, phagocytosis and leukocyte 
extravasation, which is upregulated on the neutrophil surface upon activation.596–598 CD62L 
is also known as L-selectin and is another adhesion molecule, which is constitutively 
expressed in leukocytes and functions in the binding and rolling of leukocytes on 
endothelial cells to facilitate their migration out of the blood to a site of inflammation. After 
activation, CD62L is shed from the cell surface and becomes a functionally active soluble 
form of the protein in the blood, resulting in a loss from the cell surface of neutrophils upon 
activation.599,600 Both the upregulation of CD11b and the loss of CD62L can be seen upon 
activation of neutrophils in vitro with inflammatory stimuli. 
 
This all shows that the positive and negative controls have been successfully established to 
enable investigation into the expression and release of the candidate miRNAs in both 
resting and functionally activated cells. 
 
4.3.2 Cell-specific expression and release of miRs 
This Chapter provides evidence that miR-223 is expressed and released only by neutrophils 
and monocytes, but not by HPMCs or HPFBs corroborating earlier reports that this miRNA 
is only expressed by cells from the myeloid lineage.472,473 This high expression by infiltrating 
immune cells probably explains the large increase in detected levels in cell-free PD effluent 
in infected compared to uninfected patients (Figure 3.5A). miR-223 has also been seen to 
increase in a range of inflammatory and infectious diseases, suggesting it has a role either 
as a biomarker of the immune response or a functional role in the response.473,474 For 
example, miR-223 is increased in sepsis474,475 and rheumatoid arthritis (RA),478,479 as well as 
viral infections482,484,485 and animal models of bacterial infections.483,486 The important 
discovery that miR-223 is increased in spontaneous bacterial peritonitis in ascites confirms 
what is seen here, in that there is a large influx of neutrophils and accompanying increase 
in miR-223 in the peritoneum upon infection.449 This suggests that miR-223 may be 
important in the acute immune response to infection. It is important to investigate now 
whether this miRNA is functional, or merely a surrogate marker of the immune cell 
infiltration to the site of infection. 
 
As shown in this Chapter, miR-31 is expressed only by resident peritoneal membrane cells, 
HPMCs and HPFBs, but not neutrophils and monocytes. This is in in line with reports that 
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miR-31 is an epithelial-specific miRNA,535 although there is some evidence of miR-31 
expression in other cells types such as Tregs.537 The pleiotropic role of miR-31 in immune 
responses suggests that it is very sensitive to a range of different stimuli, including in a 
variety of inflammatory disorders548,549,553–555 and infectious diseases.557,558 There is a 
proposed role for miR-31 in the recruitment of neutrophils in allergic airway disease, and 
in the alteration of important inflammatory pathways including NF-kB.548 miR-31 was only 
produced by the resident HPMCs and HPFBs, and it appears to be downregulated in cell-
free PD effluent (Figure 3.5G). It is known that HPMCs and HPFBs produce many 
immunomodulatory factors,578,579,581 and miR-31 is important in fibrosis in PD.327 Together 
these studies suggest that miR-31 may be crucial in controlling or modulating the immune 
response in acute peritonitis. 
 
miR-27a and miR-21 were expressed by all four cell types at similar levels. miR-21 is one of 
the most highly expressed miRNAs across most cell types under different 
conditions.508,510,522,523,528 The expression pattern seen in this Chapter agrees with the 
expression patterns of this miRNA across many experimental and clinical scenarios. miR-
27a is less well studied, but there is no current evidence to suggest it is restricted to specific 
cell types, with expression altered in a range of disorders including multiple sclerosis, sepsis 
and viral infections.501–506 This also explains why the expression levels and amounts 
released in this Chapter were consistent across all cell types. 
 
4.3.3 Effect of inflammatory stimuli on miRNA expression 
This Chapter shows that a range of different inflammatory stimuli do not alter either the 
expression or release of four miRNAs of interest. Any alterations in the amount of the four 
miRNAs expressed was minimal. There was more variation in the amount of the miRNAs 
released, due partly to the technical challenges in working with cell-free fluids for miRNA 
work. The extraction method used did not allow quantification of the RNA content, 
therefore consistent amounts of RNA could not be used for RT-qPCR reactions. The use of 
cel-miR-39 as a control for the extraction, RT and qPCR showed that any small variation in 
the levels of the miRNAs released into the media was not due to the different culture 
conditions. The lack of effect of inflammatory stimuli on levels of miRNA expression and 
release was unexpected due to the sensitive nature of miRNAs and their ability to respond 
to a wide range of stimuli. In this respect, the findings in this Chapter do not support 
previous reports showing alterations of miRNAs levels in response to inflammatory stimuli. 
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For instance, after treating macrophages with LPS, expression profiling showed alterations 
in 41 miRNAs, which included decreased levels of miR-31 and miR-27a, two miRNA studied 
in this thesis.601 It may be the case that any differences were masked due to the issues with 
donor-to-donor variation, as well as technical variations observed across the board. 
 
4.3.4 Proposed model of miRNA release in PD-related peritonitis 
These data demonstrate that the four miRNAs of interest are expressed and released in a 
cell-specific pattern, and that inflammatory stimuli do not affect this expression 
significantly. The potential cellular sources of the miRNAs identified here may help explain 
why the miRNAs are altered in cell-free PD effluent in infection, as depicted by the 
proposed model in Figure 4.4, where each cell type expresses distinct patterns of miRNA 
expression. For example, HPMCs and HPFBs express miR-21, miR-31 and miR-27a, whilst 
neutrophils and monocytes express miR-21, miR-27a and miR-223. 
 
Taken together, these data suggest that the increase in miR-223 in infection observed in 
the previous Chapter can be partly explained by the increased number of neutrophils and 
macrophages, which infiltrate the peritoneum, as these cell types express and release high 
levels of miR-223. On the other hand, the observed decrease in miR-31 levels during acute 
peritonitis could be due to the fact that the infiltrating immune cells do not express 
detectable levels of this miRNA. As consequence, miR-31 levels may appear to go down in 
infection as there are large numbers of infiltrating cells that release other miRNAs 
(including miR-223), meaning miR-31 is diluted out. miR-21 and miR-27a are expressed by 
all cell types, but the levels of these are decreased in infection. This could also be due to a 
dilution by miR-223 and other leukocyte-specific miRNAs not investigated in this study. 
 
Overall, these data suggest a potential cell-specific expression pattern for the four miRNAs 
of interest, as shown in Figure 4.4. According to this model, miR-223 is only expressed and 
released by the immune cells which infiltrate the peritoneum upon infection, whilst miR-
31 is only expressed and released by the resident cells of the peritoneal membrane. miR-
21 and miR-27a are expressed and released by all four cell types at relatively consistent 
levels. This model partly explains the alterations in miRNA level seen in patient PD effluent, 
with increased miR-223 due to an increase in the infiltrating immune cells which express 
and release it. The other three miRNAs are decreased due to the fact they are diluted out, 
compared to miR-223. Further work is required to investigate whether these miRNAs are  
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Figure 4.4: Diagram proposing model of miRNA expression in PD effluent 
Showing a proposed model of the cell-specific expression pattern of miR-21, miR-31, miR-
27a and miR-223 in PD effluent both before and after a bacterial peritonitis infection. 
miR-21 and miR-27a are expressed by all cell types, miR-31 is only expressed by resident 
HPMCs and HPFBs, whilst miR-223 is only expressed by infiltrating neutrophils and 
macrophages. 
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functional in the acute response to PD-related peritonitis infections, or if they are merely 
biomarkers of infection. 
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5 In silico target prediction 
5.1 Introduction 
One of the most important factors in the elucidation of the biological relevance of miRNAs 
(miRs) is the identification of the biological pathways they influence, primarily by the 
mRNAs they regulate. This can be done in multiple ways. Often an initial step is to predict 
potential mRNA targets through appropriate algorithms.459 There are multiple algorithms 
that have been developed to identify mRNA targets that take into account different 
features thought to be important in the binding of miRs to their target mRNAs. Due to the 
relatively high rates of false positives resulting from each algorithm, it is common practice 
to use multiple algorithms and then attempt to validate targets which have been identified 
by complementary methods.602,603 In this study, four different algorithms were used to 
identify a list of potential targets for the four candidate miRs previously identified; miR-
223, miR-21, miR-31 and miR-27a. The algorithms used were all freely available online, and 
results could be ranked by the strength of the prediction. 
 
The four methods used were Diana,451,452 miRanda,453,454 miRDB455,456 and TargetScan.  The 
differences and similarities of the four algorithms will be discussed in detail later on. Briefly, 
they all look at the seed sequence, identifying the sequences that match with the miR seed 
sequence (or wider miR sequence) in the 3’ UTR (or whole coding sequence) of the mRNA. 
This is required for the miR to bind to the mRNA they regulate, and is therefore an 
important criterion that all algorithms use to identify predicted targets.459,602,604,605 The 
next main criterion for identifying predicted targets is the conservation between species of 
the target site, and the surrounding region. This is important due to the fact that miR target 
sites are often more highly conserved than other regions of the gene. However, due to the 
variations in pathways that miRs regulate across different species, even closely related 
ones, this may miss some interactions. Regulatory elements, such as regions of the 3’ UTR 
targeted by miRs, are more likely to be evolutionarily conserved, therefore this is an 
important consideration when attempting to predict functional regulation of 
targets.459,602,604–606 The final component used to identify predicted miR targets is the 
energetic evaluation of the predicted interaction, i.e. the free energy of the miR binding to 
the mRNA and the accessibility of the target site, in terms of secondary structure. These 
parameters are important to evaluate if a potential interaction is likely to be energetically 
favourable, therefore more likely to be “real”.459,602,604,605 These different criteria have been 
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used by the different algorithms to rate potential targets of the miRs of interest, and the 
lists generated can be compared to find targets that are predicted by multiple algorithms, 
as these are most likely to be functionally relevant. 
 
This bioinformatics-based approach of target prediction is well established in the literature; 
however, it does not show any functional relationships between a miR and its potential 
mRNA target. To identify functional changes regulated by miRs requires experimental 
validation.603 One way to do this is by transfecting cells of interest with the candidate miRs, 
and then conducting ‘omics approaches (RNAseq or proteomics analysis) to find targets 
whose expression levels are changed when the miR is present. This will identify both direct 
and indirect targets, but may pull out whole pathways which are altered, therefore those 
that are functionally important.607,608 It is thought that the effect on individual mRNAs by a 
specific miR may be only marginal, and that phenotypic changes are due to modest 
targeting of multiple mRNAs in the same pathway to produce a large effect,609 and ‘omics-
based technologies can help assess this. 
 
Once predicted targets have been identified using bioinformatics or ‘omics approaches, it 
is important to validate these interactions to identify which are “real” interactions and have 
functional consequences. To do this, the region of the gene that is predicted to be targeted 
by the miR is normally cloned into a reporter assay system, often luciferase-based, to 
identify whether the readout changes when the miR is present.607,608,610 To confirm this 
interaction is specific, the region of interest is often subject to point mutations to confirm 
the interaction is lost when the specific binding cannot take place between the miR and the 
target region of the mRNA. This is the best direct method of confirming an interaction 
between a miR and a mRNA is functional.610 
 
Another possible way is to transfect cells with the miR of interest and see if there is a 
change in the protein level of the predicted target. This is a simple way of validating the 
pathways that are thought to be important and are regulated by the miR, however it does 
not confirm if the interaction is a direct one or merely indirect.610,611 This must normally be 
accompanied by a reporter assay system as described above, to identify the specific gene 
that is regulated by the miR.610 
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In this Chapter, a list of predicted targets for miR-223, miR-21, miR-31 and miR-27a was 
generated, then cross-referenced to identify candidates that are predicted to be targeted 
by multiple miRs. A select number of predicted targets were evaluated in the context of 
what is already known about these proteins in infection, inflammation and immune 
responses, as well as which interactions with miRs is already known. 
 
5.1.1 Aims 
The aims of this chapter were to: 
1. Identify predicted targets for miR-223, miR-21, miR-31 and miR-27a using four 
complementary prediction algorithms 
2. Identify targets predicted to be targeted by multiple miRs 
3. Discuss a select number of predicted targets for their potential relevance in 
biologically relevant situations 
 
5.2 Results 
5.2.1 Target prediction for individual miRs 
To predict potential mRNA targets for the four miRs identified previously, four different 
algorithms were used: Diana,451,452 miRDB,455,456 miRanda453,454 and TargetScan.457,458 Each 
uses different criteria to predict potential targets, therefore the most likely to be real mRNA 
targets of miR-223, miR-21, miR-31 and miR-27a were thought to be those predicted by 
multiple algorithms. Stringent criteria (defined in the Materials and Methods) were used 
to generate lists of potential targets from each algorithm, and Venn diagrams were used to 
show these predicted targets. 
 
For miR-223 there were 160 predicted using Diana, 385 using miRanda, 64 using miRDB 
and 146 using TargetScan. There were 49 predicted targets which were identified from at 
least 3 of the 4 algorithms, with 16 targets predicted by all 4 algorithms (Figure 5.1, Table 
5.1).  
 
miR-21 had 108 predicted targets using Diana, 421 using miRanda, 67 using miRDB and 126 
using TargetScan. Of these, 53 targets were predicted by 3 or more algorithms, and 19 
targets predicted by all 4 algorithms (Figure 5.2, Table 5.2).  
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Figure 5.1: Predicted targets of miR-223 
Venn diagram showing the predicted targets of miR-223 generated from four different 
prediction algorithms (Diana, miRanda, miRDB and TargetScan). 
 
Table 5.1: Predicted targets of miR-223 
Table showing the names of miR-223 targets as predicted by three or more of the four 
target prediction algorithms (Diana, miRanda, miRDB and TargetScan). Colour of cells 
shows corresponding section of the above Venn diagram they represent. 
  
Diana, miRanda 
and miRDB 
Diana, miRDB 
and TargetScan 
Diana, miRanda 
and TargetScan 
miRanda, miRDB 
and TargetScan 
All 4 algorithms 
DUSP10 GALNT18 GTSF1 HSP90B1 FBXW7 
RRAS2 LACC1 LELP1 SEPT6 FBXO8 
 SMARCD1 WDR62 INPP5B SP3 
 RAB8B DNAJB13 CRIM1 RHOB 
 SIAH1 FAM46A INPP4A ARMCX1 
 TMEM178B SORBS1 SLC39A1 NUP210 
  C18ORF54 NLRP3 PRDM1 
  CBLB ANKRD17 PTBP2 
  ATP2B1 ATP1B1 SLC4A4 
  CYTIP F3 IL6ST 
  ATP10D  ATP7A 
  NXF1  CDK17 
  USP16  ACSL3 
  SYAP1  LMO2 
  RASA1  ECT2 
    KPNA3 
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Figure 5.2: Predicted targets of miR-21 
Venn diagram showing the predicted targets of miR-21 generated from four different 
prediction algorithms (Diana, miRanda, miRDB and TargetScan). 
Table 5.2: Predicted targets of miR-21 
Table showing the names of miR-21 targets as predicted by three or more of the four 
target prediction algorithms (Diana, miRanda, miRDB and TargetScan). Colour of cells 
shows corresponding section of the above Venn diagram they represent. 
  
Diana, miRanda 
and miRDB 
Diana, miRDB 
and TargetScan 
Diana, miRanda 
and TargetScan 
miRanda, miRDB 
and TargetScan 
All 4 algorithms 
KLF3 YOD1 RECK NTF3 ZNF367 
VCL FGF18 CCL1 PITX2 SKI 
YAP1 SPRY2 PDCD4 TIAM1 PELI1 
 JAG1 SOX5 C10orf12 STAG2 
 HIPK3 IL12A SATB1 GPR64 
 PLAG1 GLIS2 MAP3K1 PBRM1 
 ARHGAP24 SMAD7 PAN3 PLEKHA1 
 NFIA MATN2 PCBP1 SCML2 
  FASLG GLCCI1 ZSWIM6 
  SLC16A10 BEST3 TGFBI 
  KLF5  KRIT1 
  LRRC57  ARMCX1 
  RASGRP1  CASKIN1 
    PPP1R3A 
    CPEB3 
    SPRY1 
    PCSK6 
    ELF2 
    RBPJ 
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miR-31 was predicted to target 116 mRNAs by Diana, 340 by miRanda, 113 by miRDB and 
209 by TargetScan. 55 of these targets were predicted by at least 3 algorithms, with 14 
targets predicted by all 4 algorithms (Figure 5.3, Table 5.3).  
 
For miR-27a, there were 726 predicted targets using Diana, 282 using miRDB, 706 using 
miRanda and 498 using TargetScan. 213 of these targets were predicted by at least 3 
algorithms, with 75 predicted by all 4 algorithms (Figure 5.4, Table 5.4). 
 
5.2.2 Predicted targets for multiple miRs 
The above analysis resulted in a large number of potential targets for each miR to 
investigate further. As three of the four miRs investigated here were decreased in the acute 
response to PD-related peritonitis (miR-21, miR-31 and miR-27a), it was interesting to 
investigate whether there were any common targets predicted to be regulated by multiple 
miRs, suggesting possible redundancy in the acute immune response. Although miR-223 is 
increased in infection, whilst the other three miRs are decreased, it is interesting to see if 
any of the same mRNAs are regulated by this miR, to attempt to understand the molecular 
signalling during the acute response to infection. This was done using Venn diagrams 
comparing the lists of targets predicted by 3 or more of the 4 algorithms. To this end, there 
were very few targets predicted to be regulated by multiple miRs (Figure 5.5B): 
miR-21 and miR-31 = ZSWIM6 
miR-223 and miR-21 = ARMCX1* 
miR-31 and miR-27a = VAV3, CCNC and PAX9 
miR-223 and miR-31 = RASA1 
miR-21 and miR-27a = SPRY2 and ALC16A10 
miR-223 and miR-27a = FBXW7* 
* = identified when lists of targets predicted by all four algorithms were also compared 
(Figure 5.5A) 
 
This lack of crossover between predicted targets fits with the different direction of changes 
in miR levels in infected PD effluent (i.e. miR-223 increases, whilst miR-21, miR-31 and miR-
27a decrease), therefore they are likely to be important in different components of the 
acute response to peritonitis infection. However, it is interesting that the miRs that are all 
decreased in infection do not appear to target the same mRNAs. This is likely due to the  
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Figure 5.3: Predicted targets of miR-31 
Venn diagram showing the predicted targets of miR-31 generated from four different 
prediction algorithms (Diana, miRanda, miRDB and TargetScan). 
Table 5.3: Predicted targets of miR-31 
Table showing the names of miR-31 targets as predicted by three or more of the four 
target prediction algorithms (Diana, miRanda, miRDB and TargetScan). Colour of cells 
shows corresponding section of the above Venn diagram they represent. 
  
Diana, miRanda 
and miRDB 
Diana, miRDB 
and TargetScan 
Diana, miRanda 
and TargetScan 
miRanda, miRDB 
and TargetScan 
All 4 algorithms 
FAM134B IL34 SATB2 KHDRBS3 RSBN1 
ZNF512 NR5A2 STARD13 HIAT1 RHOBTB1 
HSD17B6 PDZD2 RGAG1 FGF7 MBOAT2 
FNDC5 SLC1A2 KDELR2 LATS2 SH2D1A 
 VAV3 CREG1 ATL2 PIK3C2A 
 RGS4 ZSWIM6 CRYBG3 KANK1 
 TBXA2R CCNC INSC NUMB 
 DCBLD2  HOMER1 SYDE2 
 PPP3CA  PEX5 PPP2R2A 
 RNF144A  DUSP7 LBH 
   EGLN3 PRKCE 
   CHMP7 NUP153 
   PSMB11 PAX9 
   CAMK2D SEPHS1 
   KCTD21  
   RASA1  
   CLASP2  
   PC  
   MGAT1  
   GCH1  
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Figure 5.4: Predicted targets of miR-27a 
Venn diagram showing the predicted targets of miR-21 generated from four different 
prediction algorithms (Diana, miRanda, miRDB and TargetScan). 
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Table 5.4: Predicted targets of miR-27a 
Table showing the names of miR-27a targets as predicted by three or more of the four 
target prediction algorithms (Diana, miRanda, miRDB and TargetScan). Colour of cells 
shows corresponding section of the above Venn diagram they represent. 
  
Diana, 
miRanda 
and miRDB 
Diana, miRDB and 
TargetScan 
Diana, miRanda and 
TargetScan 
miRanda, 
miRDB and 
TargetScan 
All 4 algorithms 
SFRP1 APPBP2 AFF4 GRB2 THOC1 NDUFS4 FBXW7 NEURL4 
UNC13C TSC1 STX16 KITLG KCNJ1 ITSN2 PLK2 ADORA2B 
TMBIM6 LIN28B USP46 MAP2K4 INPP1 NPEPPS KCNK2 SLC6A1 
STAG1 SZRD1 PNISR FAM65B GDF6 GLRA2 DCUN1D4 DNAJC13 
ANKRD40 
GXYLT1 GSPT1 
TMEM189-
UBE2V1 MARCKS CCNC GCC2 UNKL 
UBR5 PRKX GRIN2D ISL1 TOMM40L NLN NRK NCOA7 
SBF2 RELN USP51 KIAA1109 KHSRP FAM184A PDIA5 CEP135 
GRIA4 ABCA1 DNAJC27 RCAN2  GALNT3 CDS1 PLCL2 
SNRNP27 NGFR SEC22A FAM193B  PSMA1 AQP11 SNAP25 
VIP CREB1 EDEM3 GFPT2  VAV3 FLRT3 REPS1 
FOXP2 SEMA6A FRS3 HBEGF  NMB WSB1 NR2F6 
CPNE8 SLC35F1 CSRNP1 GABRP  CYP39A1 CKAP4 CDR2 
TRIM50 LPAR6 SS18L1 SLC16A10  NRXN1 PPARG C1orf52 
 PELI2  PARD6B  TROVE2 GRM5 YWHAQ 
 ROR1  DKK2  RPS6KA5 HOXA10 SLC39A11 
 B4GALT3  RGS17  RNF182 CSRP2 C8orf4 
 HOXA5  BMI1  KDM3A PPP1CC PDHX 
 GATC  CCDC149  SFXN2 ZHX1 STK39 
 NABP1  HOXB8  FOSB SPRY2 EYA1 
 TRPV3  YWHAB   UBE2V1 MIER3 
 CREBRF  CCNG1   RAPGEF2 LIMK1 
 ABHD17C  COL21A1   DTNA NGFRAP1 
 SNX12  FASTKD5   RPGRIP1L SLITRK1 
 CCNJ  SFXN4   PKIA LONRF1 
 SHE  MBTD1   RREB1 TRIM23 
 ZBTB34  GALNT5   AKIRIN1 RNF139 
 TMEM170B  EFNB2   ST6GALNAC3 EYA4 
 GAB1  RAD9B   ZNF800 CA10 
 GNS  HORMAD2   ZMYM4 GALNT7 
 TNPO1  TMUB1   E2F7 PDK4 
 SOWAHA  ZIC5   MMD CCNK 
 TLK2  VEGFC   GOLM1 MED14 
 GPAM  CNN3   PDE7B  
 ARHGEF26  CNOT7   CDH11  
 TAB3  CACNA2D3   NOVA1  
 TMCC1  TRAF3IP3   FAM133B  
 NXT2  PANK1   MATN3  
 DLL4  STYK1   PSPC1  
 ATXN10  NEDD4   RSBN1L  
 ZCCHC24  HOXA13   PRKCB  
 B3GNT7  PAX9   PAIP2  
 C2CD2  GCA   PDS5B  
 NIPAL4  TFPI   TNRC18  
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Figure 5.5: Predicted targets of multiple miRNAs 
Showing the common targets from the lists predicted by all four algorithms (A) or three or 
more algorithms (B) in Venn diagram format, with the named predicted crossover targets 
in tables below. Colour of cells shows corresponding section of the Venn diagram they 
represent. 
 
  
microRNAs Common predicted targets 
miR-223 and miR-21 ARMCX1 
miR-223 and miR-27a FBXW7 
microRNAs Common predicted targets 
miR-21 and miR-31 ZSWIM6 
miR-223 and miR-21 ARMCX1 
miR-31 and miR-27a VAV3 CCNC PAX9 
miR-223 and miR-31 RASA1 
miR-21 and miR-27a SPRY2 SLC16A10 
miR-223 and miR-27a FBXW7 
A 
B 
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possibility that they regulate different pathways involved in this response. This will be 
discussed further below. 
 
5.3 Discussion 
The present Chapter identified a large number of predicted targets. Given the time 
constraints of this PhD project, there was not sufficient time to evaluate potential targets 
experimentally.  This experimental validation was also not possible due to the fact that the 
cells in which the miRs act was not known, as they were identified in cell-free PD effluent. 
It was possible to characterise the cells which produced and released the miRs, but it has 
not yet been determined whether the miRs act within the cells that produce them or in 
distant cells. In the absence of functional validation, selected targets are reviewed here, 
and current literature was used to discuss whether they might be relevant in patients with 
acute PD-related peritonitis. 
 
5.3.1 Different algorithms 
The four different algorithms used here all utilise different criteria to predict mRNA targets 
of miRs of interest, as shown in the comparison in Table 2.4. All four algorithms are 
designed to look for a good seed match, by looking at the first 2-8 nucleotides from the 5’ 
end of the miR and comparing it to sequences in the mRNA for a Watson-Crick match. These 
seed sequences can comprise all eight nucleotides (8mer), seven of the eight nucleotides 
(7mer) or only six nucleotides (6mer). A seed match of at least a 6mer is essential for miR 
targeting of mRNA, and therefore is included in all algorithms used to be able to identify 
possible targets.459,602,604,605 
 
All four algorithms also compare conservation between species, due to the fact that the 
miR seed region has a generally higher evolutionary conservation than non-seed regions. 
This provides evidence that a sequence match may be functional due to the observation 
that it appears to have been evolutionarily selected for. However, data shown earlier 
(Figure 3.8) suggest that although miRs may be conserved between organisms on the level 
of the nucleotide sequence, their role may be different, even between relatively closely 
related organisms such as humans and mice. The use of conservation as a selection tool for 
predicted targets therefore means some interactions that are exclusive to humans may be 
missed. However, this tool can be used to look at some of the more conserved pathways 
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which miRs regulate, as a starting point for functional analysis of miRs in response to 
infection.459,602,604–606 
 
Free energy is another measure of stability of the interaction between an mRNA and the 
corresponding miR, with a more stable interaction identified by negative free energy. This 
is only used by three of the four algorithms (Diana, miRanda and miRDB; not TargetScan). 
Another measure of the likelihood of a reaction being “real” is the accessibility of the target 
site in the mRNA. If the secondary structure of the mRNA makes it unlikely that the 
predicted target site is open for miR targeting or requires a large energy input to make it 
available, then the interaction is not thought to be relevant. This is also used for three of 
the four algorithms to identify predicted mRNA targets (Diana, miRanda and miRDB; not 
TargetScan).459,602,604,605 
 
These are the four main criteria utilised by the four target prediction algorithms used here, 
although there are other factors involved in identifying predicted targets. For example, 
target site abundance is used by Diana, to predict the number of potential miR binding sites 
that are present in the 3’ UTR of an mRNA. Although only one target site is needed for miR-
dependent regulation of a target gene, this interaction is thought to be more functionally 
relevant if multiple target sites are present in the 3’ UTR.459,602,605 Machine learning 
approaches, often using support vector machines, are also being used more widely, where 
the prediction model is trained on a training dataset to help to predict real interactions 
more accurately. This allows determination of the predictive power of each of the criteria, 
to allow better ranking of predicted targets.459,604,605 
 
5.3.1.1 Diana 
The full name for Diana is Diana-microT-CDS. This software uses two training datasets, one 
from PAR-CLIP (photoactivatable-ribonuclease-enhanced crosslinking and 
immunoprecipitation) data and the other from microarray data (to learn the specific 
contribution of multiple sites in a target). This algorithm is different to the others used in 
this analysis, in that it looks in both the 3’ UTR and the protein coding sequence (CDS), 
whilst the others only look for target sites in the 3’ UTR. The most important features in 
ranking predicted targets are the efficiency of binding (based on an extended seed 
sequence), the distance to the nearest end of the 3’ UTR or CDS, distance to adjacent 
binding site(s), free energy, conservation and Adenylate-uridylate (AU) content (AU-rich 
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elements are markers of increased mRNA instability and thought to be involved in miR 
targeting of mRNAs). The accessibility of the 3’ UTR is another feature taken into 
consideration but not a major factor. The 3’ UTR and CDS are analysed individually, then a 
combined score is presented for each target. The results are detailed including the scores 
and information on the predicted target gene location, as well as links to relevant 
publications and whether the interaction is predicted by miRanda or TargetScan, or if it has 
been experimentally validated. This algorithm can give different results to the others due 
to the inclusion of the CDS, although the stringent conditions used for selection meant that 
the present study did not result in excessive numbers of Diana-predicted mRNA targets for 
each of the four miRs. The reference to previous experimental validation is a useful feature, 
to observe if this is worth pursuing and if it may indeed be a functional interaction. The 
targets identified here will be discussed in more detail below, including whether they have 
been experimentally validated and in which models.451,452,459,602,604,605 
 
5.3.1.2 miRanda 
The miRanda-miRSVR algorithm uses the miRanda method to identify target sites and then 
a support vector regression to rank them. miRanda has three steps: (i) identification of 
sequence matches; (ii) free energy prediction; and (iii) conservation of the binding site and 
its position. The sequence comparisons use the whole miR, not just the seed region, but 
matches within the seed region are weighted more highly. To rank the predicted targets, 
the support vector regression was trained on experiments using HeLa cells. Matches are 
ranked by the predicted effect a miR will have on the mRNA expression by taking into 
account site accessibility, AU content of flanking regions, target site position in the 3’ UTR 
and the length of the 3’ UTR. This algorithm is thought to be effective, although it does 
have some problems as it may not always use the most up to date miRBase database 
version. However, with the miRs this PhD thesis focuses on being among the most well 
studied and earliest discovered miRs, this was deemed not to be a major concern for the 
predictions in this Chapter.453,454,459,602,604,605 
 
5.3.1.3 miRDB 
miRDB is also called MirTarget2, and this algorithm is based on a support vector machine 
trained on a large microarray dataset. The features in this model include seed conservation, 
seed match (in the seed region only), base composition in the flanking regions, secondary 
structure (includes site accessibility and free energy), and location within the 3’ UTR. One 
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major limitation with this algorithm is that the training dataset only contains mRNAs with 
one target site, and that there are none with multiple binding sites. This was done by the 
software developers to limit potential confounding factors and reduce the complexity 
involved with multiple sites, however this limitation may skew the dataset somewhat, as 
an increased number of potential target sites in a 3’ UTR may suggest an increased 
possibility of a “real” miR:mRNA interaction.455,456,459,604 
 
5.3.1.4 TargetScan 
This prediction software can either rank candidates on their predicted efficiency of 
targeting or conservation. For this analysis, predicted efficiency of targeting was used, 
where the score is derived from experimental results with factors including 3’ 
compensatory pairing, local AU content and position contribution. The conservation rating 
takes into account how strongly conserved each k-mer is (8mer, 7mer, etc.). This software 
contains links to the 3’ UTR and previous publications where this interaction has been 
published. To be able to clearly see the number of predicted target sites for a specific miR, 
as well as the different miRs predicted to bind to a specific mRNA 3’ UTR, allows ease of 
use and simple interpretation of results. The ability to see all predicted target sites, ignoring 
conservation, is also an option to remove the bias explained above for other algorithms 
that rely on conservation as a selection criterion. However, as this is a preliminary screen 
for potentially well conserved targets and pathways, this option was not used and the 
target list presented in this Chapter contains only well conserved sites.457–459,602,604–606 
 
The sensitivity and specificity of target prediction algorithms can often be quite low, with 
false positive rates a problem.602 For example, one study showed that TargetScan had a 
sensitivity of only 20%.604,612 This is another reason for using all four algorithms in parallel, 
as any target predicted by multiple algorithms is more likely to represent a real interaction, 
therefore suggests most promise for experimental validation. 
 
5.3.2 Selected genes predicted to be targeted by only one miR 
A selection of genes that were only predicted to be targeted by one miR and their potential 
biological relevance in acute infection is discussed below. Those selected were thought to 
be most relevant due to their reported roles in either infection or the immune system, 
specifically innate immune responses or inflammation. 
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5.3.2.1 Predicted miR-223 targets: 
5.3.2.1.1 PR/SET domain 1 (PRDM1) 
PRDM1 is a repressor of beta-interferon (IFN-β) gene expression, with its gene located on 
chromosome 6, and it is predicted to be targeted by miR-223 as its mRNA is predicted to 
contain a 7mer in its 3’ UTR. This protein is expressed across many different types of tissues, 
including the oesophagus, endometrium and colon.613 PRDM1 is an attractive candidate for 
future investigations due to its known role in the immune response. It controls expression 
of effector cytokines in natural killer cells, both IFNg (interferon gamma) and TNF-a and 
TNF-b (tumour necrosis factor alpha and beta).614 PRDM1 is induced during dendritic cell 
maturation615 and is important in antigen presentation.616 There are many links between 
PRDM1 and autoimmunity. For example, PRDM1 missense mutations increased T cell 
proliferation, cytokine secretion and L-selectin expression in Crohn’s disease.617 The 
mechanism of autoimmune pathogenesis is thought to be through expression in thymic 
epithelial cells,618 or through interaction with human parvovirus B19 in autoimmune 
thyroiditis.619 These studies propose that PRDM1 can affect many different elements of the 
immune response, suggesting it may be important in the acute response to PD-related 
peritonitis.  
 
5.3.2.1.2 Interleukin 6 signal transducer (IL6ST) 
IL6ST (also known as gp130) is not only a signal transducer for IL-6 (interleukin 6), but a 
range of other cytokines in the IL-6 family, as part of a receptor complex. When a member 
of the IL-6 cytokine family binds to IL6ST, the receptor dimerises and intracellular signalling 
cascades are initiated.620 The IL6ST gene is located on chromosome 5, and the IL6ST mRNA 
has two predicted binding sites for miR-223 in its 3’ UTR; one 8mer and one 7mer. It is 
expressed across a wide range of tissues, including in the placenta, liver and spleen.613 IL-6 
is one of the most important cytokines in the acute immune response, and was first 
identified as a B-cell differentiation factor and required for antibody production.621 IL-6 and 
IL6ST are important in immunity against infections, for example IL-6 can be used as a 
specific biomarker for infection over other inflammatory conditions,622 and this has also 
been shown in PD-related peritonitis.222 IL6ST has a key role to play in anti-viral immunity 
through both CD4+ and CD8+ T cells.623 IL-6/IL6ST are also important in many other parts of 
the immune response including T cell differentiation,624 neutrophil trafficking625 and acute-
phase protein expression.621,626 IL-6, and IL6ST, have been implicated in a number of 
pathological conditions, most notably autoimmune disorders due to their roles in the 
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immune response,627 as well as inflammatory conditions including atherosclerosis,628 
sarcoidosis629 and myocardial infarction.630 All of this suggests that IL-6 and IL6ST may be 
important in the acute response to PD-related peritonitis, therefore it is conceivable that 
targeting by miR-223 may be important to regulate this inflammatory reaction. The 
interaction between IL6ST and miR-223 has not been experimentally validated, therefore 
further work would need to confirm this, however it has been shown that miR-142 and 
miR-143 can regulate IL6ST in a fever-induced immune response.631 It will be interesting to 
investigate whether miR-223 also regulates IL6ST and if this has a role in the acute immune 
response to infection. 
 
5.3.2.2 Predicted miR-21 targets: 
5.3.2.2.1 Transforming growth factor beta 1 (TGFB1) 
TGF-β1 is the secreted ligand of the TGF-beta superfamily of proteins, which binds to TGF 
receptors and activates transcriptional pathways via Smad proteins, among others.632,633 
The TGFB1 gene is expressed on chromosome 19, and the corresponding mRNA contains 
one highly conserved 8mer predicted miR-21 binding site in its 3’ UTR. TGF-β1 is expressed 
across a wide range of tissues, including the spleen, bone marrow and lung.613 It is a well-
studied protein with roles across many different biological pathways, including embryonic 
development and tissue homeostasis, proliferation, apoptosis, differentiation and 
inflammation. Most interesting for the present study is its function in inflammatory 
pathways and the immune response. TGF-β1 can be both pro- and anti-inflammatory, 
dependent on the local microenvironment, co-stimulatory factors and the specific cell 
type.632,634,635 TGF-β1 can act on naïve T cells, controlling their differentiation towards the 
pro-inflammatory Th17 phenotype when IL-6 is present, whilst Treg cells are generated 
when there is no IL-6 present. This suggests that TGF-β1 may help regulate the T cell 
response dependent on the state of the innate immune reaction.636 TGFB1 knockout 
animals have confirmed the regulatory role for this gene in inflammatory processes, when 
there is no stimulus of the innate immune system. These animals have high rates of death 
in utero, and those that do survive to birth develop inflammatory disease in many tissues, 
especially the heart and lungs.213,637 The presence of IL-6 (and other pro-inflammatory 
acute response proteins) in the peritoneum of peritonitis patients suggests that TGF-β1 
would have a pro-inflammatory role in the peritoneum of a peritonitis patient. The 
proposed suppression by miR-21 may have a protective effect to reduce the inflammatory 
reaction, however there is a lower level of miR-21 in infected PD effluent. All this means 
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that it is possible that reduced miR-21 may mean increased TGFB1, therefore a stronger 
inflammatory reaction, which may influence the resolution of infection. However, this 
would be dependent on confirmation of a functional interaction between miR-21 and 
TGFB1. It has been suggested that miR-21 may be regulated by Smad proteins in renal 
fibrosis, which are controlled by TGFB1,632 therefore the reverse method of control may be 
important. It is yet to be proven experimentally whether miR-21 regulates TGFB1, and how 
this may modulate the acute immune response to infection. 
 
5.3.2.2.2 Recombination signal binding protein for immunoglobulin kappa J region (RBPJ) 
RBPJ is a transcriptional regulator involved in the Notch signalling pathway, which regulates 
multiple cellular processes, including differentiation, proliferation and survival.638 The RBPJ 
gene is located on chromosome 4 and its mRNA contains one predicted 7mer binding site 
for miR-21 in its 3’ UTR. RBPJ is expressed in a variety of different human tissues, including 
the placenta, endometrium and bone marrow.613 RBPJ and Notch signalling are involved in 
many different aspects of the immune response including T cell cytotoxicity,639 CD4+ 
memory T cell function,640,641 B cell development642 and Th17 cell heterogeneity.643,644 
However, most relevant to acute PD-related peritonitis is the role of RBPJ in the innate, 
inflammatory acute response. RBPJ has many roles in dendritic cells, including in their 
homeostasis, tissue-specific development, maturation and control of T cell activation (in 
both infection and tumour immunity).638,645,646 RBPJ also affects macrophage activation and 
TLR-induced gene expression.638,647 RBPJ is involved in the pathogenesis of inflammatory 
diseases in skin and the intestinal epithelium,638,648 as well as in the recruitment of 
inflammatory leukocytes in vascular inflammation.649 In this analysis, it is predicted that 
miR-21 targets RBPJ, but this has not been evaluated experimentally to date. However, it 
has been shown that miR-133a can regulate RBPJ in dendritic cells in osteosarcoma.645 The 
large number of functions of RBPJ in immune responses, both innate and adaptive, suggest 
that it may be important in acute PD-related peritonitis. It is yet to be evaluated whether 
targeting by miR-21 is functional, and whether this is important in the acute immune 
responses. 
 
5.3.2.3 Predicted miR-31 targets: 
5.3.2.3.1 Limb bud and heart development (LBH) 
LBH, as its name suggests, was first identified in development of limbs and the heart,650 but 
it is now known to be a conserved transcriptional regulator with roles in autoimmune 
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pathologies, cancers and cardiac diseases, as well as development. The gene is located on 
chromosome 2 and its mRNA has a 7mer predicted to be a binding site for miR-31 in its 3’ 
UTR. LBH is expressed across multiple different human tissues, with high levels in the lung 
and lymph nodes, among others.613 LBH has potential roles in cardiac pathologies, due to 
its association with heart development.650–652 It has also been identified as a biomarker and 
potential therapeutic target in breast, lung and nasopharyngeal cancer.653–655 The 
mechanistic role of LBH in autoimmune disorders is not clearly defined, but it is a genetic 
factor associated with rheumatoid arthritis, celiac disease and systemic lupus 
erythematosus through genome-wide association studies (GWAS), mechanistic and 
association studies.656–660 Due to the limited current knowledge on the function of LBH in 
the immune system, one can only speculate whether LBH has a role in regulation of the 
immune response, especially during infection. The functional relevance of the proposed 
interaction between miR-31 and LBH awaits experimental confirmation. 
 
5.3.2.3.2 Protein kinase C epsilon (PRKCE) 
PKCε is a serine- and threonine-specific protein kinase that phosphorylates multiple 
proteins in a range of cellular processes,661 with expression across a wide range of tissues, 
including the brain, lung, kidney and many others.613 The PRKCE gene is located on 
chromosome 2 and its mRNA contains one 8mer predicted binding site for miR-31 in its 3’ 
UTR. Due to its role in multiple cellular processes, PKCε has been identified as a risk factor 
in cancers,661 including lung cancer,662 small B-cell lymphoma663 and gallbladder cancer.664 
PKCε is involved in inflammatory pathways and a range of inflammatory pathologies. For 
example, PKCε was identified as altered in asthma and important in its pathogenesis.665 
Also, PRKCE is a risk factor for diabetic nephropathy, with links to the inflammatory 
pathogenesis.666 Here, the PRKCE mRNA was identified as a potential target for miR-31, but 
this has not been experimentally validated. However, PRKCE has been shown to be 
targeted by other miRs including by miR-146a (an inflammatory miR) in anterior uveitis, a 
rare inflammatory eye condition, and papillary thyroid tumorigenesis;667,668 by miR-218 in 
gallbladder cancer;664 by miR-182 in lung cancer;669 and by miR-129 in cell cycle arrest.670 
What is already known about the many roles of PKCε in inflammation and immune 
responses suggest that this protein may be important in the acute response to PD-related 
peritonitis, although this has not yet been investigated. It is also potentially regulated by 
miR-31, which would need to be experimentally validated to see if this is a functional 
interaction and if it has a role in peritonitis. 
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5.3.2.4 Predicted miR-27a targets: 
5.3.2.4.1 Monocyte to macrophage differentiation associated (MMD) 
MMD is not a well-studied gene, and not much is known about its function. It is expressed 
in in vitro differentiated macrophages, but not freshly isolated monocytes.671 It is also 
expressed highly in fat, and in a range of other tissues including the brain, placenta and 
lymph node. The gene is located on chromosome 17 and contains one highly conserved 
8mer in the 3’ UTR of its mRNA that is predicted to be a miR-27a binding site. This protein 
has seven transmembrane regions and is part of the progesterone and adipoQ receptor 
family.672 MMD has a role in nitric oxide (NO) and TNF-a production in macrophages via 
the ERK pathway,673 as well as in macrophage differentiation.671 MMD has been localised 
to organelles within the cell such as the Golgi apparatus,673,674 where it functions via the 
ERK pathway to sense Ras,675 and may have a role in EMT in tumour cells.676 In the present 
study, MMD is predicted to be a target of miR-27a, this has not been experimentally 
validated. However, it has been shown that MMD is functionally regulated by miR-140, and 
the knock-on effects on the ERK pathway have effects on the growth of lung cancer cells.677 
Due to the role that MMD plays in the differentiation and function of macrophages, which 
are important cells in the acute immune response to peritonitis, it is likely that changes in 
MMD may be functionally relevant. The regulation of this protein by miR-27a is yet to be 
proved, and it would be interesting to investigate this in acute PD-related peritonitis. 
 
5.3.2.4.2 Transcriptional and immune response regulator (TCIM or C8orf4) 
TCIM, also known as C8orf4 and TC-1, encodes a positive regulator of the Wnt/b-catenin 
pathway expressed across a wide range of tissues, although there are low levels in 
leukocytes, the brain and thymus.678 The gene is located on chromosome 8 and its mRNA 
contains a conserved 8mer predicted binding site for miR-27a in its 3’ UTR. TCIM has been 
associated with worse prognosis in multiple types of cancer due to positive regulation of 
b-catenin genes which are associated with invasiveness and aggressiveness.679 These 
pathologies include lung cancer,680,681 ovarian cancer682 and breast cancer,683 as well as 
thyroid cancer, from which it got its original name of TC-1 (thyroid cancer-1).678,684 TCIM is 
an endothelial inflammatory factor, which both induces, and is induced by, inflammatory 
stimuli to form a positive feedback mechanism.685 TCIM is involved in mediating responses 
to cellular stress in models of both heat shock responses and lung fibrosis.686,687 Although 
the levels of TCIM detected in leukocytes are low, this is due to the fact that it is a 
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haematopoietic regulator determining lineage differentiation from progenitor cells, 
meaning that levels in differentiated cells are generally much lower.688 TCIM appears to be 
involved in the reaction of non-myeloid cells to inflammatory stimuli, suggesting that this 
might be important in the mesothelial cells and fibroblasts in the peritoneum. While there 
are no published studies showing miR targeting of TCIM, it can speculated that, if the 
interaction between miR-27a and TCIM is shown to be functional, this may be important 
to control the positive feedback loop initiated in mesothelial cells and fibroblasts by 
inflammatory conditions, which may exacerbate the damage caused by a peritonitis 
episode. This theory would need substantial experimental evidence to support it. 
 
5.3.3 Selected genes predicted to be targeted by multiple miRs 
These targets discussed below were evaluated, in terms of what is already known about 
them, due to the fact that they were predicted by multiple algorithms to be targeted by 
multiple miRs. 
 
5.3.3.1 F-box and WD repeat domain containing 7 (FBXW7) 
The FBXW7 gene encodes an E3 ubiquitin ligase and is located on chromosome 4. The 
mRNA it encodes is predicted to have three 8mer binding sites for miR-223 in its 3’ UTR. 
This protein is expressed across a wide range of tissues, with highest expression in the skin 
and brain.613 FBXW7 has a major role in many pathways including tumorigenesis (as a 
potent tumour suppressor), lipid metabolism, cell proliferation, stemness and 
differentiation.689–691 Recent studies have also shown its importance in both infection, 
including antiviral and anti-prion innate immune responses,690,692,693 and inflammation. For 
example, FBXW7 regulates C/EBPd which then attenuates inflammatory signalling via 
TLR4,694 and it has a role in the inflammatory component of cancers.695 FBXW7 is important 
in autophagy in both antiviral immunity692 and inflammation in acute kidney injury,696 
whilst it also has a role in regulating the NF-kB pathway.697 The miR-223/FBXW7 axis is 
important in the macrophage activation state and response to inflammatory stimulus, via 
TLR4.489 miR-223 can directly target FBXW7, shown by a luciferase reporter assay in gastric 
cancer cells.698,699 All of this evidence, along with studies showing an inverse correlation 
between miR-223 levels and FBXW7 mRNA levels,700–702 suggest that this is a real target of 
miR-223. Also, it may be relevant in acute peritonitis infections due to the relevance in 
other models of innate immunity.690,692,693 FBXW7 has also been suggested to be a target 
of miR-27a, with direct targeting shown via a luciferase reporter assay in oesophageal 
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squamous cell carcinoma cells, with this being an important pathway for tumorigenesis.703 
The direct targeting of FBXW7 via miR-27a is also implicated in clear cell renal cell 
carcinoma migration and invasion.704 There is less indication of the role of this 
interaction/regulation in infection or inflammation, but there is a likelihood that the 
interaction between FBXW7 and both miR-223 and miR-27a may play a role in the acute 
immune response to infection. This needs further work to investigate its relevance in PD-
related peritonitis. 
 
5.3.3.2 Armadillo repeat containing X-linked 1 (ARMCX1) 
ARMCX1, also known as ALEX1 (Arm protein lost in epithelial cancers chromosome X 
protein 1), is a gene located on the X chromosome705,706 and is a tumour suppressor, 
therefore is lost in epithelial cancers.707–711 However, it is proposed that ARMCX1 can also 
act as an oncogene, for example in cervical cancer.707 ARMCX1 is expressed by all cells 
except peripheral blood leukocytes,711 with highest levels in the ovary.613 This 
mitochondrial protein is specific to eukaryotes and is highly expressed in neuronal 
tissues.712 There is limited research on this protein, with no implications so far for a role in 
either infection or inflammation. Although it is a predicted target of both miR-223 and miR-
21 (with one 8mer predicted for both miRs), no functional interaction between miR-223 
and ARMCX1 has been shown. There is one study that looked into the relationship between 
ARMCX1 and miR-21 in rats, showing a negative correlation between miR-21 expression 
and ARMCX1 expression, although there is no indication of whether this is a direct or 
indirect effect.713 The role of this protein in acute infection is unknown, but its identification 
as a potentially important target for miR-223 and miR-21 during PD-related peritonitis 
suggests it may be important in inflammation. This would need substantial further 
investigation to confirm if this protein and the interaction with miR-223 and miR-21 is 
relevant for acute inflammatory processes. 
 
5.3.3.3 Sprouty RTK signalling antagonist 2 (SPRY2) 
SPRY2 is a member of the sprouty family of genes, which encode RTK signalling agonists. 
SPRY2 is expressed across a wide range of tissues, including fat, gall bladder, spleen and 
brain.613 This gene is on chromosome 13 and its mRNA predicted to have an 8mer binding 
site for both miR-21 and miR-27a in its 3’ UTR. In fact, it has been experimentally validated 
that miR-21 represses SPRY2 expression in a range of cancer cell types, in liver fibrosis and 
in T cells activated by space flight.714–721 It is also regulated by miR-27b (which has the same 
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recognition sequence as miR-27a) in glioma cells,722 with functional effects on the cancer 
progression, mostly due to the effect of SPRY2 on EMT or on the extracellular-signal-
regulated kinase (ERK) pathway, as SPRY2 is an antagonist of ERK.719,720 A decrease in SPRY2 
promotes EMT in multiple cancer models,719,720 as well as in lens epithelial cells in 
cataracts,723 whilst an anti-inflammatory role for SPRY2 via ERK signalling in both 
rheumatoid arthritis and IgA nephropathy has also been reported.724–726 The role of SPRY2 
is varied; it can control proliferation or phenotypic variation in a range of cell types and 
conditions, including T cells, B cells and macrophages in cancers and inflammatory 
conditions.727–734 SPRY2 may have a role in endotoxin tolerance in monocytes,735 and 
inhibition of SPRY2 polarises macrophages towards the M2 phenotype,729 suggesting it has 
a role in the innate immune response. SPRY2 has many roles in the immune response (both 
acute and adaptive) and is a validated target of two of the miRs identified in this Chapter 
as important in PD-related peritonitis (miR-21 and miR-27a). It is therefore conceivable that 
decreased levels of miR-21 and miR-27a may lead to an increase in SPRY2 expression which 
might enhance EMT. This could have a serious effect on the consequences of a peritonitis 
episode, accelerating the progression to technique failure. This hypothesis would need to 
be tested further by evaluating which cell types are taking up, and responding to, miR-21 
and miR-27a, and by investigating the effects of this on SPRY2 protein levels. 
 
5.3.3.4 Ras p21 protein activator 1 (RASA1) 
RASA1 is located on chromosome 5 and encodes a cytoplasmic GTPase activating protein 
that suppresses RAS function by enhancing its weak GTPase activity. It is abundantly 
expressed in the placenta, with lower levels across many adult human tissues.613 In the 3’ 
UTR of its mRNA it is predicted to have one 8mer for both miR-223 and miR-31, as well as 
a 7mer-A1 for miR-21. In the analysis conducted here, RASA1 was only predicted to be 
targeted by miR-223 and miR-31, although there is some experimental evidence that miR-
21 may functionally target RASA1, too.736–738 RASA1 is an important protein in vascular 
development, as RASA1 knockout animals are not viable and mutations in humans are 
strongly linked to a vascular condition called capillary malformation–arteriovenous 
malformation.739–741 RASA1 has been well studied in different cancers including ovarian, 
lung and breast cancers.742–744 miR-223 has been shown to functionally target RASA1 in 
colorectal cancer and macrophage activation, showing roles in cell proliferation and 
activation.745,746 RASA1 is essential for immune cell function, as demonstrated by its role in 
the positive selection of thymocytes.747 The link between miR-223 and RASA1 has also been 
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demonstrated functionally in cardiac fibroblasts after myocardial infarction, where miR-
223 regulates cardiac fibrosis through the direct targeting of RASA1.748 miR-31 can directly 
target RASA1 in the oncogenesis of intrahepatic cholangiocarcinoma,749 colorectal 
cancer750 and pancreatic cancer,751 as well as in the re-epithelialisation stage of wound 
healing752. These important roles in many different cellular processes in both epithelial cells 
and macrophages suggest that RASA1 may be important in the acute immune response to 
infection, given its roles in thymocyte selection and macrophage polarisation,746,747 which 
may be important in the response to PD-related peritonitis. 
 
5.3.3.5 Vav guanine nucleotide exchange factor 3 (VAV3) 
VAV3 is a member of the guanine nucleotide exchange factors for Rho GTPases, with 
involvement in actin cytoskeleton rearrangements and transcriptional alterations. Its gene 
is located on chromosome 1 and is expressed in a wide variety of tissues, with high levels 
in kidney, skin, colon and oesophagus, amongst others.613 The 3’ UTR of VAV3 mRNA has 
many predicted binding sites for different miRs, including a 7mer for both miR-31 and miR-
27a. VAV3 knockout animals have a wide range of pathologies, including cardiovascular 
disorders and impaired cerebellum development.753 VAV3 has been implicated in different 
human pathologies, with roles in cardiovascular disorders,754 glaucoma755 and 
osteoporosis,756 as well as acting as an oncogene in multiple cancers, including gastric and 
breast cancers.757,758 The role for VAV3 in immune cell function has been well studied, with 
roles in B and T cell signalling,759,760 neutrophil function,761,762 macrophage phagocytosis762–
764 and natural killer cell cytotoxicity.765 VAV3 is also essential for the innate immune 
response to fungal infections,766 and confers a risk factor for inflammatory diseases such 
as colitis, IgA nephropathy and type 1 diabetes.767–769 VAV3 is a direct target of other miRs 
including miR-489 and miR-499,770,771 but it is unknown whether the predicted interaction 
with miR-31 or miR-27a is a functional one. The relevance of a possible regulation by the 
candidate miRs identified here is unknown, although this protein is important in neutrophil 
recruitment in response to inflammatory stimuli772 and is altered in lymphocytes 
stimulated with LPS or infected with EBV.773,774 This confirmed role of VAV3 in the immune 
system identifies it as a strong candidate for further research into acute responses to PD-
related peritonitis. 
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5.3.3.6 Cyclin C (CCNC) 
CCNC controls cell cycle progression by interacting with cyclin dependent kinase 8 (CDK8). 
This growth-promoting role means it is associated with some types of cancer.775–778 The 
gene is located on chromosome 6 and is expressed in a wide range of tissues, including the 
thyroid, gall bladder and kidney.613 The 3’ UTR of its mRNA contains one predicted 
conserved 8mer for both miR-31 and miR-27a and is therefore predicted to be a target of 
both miRs. CCNC has been implicated in viral infections, with roles in the innate response 
including the initiation of innate immunity genes in Drosophila779 and plants (specifically 
upon infection with Fusarium graminearum).780 The CCNC and CDK8 complex is important 
in regulation of innate immune activation in myeloid cells, especially upon TLR9 
activation.781,782 The role of CCNC in maintaining cell growth is also important in 
maintaining PBMC viability in culture after exposure to hypoxic conditions, when other 
cyclins are decreased by hypoxia.783 The main focus of research on this protein has been 
on its primary role in the cell cycle, whilst there is some evidence that it has a potential role 
within the immune system. Although there is no experimental evidence suggesting CCNC 
may be targeted by miR-31 or miR-27a, it has been shown to be directly regulated by miR-
206 in melanoma.784 The potential for CCNC to be an important regulator of the acute 
immune response will need to be analysed further. 
 
5.3.3.7 Paired box 9 (PAX9) 
PAX9 is a member of the paired box family of transcription factors encoded by genes on 
chromosome 14. The mRNA is predicted to have an 8mer binding site for miR-31 and an 
8mer for miR-27a in its 3’ UTR. The expression of this gene is very high in the oesophagus, 
with high levels also present in the salivary gland and prostate.613 This protein is one of the 
most widely studied and most important genes in odontogenesis (tooth development), 
with mutations being involved in tooth developmental conditions785–788 including 
oligodontia,789–791 hypodontia792,793 and anodontia.794 PAX9 has been studied in cancers, 
including oral squamous cell carcinoma, chronic lymphocytic lymphoma and lung cancer. 
This tumorigenic protein maintains proliferation and inhibits apoptosis in cancer.795,796 The 
role in craniofacial development is also described, with an association between PAX9 
polymorphisms and the formation of a cleft lip or palate.797,798 PAX9 has also been shown 
to be involved in epithelial differentiation.796 There is a potential role for single nucleotide 
polymorphisms (SNPs) in PAX9 in aggravating the effect of human cytomegalovirus (HCMV) 
on reducing the birth weight of new-borns.799 PAX9, as a transcription factor, is known to 
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regulate expression of genes involved in many different roles, including cell proliferation, 
resistance to apoptosis and migration. The conservation of PAX9 across all vertebrates 
allowed for further studies in mouse models,796 although there are no reported roles for 
PAX9 in immunity and inflammation, with most studies focusing on developmental 
associations. With regard to its potential role during PD-related peritonitis, its strong 
expression in many different epithelial cells suggest it could be present in the resident cells 
lining the peritoneal cavity, and therefore may be targeted by miRs present in the PD fluid. 
However, this would need further investigation to verify if this is the case. 
 
5.3.3.8 Zinc finger SWIM-type containing 6 (ZSWIM6) 
ZSWIM6 is located on chromosome 5 with one predicted 8mer binding site for miR-21 and 
a 7mer site for miR-31 in the 3’ UTR of its mRNA. This conserved protein is currently of 
unknown function, but it has been associated with neurodevelopment and neurocognitive 
disorders.800–805 GWAS suggest a possible link to schizophrenia,804 as well as an association 
with severe intellectual disability and acromelic frontonasal dysostosis (a 
neurodevelopmental disorder).800,801,803,805 It is thought to have a role in the epigenetic 
regulation of gene transcription, through interacting with chromatin remodelling 
complexes, as well as possibly in the ubiquitination pathway.800 A knockout mouse for 
ZSWIM6 is viable, although it has severe neurocognitive problems, similar to the 
intellectual and neurodevelopmental deficiencies shown in humans with mutations in 
ZSWIM6.800,805 Current work has focused on the role in neurological disorders, while its role 
in response to infection or inflammation is unknown. A range of tissues and cell types 
express ZSWIM6, including the brain, gall bladder and colon.613,800–805 Targeting by miR-21 
and miR-31, if validated, may be relevant in PD-related peritonitis, but this has not been 
investigated yet and may require considerable work to examine. 
 
5.3.3.9 Solute carrier family 16 member 10 (SLC16A10) 
SLC16A10 (also called TAT1 and MCT10) is located on chromosome 6 and encodes an 
aromatic amino acid transporter located at the plasma membrane and expressed across a 
range of tissues including the placenta, skin and kidney.613,806 In the 3’ UTR of its mRNA it 
is predicted to have an 8mer binding site for both miR-21 and miR-27a. There is a knockout 
model for SLC16A10, and these SLC16A10 deficient animals develops normally but have 
higher blood plasma and urine concentrations of the aromatic amino acids (phenylalanine, 
tryptophan and tyrosine). This transporter also plays a role in the uptake and efflux of 
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thyroid hormone.807–811 The role in tryptophan transport indicates that this protein may be 
important in the pathogenesis of a rare autosomal recessive metabolic disorder called blue 
diaper syndrome.806,811,812 SLC16A10 is involved in a range of cancers, both as a biomarker 
and in the pathogenesis, including endometrial, ovarian and bladder cancers, with 
increased levels detected in the blood of patients with malignant tumours, and a negative 
correlation with prognosis, as well as a biomarker for benign tumours in some disorders.813–
816 There have been no published studies relating SLC16A10 to either the immune 
response, inflammation or infection. However, it is known that tryptophan can modulate 
immune responses, especially in the generation of tolerance.817 With regard to PD-related 
peritonitis one could therefore speculate that alterations in SLC16A10 may play a role in 
differing tryptophan levels, which may contribute to the immune response during acute 
infection. This would require further investigation, as well as validation whether SLC16A10 
is indeed a direct target of miR-21 and/or miR-27a. 
 
5.4 Future prospects 
This chapter investigates potential targets of the four candidate miRs and briefly evaluates 
their potential role in the response to acute PD-related peritonitis. Due to the nature of 
target prediction, and the large number of potential targets that have been identified 
through this analysis, it is essential to further this work through experimental 
investigations. For example, it would be prudent to investigate the levels of these target 
proteins in cell-free PD effluent samples and levels of the mRNAs in cells from patients, to 
attempt to correlate with the levels of the candidate miRs. It would also be important to 
construct reporter assays to ascertain if the predicted interactions between miR and mRNA 
are functional. Until these investigations are conducted, this analysis is merely theoretical, 
and the importance of the proposed interactions can only be speculated upon. 
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6 Stabilisation of extracellular microRNAs in PD effluent 
6.1 Introduction 
miRNAs are useful biomarkers in biological fluids due to their stability outside cells,389 
either by association with protein complexes431,435,436 or inside extracellular vesicles 
(EVs).389 There are a range of different types of EVs, as defined by both size and method of 
generation. The smallest form are exosomes, which are 30-120 nm in diameter and are 
released from cells when multivesicular bodies, which enclose them inside the cell, fuse 
with the cell membrane, expelling the contents.389,401,412 Microvesicles are larger EVs, of 
approximately 100-1000 nm diameter. These are released by direct budding off from 
protrusions of the plasma membrane.401,412,415 The final type of EV currently classified are 
apoptotic bodies. These are larger (1-5 µm) and are formed by membrane blebbing during 
the later stages of apoptosis424. All three types of EVs contain miRNAs, with the miRNA 
composition different to the cells from which they originate, suggesting they are 
specifically packaged into EVs for functions including intercellular 
communication.406,415,416,424 It has been shown that miRNAs released in EVs can be taken 
up and are functionally active in distant target cells.403–405 
 
miRNAs can also be stabilised by association with protein complexes. For example, the 
Argonaute (AGO) proteins form part of the RNA-induced silencing complex (RISC), which 
allow miRNAs to target and repress mRNA targets.399,436 miRNAs bound to AGO proteins 
are highly abundant in biological fluids and are protected from natural RNases.436 This is 
thought to be an active and functional form of intercellular communication.399,437,438 
miRNAs are also often found bound to lipoprotein complexes.431 This is an active process 
as miRNAs are specifically selected for extracellular secretion, meaning they have a 
functional role in communicating between cells.431–435 
 
Although it is known that miRNAs are stable in PD effluent,327 it has not been demonstrated 
how this stability is achieved, either through EVs, protein complexes, or a combination of 
both. To investigate this, PD effluent from infected and stable patients, as well as cell 
culture supernatant from cultured neutrophils, was analysed for the presence of miR-223 
in fractions representative of EVs generated by differential centrifugation. The samples 
both before and after EV-depletion were tested to determine the susceptibility of miR-223 
to RNase treatment before and after proteinase treatment. Size-based chromatography 
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and subsequent plate-based immunological assays determined the particle characteristics 
and cellular origin of miR-223-containing fractions from PD effluent. A reporter assay was 
then set up to identify functional uptake of miR-223 from PD effluent, both with and 
without EVs present. 
 
6.1.1 Aims: 
The aims of this chapter were to: 
1. Identify how miR-223 is stabilised in PD effluent and medium supernatant from 
cultured neutrophils 
2. Investigate the cellular origin of extracellular miR-223 in PD effluent 
3. Set up a luciferase-based reporter assay to determine functional miR-223 
uptake  
 
6.2 Results 
6.2.1 Identification of miR-223 in extracellular vesicles in PD effluent 
To identify how miR-223 is stabilised in PD effluent and media supernatant from cultured 
neutrophils, differential centrifugation was used to isolate fractions from cell-free PD 
effluent and media supernatant. These were representative of cell debris (P2), larger 
microvesicles (P3) and smaller exosomes (P4), with miR-223 measured in the supernatants 
and pellets after each step (Figure 6.1). This was conducted in PD effluent from patients 
with PD-related peritonitis (Figure 6.1A) and from stable PD patients (Figure 6.1B). Culture 
supernatants of neutrophils from healthy donors stimulated with LPS were processed in 
the same manner and served as experimental controls (Figure 6.1C). miR-223 was 
abundantly present in samples after all centrifugation steps in infected PD effluent, but 
there was a substantial amount of miR-223 present in each of the pellets. This was 
especially important in the pellets representing the different forms of EVs (microvesicles, 
P3, and exosomes, P4) (Figure 6.1A). In the PD effluent from stable patients, the amount of 
miR-223 present in the starting material was low, therefore the amount in each of the 
supernatants and pellets from the differential centrifugation steps was variable. This does 
however indicate that the small amount of miR-223 present was not abundantly protected 
by EVs, as P3 and P4 did not contain a large proportion of the remaining miR-223 (Figure 
6.1B). In the media supernatant from cultured, stimulated neutrophils there was a very 
small amount of miR-223 present in the pellets representative of the EVs (P3 and P4), with  
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Figure 6.1: miR-223 is present in fractions representative of extracellular vesicles in 
infected PD effluent 
miR-223 levels detected in differentially spun cell-free PD effluent from infected (A) and 
stable (B) patients, compared to media supernatant from cultured, LPS-stimulated 
neutrophils (C). S1 represents the cell-free supernatant before centrifugation, S2 
represents removal of dead cells and large cellular debris (present in P2), S3 represents 
removal of larger extracellular vesicles or microvesicles (present in P3) and S4 represents 
supernatant after removal of smaller extracellular vesicles or exosomes (present in S4). 
Data presented as mean ± SEM of 5 separate patients (A and B) or 4 donors (C), and as a 
percentage of amount of miR-223 present in the uncentrifuged supernatant (S1). 
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the majority still in the supernatants after high speed ultracentrifugation (Figure 6.1C). This 
suggests that miR-223 is present in EVs in infected PD effluent but not in medium 
supernatant from cultured neutrophils, implying that the culture conditions used here for 
neutrophils were dissimilar to those experienced in an infected peritoneum. 
 
6.2.2 Stability of miR-223 to RNase and Proteinase treatment 
To understand how miR-223 is stabilised in biological samples, selective treatment with 
RNase A and proteinase K was employed, alone and in combination. To do this, PD effluent 
from infected and stable patients, and culture supernatant from stimulated neutrophils, 
was treated with RNase A and Proteinase K, before and after EV depletion (Figure 6.2). As 
a positive control for this experiment, cel-miR-39 was spiked into the samples before 
treatment. This miRNA is not protected from RNase activity therefore acts as a control to 
show the RNase is functional, as demonstrated in Figure 6.2. 
 
Before EV-depletion, the miR-223 in infected PD effluent was resistant to both RNase A and 
proteinase K treatment, both alone and in combination (Figure 6.2A). This suggests that 
miR-223 is mostly present inside EVs, not associated with protein complexes. When EVs 
were depleted by ultracentrifugation, the remainder of miR-223 was more susceptible to 
RNase A treatment and addition of proteinase K also increased degradation (Figure 6.2B). 
This suggested that the miR-223 that was outside EVs was likely to be bound to protein 
complexes to protect it from RNases. There was, however, still a proportion of miR-223 
that was not protected from RNase activity. 
 
Stable PD effluent contained low levels of miR-223 to start with, so the variability of miR-
223 detection in these samples was high. A proportion of the miR-223 present was 
susceptible to degradation after both RNase A and proteinase K treatment, alone and in 
combination. This was true for effluent before and after EV depletion (Figures 6.2C and D). 
This suggested that a proportion of the total miR-223 might have been protected by both 
EVs and protein complexes. However, the low amount of miR-223 present meant it was 
difficult to understand the biological relevance of these mechanisms of stabilisation. 
 
Culture supernatant from stimulated neutrophils (Figures 6.2E and F) was treated similarly 
as control. Of note, the miR-223 present before EV-depletion was more susceptible to 
degradation by RNases than in PD effluent (Figure 6.2E compared to Figure 6.2A),  
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Figure 6.2: miR-223 is protected from RNase A and Proteinase K treatment in PD 
effluent 
PD effluent from infected patients (A and B), from uninfected patients (C and D), and 
media supernatants from cultured, LPS-treated neutrophils (E and F) was treated with 
RNase A, proteinase K or a combination of both. Showing both cell-free supernatant (A, C 
and E) and supernatant that has been depleted of small extracellular vesicles (B, D and F). 
Data represented as mean ± SEM for 5 patients (A and B), 4 patients (C and D), or 3 
donors (E and F), with raw 40-Ct data showing levels of miR-223 and cel-miR-39. 
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suggesting a proportion of the extracellular miR-223 was not protected. Proteinase K 
treatment also decreased the amount of miR-223 detected, suggesting a proportion was 
stabilised by association with protein complexes. When RNase treatment followed 
proteinase treatment, a similar amount of miR-223 was present as when RNase A was used 
alone, confirming that miR-223 was bound to protein complexes to prevent degradation 
(Figure 6.2E). When EVs were depleted from medium supernatant from cultured 
neutrophils (Figure 6.2F), a larger proportion of miR-223 was susceptible to RNase 
treatment, suggesting it was not protected by either EVs or protein complexes. Proteinase 
treatment alone also decreased the level of miR-223 slightly, although the difference 
between RNase treatment alone and RNase following proteinase treatment was minimal, 
suggesting that only a small proportion of miR-223 was protected in this way. 
 
Taken together, there was a difference between how cells at the site of infection release 
miR-223 and how neutrophils under controlled culture conditions release miR-223 in 
reaction to inflammatory stimuli. It is likely that a combination of both EVs and protein 
complexes are used to stabilise miR-223 in both PD effluent and culture supernatant, but 
these proportions are different between the two types of samples, with miR-223 present 
in a higher proportion of EVs in PD effluent whilst it is protected by protein complexes in 
media supernatants. 
 
6.2.3 miR-223 is present in exosomes 
To confirm whether miR-223 was indeed present in EVs, specifically in exosomes as shown 
in an unrelated study before,410 PD effluent samples from 5 infected patients were passed 
through a size exclusion chromatography column to separate different sized particles. 
These fractions were then analysed for markers of exosomes (CD9 and CD81), neutrophil 
surface markers (CD15), soluble protein complexes (represented by human serum albumin) 
and miR-223. This was to detect whether miR-223 was present in the fractions which 
represented exosomes, and co-localised with neutrophil markers or with soluble protein 
complexes. Neutrophils were thought to be the main source of extracellular miR-223 as 
they produce and release the most miR-223 of the cell types investigated previously in the 
in vitro models (Figure 4.3). They are also the most abundant cell type in infected PD 
effluent when there is a considerable increase in miR-223 (Figure 3.5), and it is known that 
they produce functional miR-223 in other experimental models.410 
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PD effluents from 5 patients were each separated into 25 fractions by size-exclusion 
chromatography. Each fraction was analysed on a plate-based immunological assay for CD9 
and CD81 to identify which fractions represented exosomes. As seen in Figure 6.3A and B, 
CD9 was present in high levels only in fractions 4-7, with a peak at fraction 6 suggesting the 
majority of exosomes were present in this fraction. CD81 was presenting two peaks, one at 
fraction 6 and another at fraction 11 (Figure 6.3C and D). This suggested that there might 
have been two populations of EVs of different sizes, possible exosomes and microvesicles. 
The reason for this second peak is not known at this time. Co-separation of the EVs labelled 
with CD9 and/or CD81 with the neutrophil marker CD15 (Figure 6.3E and F) indicated that 
a proportion of the EVs in the infected effluent samples was derived from neutrophils. 
 
As control, the samples were also probed for human serum albumin, as a representative of 
total soluble protein. Here, the largest amounts of this marker were observed in later 
fractions, from 7 to 15 (Figure 6.3G and H), demonstrating that fractions representing 
soluble protein complexes could be clearly separated from those containing EVs. 
 
Finally, selected fractions were subjected to RT-qPCR to detect miR-223. To this end, 
fractions 1, 6, 8, 11 and 20 were selected as they represented the different types of 
particles present; void column volume (1), CD9+ exosomes (6), particles that were not 
tetraspanin-positive (i.e. CD9− and CD81−) (8), free protein (11), and negative for all 
markers (20) (Figure 6.3). miR-223 was not detectable in the void volume or the negative 
fractions (1 and 20, Figure 6.3I and J). The largest amount of miR-223 was present in 
fraction 6 (Figure 6.3J), which represented the exosome fraction, a substantial proportion 
of which was likely derived from neutrophils. This suggested that the majority of miR-223 
in patient effluent was stabilised by incorporation into exosomes. There was still some miR-
223 present in the later fraction 11, which was representative of free protein (Figure 6.3J). 
This confirmed that some miR-223 was indeed bound to protein complexes, as predicted 
by the previous experiments. 
 
The main outcome of these experiments was that a large proportion of miR-223 was 
stabilised extracellularly in infected PD effluent by incorporation into exosomes, most likely 
neutrophil-derived exosomes, suggesting that miR-223 may be actively released by 
neutrophils in response to infection. 
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Figure 6.3: Levels of CD9, CD81, CD15, human serum albumin and miR-223 in different 
fractions representing different sized particles from infected PD effluent 
Levels of CD9 and CD81 (EV markers), CD15 (neutrophil surface marker), human serum 
albumin (representative of soluble protein) and miR-223 in fractionated PD effluent from 
5 PD patients on day 1 of a peritonitis episode. A, C, E, G and I show all fractions tested 
across 5 patient samples (25 for all protein markers, 5 for miR-223) as percentage level 
compared to the fraction containing the maximum amount of each marker. B, D, F, H and 
J show the 5 fractions measured for all markers, and the percentage level compared to 
the fraction containing the maximum amount of each marker, shown as mean ± SEM for 
5 patients. 
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6.2.4 miR-223 reporter assay 
To determine whether miR-223 is functional when released into PD effluent, and 
specifically whether it is taken up by recipient cells, a luciferase-based reporter assay was 
developed to allow the observation of changes in miR-223 activity in a cell line that does 
not express miR-223. To achieve this, a miR-223 reporter plasmid was generated by using 
the pGL3 control plasmid and inserting five perfect miR-223 binding sites to generate an 
artificial 3’ UTR attached to the luciferase gene. Using this construct, any miR-223 that was 
functional and taken up by the reporter cell was expected to result in a decrease in 
luciferase activity. 
 
The reporter plasmid was generated through cloning of an artificial 3’ UTR into the pGL3 
control plasmid as detailed in the Materials and Methods (Figure 2.1). Briefly, it involved 
linearization of the pGL3 control plasmid and cloning in the synthetic 3’ UTR, which was 
formed by two overlapping oligonucleotides. Stellar competent E. coli were transformed 
with the newly generated miR-223 reporter plasmid and positive colonies were selected by 
positive growth on agar supplemented with ampicillin (Figure 6.4A), and colony PCR 
confirmed the cloning was successful (Figure 6.4B). Positive bacteria were grown up and 
plasmid DNA was extracted by Miniprep. Sequencing results confirmed the plasmid 
contained the artificial 3’ UTR as designed (sequence and alignment in appendix 9.3). 
 
A previous study showed that miR-223 released in exosomes by neutrophils can be taken 
up and be functional in lung epithelial cells as recipient cells.410 In the case of PD-related 
peritonitis, it was speculated that resident peritoneal cells may take up extracellular 
miRNAs. Hence, MeT-5A cells, a mesothelial-like cell line, were selected for transfection of 
the reporter assay plasmid. Importantly, MeT-5A cells only express very low levels of miR-
223 under normal culture conditions, as shown in Figure 6.5A.  
 
To confirm that the plasmid was working as desired, both the reporter plasmid and the 
pGL3 control plasmid (without the artificial 3’ UTR) were transfected into MeT-5A cells, and 
24 hr later miRNA mimics were co-transfected into the cells, either miR-223 or a control 
miRNA (miR-C). Luciferase activity was determined 48 hr after this second transfection. As 
seen in Figure 6.5B, there was an approximately 70% reduction in luciferase activity when 
the reporter plasmid and the miR-223 mimic were co-transfected into the cells, whilst the  
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Figure 6.4: Positive cloning for generation of miR-223 reporter plasmid 
A shows positive colonies for transformation of miR-223 reporter plasmid into Stellar 
competent E. coli, represented by white colonies on Amp+ agar plate conferring 
resistance to ampicillin. B shows colony PCR results from six selected colonies run 
alongside pGL3 control plasmid. pGL3 control plasmid without insertion is represented by 
band of approximately 115bp, whilst pGL3 control plasmid with inserted artificial 3’ UTR 
is represented by band of approximately 283bp, as seen in colonies 2, 3 and 6. 
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Figure 6.5: Reporter assay showing functional uptake of miR-223 alters luciferase 
activity 
A shows MeT-5A cells have no endogenous miR-223 expression, compared to neutrophils 
and water, with horizontal line drawn at 40-Ct = 5 to represent the limit of detection. B 
demonstrates reporter assay controls with transfection of miR-223 reporter or pGL3 
control plasmids, and then transfection with miRNA mimics (control (miR-C) or miR-223). 
C and D show cells transfected with either miR-223 reporter or pGL3 control plasmid, and 
then treated with either cell-free PD effluent, PD effluent depleted of extracellular 
vesicles (EVs, by ultracentrifugation) or concentrated EVs isolated from PD effluent (by 
ultracentrifugation), from 2 separate patients. Data represented as mean ± SEM for 
triplicate wells and plotted as % luciferase activity relative to cells transfected with 
relevant plasmid and control miRNA mimic (miR-C). 
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control plasmid or the control miRNA mimic did not affect the luciferase activity, showing 
this effect was specific for miR-223. 
 
Next, we wanted to determine whether the miR-223 observed in neutrophil-derived EVs in 
infected PD effluent was functionally taken up by recipient cells. To do this, a preliminary 
experiment was conducted where MeT-5A cells were transfected with the reporter plasmid 
(or control plasmid), then treated with either PD effluent, EV-depleted PD effluent or 
concentrated EVs from PD effluent from two separate patients (Figure 6.5C-D). Although 
there were differences between the treatments, there was no specific downregulation of 
luciferase activity detectable, i.e. reporter plasmid transfection and PD effluent treatment 
was not different from control plasmid transfection and PD effluent treatment. The altered 
luciferase levels observed by addition of the different forms of PD effluent was likely a non-
specific effect due to the complex nature of this biological fluid.  
 
Taken together, while a robust miR-223 reporter assay could be established in this chapter, 
preliminary experiments applying this reporter assay to infected PD effluent did so far not 
reveal a specific functional role of extracellular miR-223 in patient samples. This assay 
would need further optimisation to determine whether the miR-223 released into the PD 
effluent in EVs is functionally taken up by a specific recipient cell type. 
 
6.3 Discussion 
In this Chapter, I show that miR-223 is stabilised extracellularly in PD effluent partly by 
incorporation into EVs, it is likely that these include neutrophil-derived exosomes, as 
evidenced by co-segregation of miR-223 and the exosome and neutrophil markers CD9, 
CD81 and CD15 by size exclusion chromatography, and by resistance to degradation by 
RNase A. This Chapter also shows that miR-223 is likely to be stabilised in a different way 
when released from neutrophils in culture, with a larger proportion likely to be stabilised 
in the soluble phase by protein complexes rather than being released within EVs. A reporter 
assay was set up to determine whether miR-223 released into PD effluent can be taken up 
and functional in a recipient cell line. This was provisionally tested using PD effluent from 
two infected patients but requires further optimisation. 
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6.3.1 miR-223 is stabilised by EVs and protein complexes 
This Chapter provides evidence that miR-223 is stabilised in PD effluent, by both a 
combination of incorporation into EVs and association with protein complexes. This was 
shown by ultracentrifugation isolating fractions containing EVs with high amounts of miR-
223 present, the stabilisation of miR-223 to both RNase and proteinase activity, and 
association of miR-223 with fractions from size-exclusion chromatography that co-
segregates with exosome markers. It is likely that some of these EVs are released from 
neutrophils, as shown by EV-containing fractions showing CD15+ staining. These 
experiments also showed that some miR-223 in infected PD effluent is associated with 
protein complexes as demonstrated by its presence in supernatants after removal of EVs, 
susceptibility to proteinase activity, and association of miR-223 with fractions 
representative of soluble protein. These data demonstrate how multiple biological 
pathways are likely used to release stable extracellular miR-223, with this increasing the 
likelihood that release of miR-223 is an active process. 
 
The isolation of EVs by ultracentrifugation is a standardised procedure that is reliable and 
reproducible for cell culture supernatants and biological fluids, and is widely used as a first 
step in EV characterisation.818 Although no quality control steps were used here to confirm 
the purity of EV isolation or to characterise the pellets, it could reasonably be assumed that 
the protocol allowed sufficient preparation of the desired EVs, as described. For the RNase 
and proteinase treatment of samples, there was a positive control to show susceptibility to 
RNase A degradation of “spiked-in” cel-miR-39, but no positive control to confirm protease 
activity. However, the protocol was optimised and published previously by our lab,438 
therefore we can assume that any changes in miR-223 levels here were due to degradation 
as a result of the treatments. 
 
This is the first time a characterisation of EVs has been conducted in PD effluent to establish 
extracellular miRNA stability, including the use of size-exclusion chromatography columns. 
The physical properties of PD effluent, once rendered cell-free, are similar to urine so the 
protocols followed were adapted from those already optimal for urine. The markers used 
to detect the presence of exosomes were CD9 and CD81. These tetraspanins, named due 
to their four transmembrane domains, are almost always found across a lipid membrane 
and are often used as a marker for exosomes.819 One novel observation for PD effluent is a 
double CD81 peak in the size-exclusion chromatography characterisation of particle sizes 
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(Figure 6.3C). This methodology is effective at separating EVs from protein, as 
demonstrated in the literature820 and by separation of the CD9 and human serum albumin 
peaks in Figures 6.3A and 6.3G. It is not clear why there was a second peak, possibly 
representing a separate population of CD81+ particles or CD81 unbound to a membrane. 
This could also be due to the complex nature of the infected patient samples which were 
used. PD effluent is a mixture of many different cells and soluble factors, which are likely 
to influence the EVs released. This could be a novel finding that a second population of 
CD81+ vesicles are present in PD effluent, or it could be a result of the many different 
variables present in PD effluent. The deviation between the five samples analysed here 
demonstrates how variable PD effluent from patients is. For example, Figure 6.3C shows 
some of the patient samples had a double CD81 peak whilst others only had one or other 
of these. To further investigate and characterise the particles present in PD effluent would 
require a larger number of patient samples to attempt to answer some of these questions. 
 
There are many studies detailing the role of miR-223 as a useful biomarker in cell-free 
biological fluids,471,474,821–825 but few define how it is stabilised extracellularly. Some show 
that miR-223 is incorporated into exosomes. For example, increased exosomal miR-223 is 
an inflammatory marker in lumbar disc herniation, with dysregulation in its release 
associated with persistent pain.826 Release of miR-223 in EVs is an inflammatory mediator 
in a range of different biological situations including platelet activation,418,827 macrophage 
differentiation and activation,588,828,829 different cancers828,830 and lung epithelial cell 
inflammation.410 miR-223 is also stabilised in biological fluids by protein complexes. miR-
223 is one of the most abundant miRNAs bound to high-density lipoprotein (HDL) and low-
density lipoprotein (LDL) complexes, although the majority of extracellular miRNA is not 
bound to these complexes.431,831,832 miR-223 associated with HDL can functionally regulate 
targets in recipient cells, including intercellular adhesion molecule 1 (ICAM-1) to reduce 
inflammation in endothelial cells432 and Ras homolog gene family member B (RhoB) in 
hepatocytes.431 What these earlier studies and the work shown here both demonstrate is 
that miR-223 is an important extracellular biomarker stabilised by incorporation into EVs 
and association with protein complexes, with the proportion of EVs and protein complexes 
changing according to specific conditions which the cells encounter (i.e. cultured 
neutrophils release fewer EVs compared to cells in an infected peritoneum). The 
confirmation that miR-223 is stabilised in PD effluent from peritonitis patients, likely at 
least partially, by neutrophil-derived EVs is a novel finding. 
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6.3.2 miR-223 reporter assay 
To confirm if miR-223 can be taken up and is functionally active in a distant recipient cell 
type, a luciferase-based reporter assay, with an artificial 3’ UTR targeted by miR-223, was 
set up in a MeT-5A cell line which does not itself express miR-223. Transfection with an 
artificial miR-223 mimic showed that the reporter responded specifically to miR-223 by a 
reduction in luciferase activity. However, when the reporter cell line was treated with PD 
effluent, EV-depleted PD effluent or concentrated EVs from PD effluent from two patients, 
there were alterations in luciferase activity, but none of these were specific to miR-223. 
This was likely due to the complex nature of the primary patient material tested, with many 
confounding factors present in infected PD effluent which could not be controlled for in 
this preliminary experiment. 
 
There are different reasons why this assay failed to detect a functional role for miR-223 in 
PD effluent. The primary problem may have been the complex nature of PD effluent and 
how the other components of the mixture may alter the expression of luciferase. For 
example, the cytokines present in the PD effluent may stimulate the MeT-5A cells to alter 
expression of the miR-223 reporter plasmid, therefore luciferase activity is altered in a non-
specific manner. Another is that the actual concentration of miR-223 present in the PD 
effluent or concentrated EVs was unknown, therefore it could have been too low to have 
had a specific effect. For comparison, 10 ng of the miRNA mimic was used to generate a 
positive response of functional miR-223 on the luciferase activity, and is not known 
whether this amount of miRNA is biologically relevant. 
 
The 3’ UTR used in this reporter assay was artificially designed to give a strong effect, as is 
seen in the positive control. However, the 5 artificial binding sites for miR-223 may not be 
the most biologically relevant target for miR-223. When other studies looked for positive 
effects of miRNA regulation in distant recipient cells, they often used the full 3’ UTR of a 
validated target for that specific miRNA, with mutations in the specific binding site to show 
specificity for that miRNA. For example, FBXW7 is a validated target of miR-223 in many 
different biological systems through luciferase-based reporter assays,489,698,699 therefore it 
could have been more biologically relevant to use such a target to show true effects. 
However, this was not used in this preliminary experiment as no specific target cell type 
had been identified. It therefore was not possible to determine a likely mRNA target that 
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might be biologically relevant in this specific response to PD-related peritonitis. If the target 
cell type(s) could be identified, then experimental validation of predicted target(s) could 
be more easily conducted. 
 
Met-5A cells were chosen for these experiments due to the fact that they are a mesothelial 
cell line and hence an attractive candidate for a possible miR-223 target cell type. In 
addition, Met-5A cells lack endogenous miR-223 expression, thereby allowing the 
development of a sensitive miR-223 reporter assay in those cells. However, this cell line 
may not be representative of a true miR-223 target cell in PD-related peritonitis. The main 
cell types known to express miR-223, and therefore with proven functional roles in cellular 
processes, are those of a myeloid lineage, for example, miR-223 is important in neutrophil 
activation and recruitment via the inflammasome or IL-6/STAT3 pathways.488,833,834 
However, miR-223 can also be released by myeloid cells to act in distant recipient target 
cells. These include lung epithelial cells responding to an inflammatory stimulus410 and 
basal keratinocytes in response to injury.835 It might have been more relevant to look at 
primary cells due to the changes gained during the immortalisation process of cell line 
generation.836 However, a cell line was chosen for this proof-of-principle experiment due 
to the ability to generate a positive starting point for further investigations. To further 
optimise this reporter assay, it might now be necessary to test a range of different cell 
types, both primary cells and established cell lines, to observe which cell type(s) may 
respond best to miR-223 in EVs released in response to PD-related peritonitis. 
 
A lack of a miR-223-specific effect on luciferase activity may be due to either a lack of 
biological effect, as discussed above, or as a result of miR-223 being unable to get or 
function inside the cell. These could be biological reasons or problems with the 
experimental protocol. Further optimisation of the reporter assay is now required, using 
different cell types, attempting to assist EV entry into the cell, and determining the 
optimum miR-223 concentration to cause an effect. 
 
6.4 Conclusions 
In summary, this Chapter shows that miR-223 is stabilised in PD effluent from peritonitis 
patients. It is likely that this, at least partially, is by incorporation into neutrophil-derived 
exosomes, which protect the miRNA from RNase activity. A reporter assay was successfully 
set up to measure uptake and functional activity of miR-223 in a mesothelial cell line. This 
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assay now requires further optimisation to confirm whether the miR-223 in PD effluent is 
functional in specific distant target cells. 
 
  
 169 
7 General Discussion and Future Work 
7.1 General discussion 
Peritonitis is a serious complication of PD and is a major cause of catheter removal and 
transition to an alternative RRT, as well as a main or contributing cause of mortality in 2-
6% of PD patient deaths.86 This serious clinical problem is exacerbated by inappropriate 
treatments, usually broad-spectrum antibiotics used to cover the most likely causes, before 
the specific pathogen can be identified through lengthy culture techniques.88 
Distinguishing between the different causative pathogens is essential to be able to classify 
patients into those that might need more intensive treatment and hospitalisation (for 
example, polymicrobial infections) from those with more minor infections that should 
recover with standard treatments (for example, CNS).223 The immune response to 
pathogens is specific enough to distinguish between different causative organisms, as 
shown through previous work on the “immune fingerprint” model. This is where a range of 
soluble and cellular factors can be used to classify patients on both causative organism and 
clinical outcome (i.e. technique failure).222 
 
It is known that miRNAs are important in the majority of cellular processes, including 
immune responses.250 The role of extracellular miRNAs as biomarkers has already been 
explored in many different biological fluids, including in PD effluent as markers of fibrosis 
or peritoneal membrane function.388,442 In this thesis it was shown that four miRNAs (miR-
223, miR-21, miR-27a and miR-31) are altered in peritonitis at the site of infection, in PD 
effluent, and that miR-21 can be used to distinguish between different pathogens 
(classified into Gram positive or Gram negative organisms). The specificity and sensitivity 
of miRNAs in so many different cellular processes228 suggests they could potentially 
contribute to the immune fingerprint model to distinguish between different pathogens. 
 
These miRNAs were thought to have different roles in the acute immune response due to 
their cell-specific expression patterns. miR-223 is predominantly expressed by the immune 
cells which enter the peritoneum during an infection, as it is a myeloid-restricted miRNA.473 
miR-21 and miR-27a are expressed by both resident and immune cells at a similar level. 
miR-21 is one of the most well-studied miRNAs, with a range of roles across many different 
cell types including in inflammatory diseases such as CVD and psoriasis.508,522 miR-27a is 
not known to be restricted to any specific cell type, however its link to inflammatory 
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conditions, such as relapsing MS, suggests it may be important in acute immune 
responses.501 miR-31 was only expressed and released by resident peritoneal mesothelial 
cells and fibroblasts. This restriction to epithelial cells is in agreement with previous studies 
that suggest it plays a pleiotropic role in regulating a range of responses to different stimuli, 
including in inflammatory and infectious diseases.535,548 
 
These four miRNAs are potentially important in pathways responsible for immune 
responses due to some of their potential mRNA targets being involved in cytokine 
signalling, production and sensing, inflammatory pathways, and macrophage 
differentiation. For example, miR-223 is predicted to regulate IL6ST, an IL-6 signal 
transducer, whilst miR-21 is predicted to target the cytokine TGF-b1. miR-31 is predicted 
to regulate PKCε, which is implicated in immune and inflammatory diseases, and miR-27a 
is predicted to target MMD, which controls differentiation of macrophages from 
monocytes. These predictions would need experimental validation to prove if they are 
functional interactions and if they are important in the acute response to PD-related 
peritonitis. 
 
The latter sections of this thesis have focused on miR-223, which is an important regulator 
of inflammation.473,474 The release of miR-223 was shown to be an active process due to its 
extracellular stability, which is crucial to suggest that it is used for intercellular 
communication. The role of miRNAs in communication between immune and non-immune 
cells is important in other inflammatory situations, for example in lung injury and heart 
disease.409,410 miR-223 has been utilised as a biomarker for diagnosis or progression of 
sepsis, RA and some infections in animals.474,478,486 It is thought that miR-223 may suppress 
inflammation due to spontaneous inflammation and more severe inflammatory reactions 
in KO animals.410 miR-223 is also important in neutrophil and macrophage differentiation 
and maturation, therefore it is predicted to be important in the acute response to 
infection.359,490 miR-223 has not previously been investigated in PD effluent, although it has 
been used in peritoneal ascites as a biomarker of spontaneous bacterial peritonitis, 
compared to peritoneal carcinomatosis. This suggests the specific inflammatory reaction 
induced by infection is different to that induced by cancer, and miR-223 can be used to 
distinguish between them.449 
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Nucleic acids that are release from cells are normally degraded by endonucleases that are 
present in biological fluids. However, miRNAs are often stable extracellularly and are 
protected from natural RNases. This stability is due to active release from cells, either 
within EVs or associated with protein complexes.389 miR-223 is abundantly released from 
myeloid cells in culture (particularly neutrophils), as well as by myeloid cells at the site of 
infection (i.e. in PD effluent from peritonitis patients). This thesis provides evidence that 
cells in culture and those at the site of infection have different mechanisms of miR-223 
release and stabilisation, with a larger proportion of miR-223 present in EVs in PD effluent 
compared to culture supernatant. It was proposed that a proportion of these EVs in PD 
effluent are derived from neutrophils, as has been demonstrated previously in other 
inflammatory conditions.410 A reporter assay to observe functional miR-223 uptake was 
developed but required further optimisation. This assay was developed using the same 
principles utilised for confirmation of predicted mRNA targets of miRNAs, where an 
artificial 3’ UTR was inserted after a luciferase reporter gene in a plasmid, which then 
reduced the luciferase activity in the presence of functional miR-223. The controls for this 
assay show a functional uptake of miR-223 causes a reduction in luciferase activity, 
however the molecular mechanisms of this process are not known. It would be prudent to 
investigate how EVs that contain miRNAs are released by cells, with a focus on how this is 
regulated particularly in response to inflammatory stimuli, as well as how they are taken 
up by target cells. 
 
In summary, the findings in this thesis show the important role miRNAs play in the acute 
response to infection. miRNAs can help diagnose peritonitis in PD patients and help 
distinguish between different infectious organisms. They are functionally expressed and 
released by specific cell types, and are potentially important in communication between 
different cell types which may not express specific miRNAs but can respond to exogenously 
produced miRNA. 
 
7.2 Future work 
The aim of my research was to investigate how local miRNAs are involved in the acute 
immune response to PD-related peritonitis, with a specific focus on use of miRNAs as 
biomarkers and any potential roles in communication between different cell types present 
in an infected peritoneum. However, further work is necessary to expand this work to 
investigate in more detail the functional role of the miRNAs identified here as potential 
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biomarkers and their role in the resolution of infection. miR-223 was identified as a myeloid 
cell-derived miRNA but it may be important in signalling pathways involving resident 
peritoneal cells. To investigate this further, the reporter assay developed here would need 
optimisation, possibly in a range of potential target cell types. Identification of the cell 
type(s) which take up extracellular miR-223 would also help elucidate the specific pathways 
regulated, by observing differences in mRNA levels of miR-223 targets. This thesis shows a 
list of potential mRNA targets for the four miRNAs of interest, without any experimental 
validation. To observe whether these interactions are functional would be important to 
help determine the role of these four miRNAs in the acute response to infection. 
 
The role of miRNAs as biomarkers in PD-related peritonitis has been shown here using a 
small, single-centre patient cohort with well-defined infections. It would be interesting to 
see if these observations could be replicated in a larger multi-centre patient cohort 
consisting of patients with a range of different infections. Work is ongoing to expand the 
immune fingerprint model to other acute infections, and detection of the specific miRNAs 
identified here would help understand the specificity of these as biomarkers and their 
transferability to other important clinical questions. 
 
Detection of miRNAs is currently reliant on RT-qPCR, which is a rapid detection method but 
requires specialist sample processing techniques. To advance this research towards a point-
of-care test that could be used by clinicians would require novel miRNA detection methods, 
for example electrochemical detection.837 Preliminary work in this area is ongoing to 
discover whether this is viable in complex biological fluids, using a variety of novel 
methodologies. Electrochemical detection of miRNAs in biological fluids is the most 
prominent method that does not require an amplification step, whilst others include the 
use of nanoparticles and magnetic beads. New techniques using novel amplification 
methods, different to traditional PCR, have also been developed including rolling circle and 
isothermal amplification.838–840 
 
The functional work conducted here preliminarily investigates into in vitro models. 
Although this is most relevant to patient outcomes, further in vivo models could be 
developed to observe systemic roles for the miRNAs identified here. As observed in the 
preliminary in vivo work conducted here, there are differences in miRNA functions between 
closely related organisms, but miR-223 has been investigated in mice and shows similar 
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alterations in clinically relevant models.410 Use of a more appropriate model of PD may 
allow further functional investigation into the role of miR-223 in acute PD-related 
peritonitis. 
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9 Appendix 
9.1 Patient information 
 
Patient ID Date Type Culture result Notes 
G00-088-02 25/05/2011 Stable N/A Never infected 
G00-098-06 16/11/2012 Stable N/A Never infected 
G00-113-01 17/11/2011 Stable N/A Never infected 
G00-114-01 24/11/2011 Stable N/A Never infected 
G00-128-06 04/04/2013 Stable N/A Never infected 
G00-132-04 26/06/2013 Stable N/A Never infected 
G00-135-02 23/04/2014 Stable N/A Never infected 
G00-140-01 10/05/2013 Stable N/A Never infected 
G00-147-01 13/11/2013 Stable N/A Never infected 
G00-219-02 28/10/2015 Stable N/A Never infected 
G00-132-15 04/09/2015 Stable N/A 9 months after 
infection 
G00-201-07 08/10/2015 Stable N/A Never infected 
G00-203-04 07/10/2015 Stable N/A Never infected 
G00-215-02 18/03/2015 Stable N/A Never infected 
G00-219-02 28/10/2015 Stable N/A Never infected 
G00-191-02 05/03/2015 Stable N/A Never infected 
G00-221-02 04/11/2015 Stable N/A Never infected 
G00-171-02 13/03/2015 Stable N/A >2 years after 
infection 
G00-246-02 25/11/2015 Stable N/A 3 months after 
infection 
G00-218-03 20/01/2016 Stable N/A Never infected 
G00-181-21 26/10/2016 Peritonitis Coagulase negative 
Staphylococcus 
Gram positive 
G00-114-07 21/11/2016 Peritonitis Coagulase negative 
Staphylococcus 
Gram positive 
G00-012-02 03/01/2012 Peritonitis Coagulase negative 
Staphylococcus 
Gram positive 
G00-080-02 12/01/2012 Peritonitis Coagulase negative 
Staphylococcus 
Gram positive 
G00-184-02 02/05/2014 Peritonitis Coagulase negative 
Staphylococcus 
Gram positive 
G00-188-04 06/03/2015 Peritonitis Coagulase negative 
Staphylococcus 
Gram positive 
G00-136-01 06/02/2015 Peritonitis Coagulase negative 
Staphylococcus 
Gram positive 
G00-009-01 19/12/2008 Peritonitis Coagulase negative 
Staphylococcus 
Gram positive 
G00-025-01 03/08/2009 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-035-01 08/03/2010 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-045-01 11/10/2010 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-152-04 27/11/2013 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
 216 
G00-184-03 23/06/2014 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-181-14 09/01/2016 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-244-02 29/02/2016 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-107-01 20/11/2011 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-143-02 27/10/2014 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-152-08 26/03/2015 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-154-01 14/10/2014 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-179-07 24/02/2015 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-215-04 30/10/2015 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-167-01 03/10/2013 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-126-02 19/03/2013 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-150-01 19/03/2013 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-184-01 07/03/2014 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-181-01 24/02/2014 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-256-01 16/03/2016 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-244-01 01/02/2016 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-098-17 11/07/2015 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-197-01 04/06/2014 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-188-08 03/02/2016 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-154-02 23/02/2015 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-154-04 10/05/2016 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-082-04 19/04/2013 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-115-03 05/09/2012 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-080-01 07/03/2011 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-068-04 29/10/2012 Peritonitis Coagulase negative 
Staphylococcus  
Gram positive 
G00-077-01 24/02/2011 Peritonitis Coagulase negative 
Staphylococcus 
Gram positive 
G00-002-01 10/09/2008 Peritonitis Coagulase negative 
Staphylococcus epidermis 
Gram positive 
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G00-188-05 07/04/2015 Peritonitis Coagulase negative 
Staphylococcus epidermis 
Gram positive 
G00-039-02 08/09/2010 Peritonitis Staphylococcus aureus Gram positive 
G00-070-01 10/02/2012 Peritonitis Staphylococcus aureus Gram positive 
G00-068-08 30/03/2014 Peritonitis Staphylococcus aureus Gram positive 
G00-098-16 11/07/2015 Peritonitis Staphylococcus aureus Gram positive 
G00-188-07 08/08/2015 Peritonitis Staphylococcus aureus Gram positive 
G00-098-25 27/07/2016 Peritonitis Staphylococcus aureus Gram positive 
G00-061-02 05/08/2016 Peritonitis Staphylococcus aureus Gram positive 
G00-098-12 09/06/2014 Peritonitis Staphylococcus aureus Gram positive 
G00-056-03 14/03/2011 Peritonitis Staphylococcus aureus (MRSA) Gram positive 
G00-027-01 16/09/2009 Peritonitis Corynebacterium amycolatum Gram positive 
G00-037-01 24/03/2010 Peritonitis Coryneform Gram positive 
G00-040-02 21/10/2010 Peritonitis Enterococcus faecalis Gram positive 
G00-150-02 19/04/2013 Peritonitis Vancomycin resistant 
Enterococcus (VRE) 
Gram positive 
G00-150-03 09/05/2013 Peritonitis Vancomycin resistant 
Enterococcus & Enterococcus 
faecium 
Gram positive 
G00-023-01 12/07/2009 Peritonitis Microaerophilic Streptococcus Gram positive 
G00-018-02 12/08/2008 Peritonitis Microaerophilic Streptococcus Gram positive 
G00-004-01 21/10/2008 Peritonitis Alpha haemolytic 
Streptococcus 
Gram positive 
G00-019-02 02/11/2010 Peritonitis Alpha haemolytic 
Streptococcus 
Gram positive 
G00-039-01 28/06/2010 Peritonitis Alpha haemolytic 
Streptococcus 
Gram positive 
G00-070-10 08/03/2013 Peritonitis Alpha haemolytic 
Streptococcus 
Gram positive 
G00-116-06 03/10/2013 Peritonitis Alpha haemolytic 
Streptococcus 
Gram positive 
G00-156-01 08/11/2013 Peritonitis Alpha haemolytic 
Streptococcus 
Gram positive 
G00-219-03 02/03/2016 Peritonitis Alpha haemolytic 
Streptococcus 
Gram positive 
G00-023-03 23/11/2011 Peritonitis Alpha haemolytic 
Streptococcus 
Gram positive 
G00-019-01 29/06/2009 Peritonitis Alpha haemolytic 
Streptococcus 
Gram positive 
G00-294-01 10/06/2017 Peritonitis Alpha haemolytic 
Streptococcus 
Gram positive 
G00-135-04 17/09/2014 Peritonitis Streptococcus sanguinis Gram positive 
G00-237-01 25/04/2015 Peritonitis Streptococcus sanguinis Gram positive 
G00-227-01 08/12/2014 Peritonitis Streptococcus B Gram positive 
G00-013-01 05/03/2009 Peritonitis Alpha haemolytic 
Streptococcus, Non- 
haemolytic Streptococcus & 
Coliform Streptococcus 
Gram positive 
G00-179-06 30/01/2015 Peritonitis Coagulase negative 
Staphylococcus, Alpha 
haemolytic Streptococcus & 
Propionibacterium 
Gram positive 
G00-021-01 30/06/2009 Peritonitis Gram +ve Bacillus & 
Corynebacterium/Diphtheroids 
Gram positive 
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G00-012-01 10/02/2009 Peritonitis Coagulase Negative 
Staphylococcus & 
Corynebacterium 
Gram positive 
G00-040-01 03/09/2010 Peritonitis Coagulase negative 
Staphylococcus & 
Enterococcus 
Gram positive 
G00-159-01 28/03/2013 Peritonitis Enterococcus faecalis & 
Streptococcus bovis 
Gram positive 
G00-181-07 25/04/2015 Peritonitis Corynebacterium jeikeium  Gram positive 
G00-011-02 03/02/2009 Peritonitis No growth  
G00-003-03 02/07/2009 Peritonitis No growth  
G00-026-01 03/08/2009 Peritonitis No growth  
G00-024-02 20/08/2008 Peritonitis No growth  
G00-003-05 07/09/2009 Peritonitis No growth  
G00-030-01 11/12/2009 Peritonitis No growth  
G00-038-01 22/04/2010 Peritonitis No growth  
G00-163-01 03/06/2013 Peritonitis No growth  
G00-177-01 04/02/2014 Peritonitis No growth  
G00-051-11 24/03/2014 Peritonitis No growth  
G00-181-02 09/06/2014 Peritonitis No growth  
G00-147-08 19/03/2015 Peritonitis No growth  
G00-257-01 20/03/2016 Peritonitis No growth  
G00-260-01 19/12/2016 Peritonitis No growth  
G00-003-01 20/10/2008 Peritonitis No growth  
G00-003-02 27/11/2008 Peritonitis No growth  
G00-011-01 19/01/2009 Peritonitis No growth  
G00-069-01 08/02/2011 Peritonitis No growth  
G00-115-01 29/11/2011 Peritonitis No growth  
G00-189-02 30/05/2014 Peritonitis No growth  
G00-016-01 21/05/2009 Peritonitis Acinetobacter Gram negative 
G00-189-01 26/05/2014 Peritonitis Acinetobacter baumannii Gram negative 
G00-238-09 12/08/2016 Peritonitis Acinetobacter ursingii Gram negative 
G00-175-01 08/01/2014 Peritonitis Enterobacter Gram negative 
G00-196-01 04/06/2014 Peritonitis Gram negative Enterobacter Gram negative 
G00-147-07 10/03/2015 Peritonitis Escherichia coli Gram negative 
G00-136-04 22/05/2015 Peritonitis Escherichia coli Gram negative 
G00-132-09 01/12/2014 Peritonitis Escherichia coli Gram negative 
G00-143-03 12/03/2015 Peritonitis Escherichia coli Gram negative 
G00-156-03 30/03/2014 Peritonitis Escherichia coli Gram negative 
G00-180-02 20/02/2015 Peritonitis Escherichia coli Gram negative 
G00-020-01 29/06/2009 Peritonitis Escherichia coli Gram negative 
G00-031-01 23/12/2009 Peritonitis Escherichia coli Gram negative 
G00-136-03 05/05/2015 Peritonitis Escherichia coli Gram negative 
G00-117-06 07/09/2012 Peritonitis Escherichia coli Gram negative 
G00-164-02 25/10/2013 Peritonitis Escherichia coli Gram negative 
G00-238-02 09/08/2015 Peritonitis Escherichia coli Gram negative 
G00-136-02 18/04/2015 Peritonitis Escherichia coli Gram negative 
G00-266-01 11/06/2016 Peritonitis Escherichia coli Gram negative 
G00-015-01 22/04/2009 Peritonitis Escherichia coli Gram negative 
G00-210-12 31/07/2017 Peritonitis Escherichia coli Gram negative 
G00-250-01 23/03/2016 Peritonitis Escherichia coli & Gram -ve 
Bacillus   
Gram negative 
G00-179-08 16/03/2015 Peritonitis Klebsiella Gram negative 
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G00-227-05 13/05/2015 Peritonitis Neisseria Gram negative 
G00-054-03 19/03/2011 Peritonitis Morganella morganii Gram negative 
G00-022-01 01/07/2009 Peritonitis Pseudomonas aeruginosa Gram negative 
G00-029-01 12/10/2009 Peritonitis Pseudomonas aeruginosa Gram negative 
G00-022-02 01/07/2009 Peritonitis Pseudomonas aeruginosa Gram negative 
G00-084-01 02/04/2011 Peritonitis Gram negative Bacillus Gram negative 
G00-248-01 16/08/2016 Peritonitis Acenetobactor & Gram +ve 
Bacillus 
Gram negative 
G00-174-01 06/12/2013 Peritonitis Pseudomonas aeruginosa & 
Anaerobic Gram -ve Bacillus 
Gram negative 
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9.2 miRNAs on TLDA cards 
 
RNU44 hsa-miR-139-5p hsa-miR-195 hsa-miR-224 hsa-miR-335 
RNU48 hsa-miR-140-3p hsa-miR-196b hsa-miR-23a hsa-miR-337-5p 
U6 snRNA hsa-miR-141 hsa-miR-197 hsa-miR-23b hsa-miR-338-3p 
ath-miR159a hsa-miR-142-3p hsa-miR-198 hsa-miR-24 hsa-miR-339-3p 
hsa-let-7a hsa-miR-142-5p hsa-miR-199a hsa-miR-25 hsa-miR-339-5p 
hsa-let-7b hsa-miR-143 hsa-miR-199a-3p hsa-miR-26a hsa-miR-33b 
hsa-let-7c hsa-miR-145 hsa-miR-199b hsa-miR-26b hsa-miR-340 
hsa-let-7d hsa-miR-146a hsa-miR-19a hsa-miR-27a hsa-miR-342-3p 
hsa-let-7e hsa-miR-146b hsa-miR-19b hsa-miR-27b hsa-miR-342-5p 
hsa-let-7f hsa-miR-146b-3p hsa-miR-200a hsa-miR-28 hsa-miR-345 
hsa-let-7g hsa-miR-147 hsa-miR-200b hsa-miR-28-3p hsa-miR-346 
hsa-miR-1 hsa-miR-147b hsa-miR-200c hsa-miR-296 hsa-miR-34a 
hsa-miR-100 hsa-miR-148a hsa-miR-202 hsa-miR-296-3p hsa-miR-34c 
hsa-miR-101 hsa-miR-148b hsa-miR-203 hsa-miR-298 hsa-miR-361 
hsa-miR-103 hsa-miR-149 hsa-miR-204 hsa-miR-299-3p hsa-miR-362 
hsa-miR-105 hsa-miR-150 hsa-miR-205 hsa-miR-299-5p hsa-miR-362-3p 
hsa-miR-106a hsa-miR-152 hsa-miR-208 hsa-miR-29a hsa-miR-363 
hsa-miR-106b hsa-miR-154 hsa-miR-208b hsa-miR-29b hsa-miR-365 
hsa-miR-107 hsa-miR-155 hsa-miR-20a hsa-miR-29c hsa-miR-367 
hsa-miR-10a hsa-miR-15a hsa-miR-20b hsa-miR-301 hsa-miR-369-3p 
hsa-miR-10b hsa-miR-15b hsa-miR-21 hsa-miR-301b hsa-miR-369-5p 
hsa-miR-122 hsa-miR-16 hsa-miR-210 hsa-miR-302a hsa-miR-370 
hsa-miR-125a-3p hsa-miR-17 hsa-miR-211 hsa-miR-302b hsa-miR-371-3p 
hsa-miR-125a-5p hsa-miR-181a hsa-miR-212 hsa-miR-302c hsa-miR-372 
hsa-miR-125b hsa-miR-181c hsa-miR-214 hsa-miR-30b hsa-miR-373 
hsa-miR-126 hsa-miR-182 hsa-miR-215 hsa-miR-30c hsa-miR-374 
hsa-miR-127 hsa-miR-183 hsa-miR-216a hsa-miR-31 hsa-miR-375 
hsa-miR-127-5p hsa-miR-184 hsa-miR-216b hsa-miR-32 hsa-miR-376a 
hsa-miR-128a hsa-miR-185 hsa-miR-217 hsa-miR-320 hsa-miR-376b 
hsa-miR-129 hsa-miR-186 hsa-miR-218 hsa-miR-323-3p hsa-miR-376c 
hsa-miR-130a hsa-miR-188-3p hsa-miR-219 hsa-miR-324-3p hsa-miR-377 
hsa-miR-130b hsa-miR-18a hsa-miR-219-1-3p hsa-miR-324-5p hsa-miR-380-3p 
hsa-miR-132 hsa-miR-18b hsa-miR-219-2-3p hsa-miR-325 hsa-miR-381 
hsa-miR-133a hsa-miR-190 hsa-miR-22 hsa-miR-326 hsa-miR-382 
hsa-miR-133b hsa-miR-191 hsa-miR-220 hsa-miR-328 hsa-miR-383 
hsa-miR-135a hsa-miR-192 hsa-miR-220b hsa-miR-329 hsa-miR-384 
hsa-miR-135b hsa-miR-193a hsa-miR-220c hsa-miR-330 hsa-miR-409-5p 
hsa-miR-136 hsa-miR-193a-5p hsa-miR-221 hsa-miR-330-5p hsa-miR-410 
hsa-miR-138 hsa-miR-193b hsa-miR-222 hsa-miR-331 hsa-miR-411 
hsa-miR-139-3p hsa-miR-194 hsa-miR-223 hsa-miR-331-5p hsa-miR-412 
hsa-miR-422a hsa-miR-505 hsa-miR-524-5p hsa-miR-628-5p mmu-miR-124a 
hsa-miR-423-5p hsa-miR-506 hsa-miR-525 hsa-miR-629 mmu-miR-129-3p 
hsa-miR-424 hsa-miR-507 hsa-miR-525-3p hsa-miR-636 mmu-miR-134 
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hsa-miR-425-5p hsa-miR-508 hsa-miR-526b hsa-miR-642 mmu-miR-137 
hsa-miR-429 hsa-miR-508-5p hsa-miR-532 hsa-miR-651 mmu-miR-140 
hsa-miR-431 hsa-miR-509-3-5p hsa-miR-532-3p hsa-miR-652 mmu-miR-153 
hsa-miR-433 hsa-miR-509-5p hsa-miR-539 hsa-miR-653 mmu-miR-187 
hsa-miR-448 hsa-miR-510 hsa-miR-541 hsa-miR-654 mmu-miR-374-5p 
hsa-miR-449 hsa-miR-511 hsa-miR-542-3p hsa-miR-654-3p mmu-miR-379 
hsa-miR-449b hsa-miR-512-3p hsa-miR-542-5p hsa-miR-655 mmu-miR-451 
hsa-miR-450a hsa-miR-512-5p hsa-miR-544 hsa-miR-660 mmu-miR-491 
hsa-miR-450b-3p hsa-miR-513-5p hsa-miR-545 hsa-miR-671-3p mmu-miR-495 
hsa-miR-450b-5p hsa-miR-515-3p hsa-miR-548a hsa-miR-672 mmu-miR-496 
hsa-miR-452 hsa-miR-515-5p hsa-miR-548a-5p hsa-miR-674 mmu-miR-499 
hsa-miR-453 hsa-miR-516a-5p hsa-miR-548b hsa-miR-708 mmu-miR-615 
hsa-miR-454 hsa-miR-516b hsa-miR-548b-5p hsa-miR-744 mmu-miR-93 
hsa-miR-455 hsa-miR-517a hsa-miR-548c hsa-miR-758 mmu-miR-96 
hsa-miR-455-3p hsa-miR-517b hsa-miR-548c-5p hsa-miR-871  
hsa-miR-483-5p hsa-miR-517c hsa-miR-548d hsa-miR-872  
hsa-miR-484 hsa-miR-518a-3p hsa-miR-548d-5p hsa-miR-873  
hsa-miR-485-3p hsa-miR-518a-5p hsa-miR-551b hsa-miR-874  
hsa-miR-485-5p hsa-miR-518b hsa-miR-556-3p hsa-miR-875-3p  
hsa-miR-486 hsa-miR-518c hsa-miR-556-5p hsa-miR-876-3p  
hsa-miR-486-3p hsa-miR-518d hsa-miR-561 hsa-miR-876-5p  
hsa-miR-487a hsa-miR-518d-5p hsa-miR-570 hsa-miR-885-3p  
hsa-miR-487b hsa-miR-518e hsa-miR-574-3p hsa-miR-885-5p  
hsa-miR-488 hsa-miR-518f hsa-miR-576-3p hsa-miR-886-3p  
hsa-miR-489 hsa-miR-519a hsa-miR-576-5p hsa-miR-886-5p  
hsa-miR-490 hsa-miR-519c hsa-miR-579 hsa-miR-887  
hsa-miR-491-3p hsa-miR-519d hsa-miR-582-3p hsa-miR-888  
hsa-miR-492 hsa-miR-519e hsa-miR-582-5p hsa-miR-889  
hsa-miR-493 hsa-miR-520a# hsa-miR-589 hsa-miR-890  
hsa-miR-494 hsa-miR-520a hsa-miR-590-5p hsa-miR-891a  
hsa-miR-499-3p hsa-miR-520b hsa-miR-597 hsa-miR-891b  
hsa-miR-500 hsa-miR-520d-5p hsa-miR-598 hsa-miR-892a  
hsa-miR-501 hsa-miR-520e hsa-miR-615-5p hsa-miR-9  
hsa-miR-501-3p hsa-miR-520f hsa-miR-616 hsa-miR-92a  
hsa-miR-502 hsa-miR-520g hsa-miR-618 hsa-miR-95  
hsa-miR-502-3p hsa-miR-521 hsa-miR-624 hsa-miR-98  
hsa-miR-503 hsa-miR-522 hsa-miR-625 hsa-miR-99a  
hsa-miR-504 hsa-miR-523 hsa-miR-627 hsa-miR-99b  
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9.3 Plasmid generation 
9.3.1 Overlapping oligos designed 
 
Fragment 1 
5’GCCGTGTAATTCTAGATCGtggggtatttgacaaactgacaATCGtggggtatttgacaaactgacaATCGtggg
gtatttgacaaactgacaCCGGTAATtggg3’ 
3’CGGCACATTAAGATCTAGCaccccataaactgtttgactgtTAGCaccccataaactgtttgactgtTAGCacccc
ataaactgtttgactgtGGCCATTAaccc5’ 
 
Fragment 2 
5’acaCCGGTAATtggggtatttgacaaactgacaATCGtggggtatttgacaaactgacaATCGCTAGAGTCGGG
GCGG3’ 
3’tgtGGCCATTAaccccataaactgtttgactgtTAGCaccccataaactgtttgactgtTAGCGATCTCAGCCCCG
CC5’ 
 
9.3.2 3’ UTR designed 
GCCGTGTAATTCTAGATCGtggggtatttgacaaactgacaATCGtggggtatttgacaaactgacaATCGtggggtat
ttgacaaactgacaCCGGTAATtggggtatttgacaaactgacaATCGtggggtatttgacaaactgacaATCGCTAGA
GTCGGGGCGG 
 
AAA = 15 bp overhang 
AAA = miR-223-3p perfect binding site 
AAA = linker sequence 
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9.3.3 Insert sequence 
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Restriction map of Clone 6
Showing restriction enzymes cutting maximum 1 time [using RELibrary as a Restriction Enzyme Library]
###
                                                                             >miR-223 binding site       
                                                   >miR-223 binding site       
                                                   |                         |
  TGTCTGCTCGAAGCGGCCGGCCGCCCCGACTCTAGCGATTGTCAGTTTGTCAAATACCCCACGATTGTCAGTTTGTCAAATACCCCAATTACCGGTGTCA  < 100
  ACAGACGAGCTTCGCCGGCCGGCGGGGCTGAGATCGCTAACAGTCAAACAGTTTATGGGGTGCTAACAGTCAAACAGTTTATGGGGTTAATGGCCACAGT
           10        20        30        40        50        60        70        80        90 
                                 >miR-223 binding site       
       >miR-223 binding site                               >miR-223 binding site       
       |                         |                         |
  GTTTGTCAAATACCCCACGATTGTCAGTTTGTCAAATACCCCACGATTGTCAGTTTGTCAAATACCCCACGATCTAGAATTACACGGCGATCTTTCCGCC  < 200
  CAAACAGTTTATGGGGTGCTAACAGTCAAACAGTTTATGGGGTGCTAACAGTCAAACAGTTTATGGGGTGCTAGATCTTAATGTGCCGCTAGAAAGGCGG
           110       120       130       140       150       160       170       180       190 
  
  CTTCTTGGCC  < 210
  GAAGAACCGG
           
Features :
miR-223 binding site   : [40 : 61]
miR-223 binding site   : [66 : 87]
miR-223 binding site   : [96 : 117]
miR-223 binding site   : [122 : 143]
miR-223 binding site   : [148 : 169]
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9.3.4 Alignment with designed 3’ UTR 
 
  
Alignment of Sequence_1:  [pGL3 miR-223 reporter seq] with  Sequence_2: [Clone 6] 
Similarity : 210/300 (70.00 %)
Seq_1  1     GGAAAACTCGACGCAAGAAAAATCAGAGAGATCCTCATAAAGGCCAAGAAGGGCGGAAAG  60
                                                      |||||||||||||||||||
Seq_2  210   -----------------------------------------GGCCAAGAAGGGCGGAAAG  192
Seq_1  61    ATCGCCGTGTAATTCTAGATCGtggggtatttgacaaactgacaATCGtggggtatttga  120
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  191   ATCGCCGTGTAATTCTAGATCGTGGGGTATTTGACAAACTGACAATCGTGGGGTATTTGA  132
Seq_1  121   caaactgacaATCGtggggtatttgacaaactgacaCCGGTAATtggggtatttgacaaa  180
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  131   CAAACTGACAATCGTGGGGTATTTGACAAACTGACACCGGTAATTGGGGTATTTGACAAA  72
Seq_1  181   ctgacaATCGtggggtatttgacaaactgacaATCGCTAGAGTCGGGGCGGCCGGCCGCT  240
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  71    CTGACAATCGTGGGGTATTTGACAAACTGACAATCGCTAGAGTCGGGGCGGCCGGCCGCT  12
Seq_1  241   TCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTG  300
             |||||||||||                                                 
Seq_2  11    TCGAGCAGACA-------------------------------------------------  1
Features [Seq_2]:
miR-223 binding site   : [40 : 61]
miR-223 binding site   : [66 : 87]
miR-223 binding site   : [96 : 117]
miR-223 binding site   : [122 : 143]
miR-223 binding site   : [148 : 169]
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9.3.5 Plasmid map 
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9.4 Presentations during my PhD studies 
9.4.1 Poster presentations 
• Cardiff University Division of Infection and Immunity Annual Meeting, Cardiff, 2016. 
Title ‘The role of local microRNAs in the pathogen-specific immune response to 
acute peritonitis in peritoneal dialysis patients’ 
• British Society of Immunology Annual Congress, Liverpool, 2016. Title ‘The role of 
local microRNAs in the pathogen-specific immune response to acute peritonitis in 
peritoneal dialysis patients’ 
• WKRU Annual Meeting, Swansea, 2016. Title ‘The role of local microRNAs in the 
pathogen-specific immune response to acute peritonitis in peritoneal dialysis 
patients’ 
• Diabetic Nephropathy Research Symposium, Cardiff, 2016. Title ‘The role of local 
microRNAs in the pathogen-specific immune response to acute peritonitis in 
peritoneal dialysis patients’ 
• 30th Cardiff University Annual School of Medicine and Dentistry Postgraduate 
Research Day, Cardiff, 2017. Title ‘The role of local microRNAs in the pathogen-
specific immune response to acute peritonitis in peritoneal dialysis patients’ 
• Cardiff University Division of Infection and Immunity Annual Meeting, Cardiff, 2017. 
Title ‘Pathogen-specific local microRNAs in peritoneal dialysis patients with acute 
peritonitis’ 
• 13th European Peritoneal Dialysis Meeting, Dublin, 2017. Title ‘Pathogen-specific 
local microRNAs in peritoneal dialysis patients with acute peritonitis’ 
• British Society of Immunology Annual Congress, Brighton, 2017. Title ‘The role of 
local microRNAs in the pathogen-specific immune response to acute peritonitis in 
peritoneal dialysis patients’ 
• WKRU Annual Meeting, Swansea, 2018. Title ‘The role of local microRNAs in the 
pathogen-specific immune response to acute peritonitis in peritoneal dialysis 
patients’ 
 
 
9.4.2 Oral presentations 
• South West RNA Club, Cardiff, 2017. Title ‘Pathogen-specific local microRNAs in 
peritoneal dialysis patients with acute peritonitis’ – best PhD presentation award 
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• 31st Cardiff University Annual School of Medicine and Dentistry Postgraduate 
Research Day, Cardiff, 2017. Title ‘The role of local microRNAs in the pathogen-
specific immune response to acute peritonitis in peritoneal dialysis patients’ 
• 13th European Peritoneal Dialysis Meeting, Dublin, 2017. Title ‘Pathogen-specific 
local microRNAs in peritoneal dialysis patients with acute peritonitis’ – best basic 
science presentation award 
• WKRU Annual Meeting, Cardiff, 2017. Invited speaker. Title ‘microRNAs as 
biomarkers of infection in PD’ 
• 32nd Cardiff University Annual School of Medicine and Dentistry Postgraduate 
Research Day, Cardiff, 2018. Title ‘The role of local microRNAs in the pathogen-
specific immune response to acute peritonitis in peritoneal dialysis patients’ 
• South West RNA Club, Exeter, 2018. Title ‘The role of local microRNAs in the 
pathogen-specific immune response to acute peritonitis in peritoneal dialysis 
patients’ 
• Cardiff University Division of Infection and Immunity Annual Meeting, Cardiff, 2018. 
Title ‘The role of local microRNAs in the pathogen-specific immune response to 
acute peritonitis in peritoneal dialysis patients’ 
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